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GENERAL INTRODUCTION 
Articular cartilage 
Articular cartilage is a specialized connective tissue that covers the surface of 
bones in diarthrodial joints. It has an essential function in the resistance of compressive 
forces and distribution of load. Articular cartilage consists of a dense network of collagen 
fibrils and a high concentration of aggregating proteoglycans (PG). The collagen fibrils, 
mainly composed of type II collagen, give the tissue tensile strength while the 
compressive stiffness of cartilage is the result of the presence of the aggregating 
proteoglycans (1). Proteoglycans are macromolecules that consist of a core protein with 
one or more sulfated glycosaminoglycan (GAG) chains. Due to the presence of the highly 
charged GAG chains, proteoglycans create a high osmotic pressure in the tissue that 
draws water into the cartilage and causes the tissue to swell (2,3). The large aggregating 
proteoglycan aggrecan consists of a core protein that can contain up to 150 GAG chains 
(2,3). The aggrecan monomers are immobilized in the matrix by the formation of large 
aggregates, created by non-covalent binding of aggrecan monomers (5-800) to hyaluronic 
acid (2). Besides aggrecan, cartilage contains several small, non-aggregating 
proteoglycans like decorin, biglycan and fibromodulin (3,4).The different extracellular 
matrix molecules in articular cartilage are produced by specialized cells, the 
chondrocytes, which are embedded in the matrix. Chondrocytes are metabolically active 
cells which continuously synthesize and degrade the extracellular matrix molecules in a 
coordinated way to 
maintain healthy cartilage. 
A schematic illustration of 
articular cartilage is shown 
in figure 1. 
Figure 1 Schematic illustration 
of articular cartilage. Shown are 
the chondrocytes, type II 
collagen fibrils, hyaluronic acid 
and large aggregates of 
aggrecan molecules. (Modified 
illustration from Poole (5)) 
AGGRECAN ΙΎΡΕ Π COLLAGEN FIBRIL 
HYALURONIC ACID CHONDROCYTE 
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Cartilage destruction in osteoarthritis and rheumatoid arthritis 
Progressive destruction of articular cartilage is a main feature of rheumatoid arthritis 
(RA) and osteoarthritis (OA). The destruction of articular cartilage will cause functional 
disability of the joints and ma3y cause invalidity. RA is a joint disease that affects — 1 % of the 
population and is characterized by chronic inflammation of the joints (6). OA is a joint disease 
that affects a great part of the population, especially the elderly (7,8). Although synovial 
hyperplasia and influx of inflammatory cells in the synovial tissue are observed in a significant 
number of patients (9-11) the disease is, in contrast to RA, primarily non-inflammatory. 
Mechanisms of proteoglycan depletion 
A main event in the process of articular cartilage destruction in RA and OA is depletion 
of proteoglycans from the cartilage which is the result of a disbalance between PG synthesis and 
PG degradation. The enhanced degradation of proteoglycans in RA and О A is mainly caused by 
action of proteinases but also nonenzymatic agents, such as reactive oxygen metabolites, might 
be involved (12,13). Until now, it is not clear which enzymes are responsible for the degradation 
of articular cartilage but there is accumulating evidence that the unidentified enzymatic activity 
"aggrecanase" plays an important role in the catabolism of aggrecan in OA and RA (14-16). In 
addition, matrix metalloproteinases (MMPs) seem to be involved in the degradation of cartilage 
since these enzymes are potent proteinases for extracellular matrix molecules and enhanced 
activity of these enzymes was shown in joints of patients with RA or OA (14,16-22). 
Destruction of articular cartilage in experimental arthritides appears to be not only the 
result of enhanced degradation of extracellular matrix molecules but also inhibition of PG 
synthesis contributes to the disbalance between matrix catabolism and anabolism. In contrast to 
the suppressed PG synthesis observed in arthritis (23,24), PG synthesis in early О A seems to 
be elevated (11,25,26) but is unable to overcome the enhanced PG degradation. 
It is assumed that the cytokines interleukin-1 (IL-1) and tumor necrosis factor α (TNFa) 
play a key role in the process of PG depletion in articular cartilage since the expression of these 
cytokines is enhanced in arthritic and osteoarthritic joints (27-31) and these cytokines are able 
to suppress PG synthesis and to stimulate PG resorption in vitro (32-36). The enhanced 
degradation of proteoglycans by IL-1 and TNFa may be the result of stimulation of MMP 
synthesis and downregulation of proteinase inhibitors like TIMPs (37-45). In addition, IL-1 can 
induce aggrecanase activity in articular cartilage (46). Although IL-1 and TNFa can stimulate 
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PG degradation in vitro, their role in PG degradation in humans has to be further elucidated 
(47-51). However, there is convincing evidence that IL-1 is responsible for the suppression of 
PG synthesis in vivo since several studies have shown that suppression of PG synthesis in 
experimental arthritides is prevented by neutralization of IL-1 (50-53). 
Anabolic factors and cartilage repair 
A challenging area of research is the development of a therapy which inhibits cartilage 
degradation. Since IL-1 and TNFa appear to be key mediators in cartilage destruction, targeting 
of these factors with antibodies, soluble binding proteins or receptor antagonists might suppress 
cartilage destruction. Suppression of MMP activity with specific proteinase inhibitors might also 
be a successful treatment to prevent further cartilage degradation. However, since articular 
cartilage has a limited capacity for self renewal it is also crucial to develop ways to stimulate 
cartilage repair. In this respect anabolic factors like insulin-like growth factor-1 (IGF-l)(54-58), 
platelet-derived growth factor (PDGF)(59-61), basic fibroblast growth factor (bFGF)(62-66), and 
epidermal growth factor (EGF)(61,67,68) have been studied but the ideal factor to stimulate 
cartilage repair has not yet been found. Because transforming growth factor-/3 (TGF-/3) and bone 
morphogenetic protein-2 (BMP-2) seem promising factors to stimulate cartilage repair, the 
effects of these factors on articular chondrocyte PG metabolism will be addressed in more detail. 
Transforming growth factor β 
Transforming growth factor β (TGF-/3) is a multifunctional growth factor that has 
profound regulatory effects on many physiological processes like embryonic development, 
inflammation and tissue repair (69). TGF-/3 belongs to the transforming growth factor ß (TGF-ß) 
family. This superfamily consists of a large group of dimeric molecules of which each monomer 
contains 7 conserved cysteine residues (70). The proteins are synthesized as large precursor 
proteins. Active TGF-ß, a homodimer with a molecular weight of 25 kDa, is generated after 
activation of the latent complex by enzymatic cleavage (71-73), deglycosylation (71) or exposure 
to acid environments (74). A schematic representation of TGF-ß synthesis and activation is 
shown in figure 2. Until now, five different isoforms have been identified of which three 
isoforms (TGF-/31-3) are present in mammals (75). These isoforms have a high degree of 
homology (75-78) and are conserved between species (75,77-80). 
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Figure 2 Synthesis and activation of TGF-ß TGF-ß is synthesized as a large dimeric molecule of which 
each molecule contains the sequence for latency-associated peptide (LAP) and mature TGF-ß After 
proteolytical cleavage the "Small latent complex" is formed in which LAP and TGF-ß are noncovalently 
associated In most cell types the small latent complex is covalently linked to latent TGF-ß binding 
proteins (LTBP) to form the "large latent complex" This complex is secreted by cells In order to elicit 
a biological response, the mature protein must be released from the latent complex 
TGF-ß receptors and signaling 
The actions of TGF-/3 are initiated after binding to specific cell surface receptors Many 
distinct membrane proteins that can bind TGF-/3 have been identified (81-84) Articular 
chondrocytes express at least four classes of TGF-/3 binding proteins, type I, type II, type III 
and type V TGF-/Î receptors (75,85) Type I and type Π TGF-/3 receptors are membrane proteins 
with an intracellular serine/threonine kinase domain These receptors appear the most important 
receptors since they are directly involved in signal transduction (84,86). Type III TGF-0 
receptor, also called betaglycan, is a membrane-bound proteoglycan and is the major TGF-/3 
binding molecule of many cell types (75) It is unlikely that this receptor is directly mvolved in 
signal transduction since this protein has a very short intracellular domain (87,88) and cells are 
described which lack betaglycan but have a normal response on TGF-0 (82,89) Although 
betaglycan is not directly involved in signal transduction it has an important function since it 
12 CHAPTER 1 
enhances ligand binding to the signaling receptors (90). This is particularly important for TGF-
/32 since cells that express only type I and type II receptors neither bind nor respond efficiently 
to TGF-/J2 (90-92). Type V TGF-/3 receptor might have a direct function in signal transduction 
as it contains a serine/threonine kinase domain (93). However, until now evidence for the 
involvement of type V receptors in signaling is lacking. 
As stated before, TGF-/J signal transduction is mediated by type I and type II TGF-/3 
receptors. Although initially it was assumed that these receptors mediate distinct signal pathways 
independently, nowadays there is accumulating evidence that type I and type II TGF-/J receptors 
signal through a heteromeric receptor complex (84,86). The type II receptors bind TGF-/3, 
directly or after presentation by type ΠΙ receptors, whereafter the complex is recognized by type 
I receptors and a heteromeric complex is formed (94-96). In this complex the type II receptor, 
which has constitutive kinase activity (95,97), transphosphorylates the type I receptor (95,98,99) 
which is the central event in TGF-/3 receptor activation. 
ITGF- β 
Type III Type II Type I 
substratos 
Figure 3 Mechanism of TGF-ß receptor binding and signaling. TGF-ß binds directly or after presentation 
by type III TGF-ß receptors to the type II TGF-ß receptor, whereafter a complex with type I TGF-ß 
receptors is formed. In this complex the constitutive active kinase domain of type II TGF-ß receptor 
phosphorylates the type I TGF-ß receptor which is the central event in TGF-ß receptor activation. 
Ρ=active serine/threonine kinase domain. 
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TGF-ß and chondrocyte metabolism 
TGF-0 is a factor which might have therapeutic value to stimulate cartilage repair. TGF-
ß is able to stimulate PG synthesis in vitro and in vivo (100-102) and increases the synthesis of 
stable PG aggregates through a coordinated increase in hyaluronic acid and PG monomer 
synthesis (101). The aggrecan molecules produced under TGF-ß stimulation are larger and more 
anionic which might have beneficial effects on tissue function (101,103,104). Besides stimulation 
of aggrecan synthesis, TGF-0 also enhances the expression of biglycan (104,105). Moreover, 
TGF-/3 might enhance the retention of newly synthesized matrix molecules by increasing the 
expression of integrins on chondrocytes (106-108). 
The effects of TGF-0 on chondrocyte PG synthesis seem to be different between normal 
articular cartilage and PG depleted cartilage. For example, TGF-/3 stimulated PG synthesis of 
human OA cartilage while under the same conditions TGF-0 did not affect the PG synthesis of 
normal articular cartilage (109). In addition, TGF-/3 enhanced the PG synthesis of IL-1 treated 
cartilage while the effects of TGF-/3 on normal cartilage were minimal (110,111). These 
differential responses between normal and PG depleted cartilage might be related to differences 
in chondrocyte phenotype and/or differences in TGF-/3 receptor expression. 
An interesting feature of TGF-/3 is the ability to counteract IL-1-induced suppression of 
articular cartilage PG synthesis (110,112). The mechanism of this action is unclear but the 
abolishment of IL-1-effects might be the result of TGF-/3-induced down-regulation of IL-1 
receptors (113,114) or suppression of nitric oxide (NO) synthesis (115,116), a factor involved 
in IL-1-induced suppression of PG synthesis (117,118). Since IL-1 is responsible for the 
suppression of articular chondrocyte PG synthesis in experimental arthritis (50-53), counteraction 
of IL-1-induced suppression of articular cartilage PG synthesis appears to be an important feature 
to stimulate cartilage repair in arthritic joints. 
Besides the effects on articular cartilage PG synthesis, TGF-/3 is also a potent regulator 
of matrix degradation. TGF-/J has been shown to inhibit matrix degradation (110,119) probably 
by down regulating the synthesis of matrix degrading enzymes (120-122) and up-regulation of 
tissue inhibitor of metalloproteinases (TIMP) (120,122-124). TGF-ß-mediated up-regulation of 
plasminogen activator inhibitor-1 (PAI-1) (125,126) might also play a role since plasmin has 
been suggested to be involved in cartilage degradation by direct cleavage of matrix molecules 
or by the activation of latent metalloproteinases (127-129). The property to stimulate articular 
cartilage PG synthesis, to counteract IL-1-induced suppression of PG synthesis and to suppress 
matrix degradation makes TGF-/? a promising factor to stimulate articular cartilage repair. 
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Figure 4 Schematic representation of mechanisms involved in TGF-ß-mediated stimulation of cartilage 
repair. 
Bone morphogenetic protein-2 (BMP-2) 
BMP-2 belongs to the family of the bone morphogenetic proteins (BMPs). This family 
belongs, like TGF-/3 to the TGF-0 superfamily. BMPs can be distinguished from other members 
of the TGF-/3 superfamily by having 7, rather than 9, conserved cysteines in the mature protein 
(130). At this moment ten different BMPs have been described of which nine belong to the TGF-
ß superfamily (130,131). In contrast to the other BMPs, BMP-1 does not belong to the TGF-/3 
superfamily but is a member of the astacin family of metalloproteinases (132,133). BMPs signal, 
like TGF-ß, through heteromeric complexes of type I and type II serine/threonine kinases. 
Specific type I and type II BMP receptors have been described (134-138). BMPs were first 
identified on the basis of their ability to induce ectopic bone but nowadays it is known that 
BMPs are involved in many physiological processes. BMPs play a prominent role in 
embryogenesis since they are involved in skeletal development, neural patterning and 
development of organs including kidney, lung, heart and skin (130). 
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BMP-2 and chondrocyte metabolism 
BMP-2 might be an interesting factor to stimulate cartilage repair since this factor has 
been shown to be a very potent stimulator of articular cartilage PG synthesis in vitro (139,140). 
In addition, BMPs have the potential to stimulate PG synthesis in the presence of IL-1 since IL-
1-induced suppression of PG synthesis was counteracted in vitro by BMP-7 (141). Members of 
the BMP family are also able of inhibiting PG degradation. BMP-7 suppressed IL-1-induced up-
regulation of collagenase (MMP-1) mRNA and stromelysin (MMP-3) mRNA and counteracted 
the IL-1-induced inhibition of their natural inhibitor (TIMP)(142). In addition, both BMP-3 and 
BMP-4 have been shown to inhibit PG degradation in cartilage expiants cultured in vitro (143). 
Although it has been reported that BMP-2 is a potent regulator of cartilage PG synthesis in vitro, 
no in vivo data are available. In addition, nothing has been reported about the ability of BMP-2 
to counteract ИЛ effects on chondrocyte metabolism or about the effects of BMP-2 on articular 
cartilage PG degradation. 
AIM AND SCOPE OF THE THIS THESIS 
The aim of this thesis was to get more insight in the regulatory role of transforming 
growth factor-/3 (TGF-|3) and bone morphogenetic protein-2 (BMP-2) on articular cartilage PG 
metabolism and to study whether these factors are able to stimulate articular cartilage repair in 
vivo. 
The reported effects of TGF-/3 on articular chondrocytes are contradictory since both 
stimulating and inhibitory effects of TGF-ß on chondrocyte PG synthesis have been described 
(101,144,145). Therefore, studies were performed to investigate whether differential effects of 
TGF-0 on chondrocytes are related to differences in the expression of TGF-0 receptors. As 
described in Chapter 2 and Chapter 3 differential responses of chondrocytes on TGF-/3 appear 
not to be correlated with differences in the relative expression of two isoforms of the type II 
TGF-/3 receptor (TGFßRII, and TGFj3RII2) but a relation was found between the response on 
TGF-/3 and the size of the type II TGF-/3 receptors. 
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Both BMP-2 and TGF-/3 had been shown to stimulate articular cartilage PG synthesis in 
vitro (100-102,139,140). To study the effects of these factors on PG synthesis in vivo, intra-
articular injections were given in murine knee joints whereafter PG synthesis was analyzed. As 
described in Chapter 4, both TGF-/3 and BMP-2 appeared to be very potent stimulators of 
articular chondrocyte PG synthesis in vivo. However, up-regulation of PG synthesis by TGF-/Î 
lasted much longer than up-regulation by BMP-2. 
IL-1 appears to be a key mediator of cartilage destruction (25,32,50,51,146). Therefore, 
the ability of BMP-2 and TGF-/3 to counteract IL-1-effects on cartilage PG synthesis and content 
was studied. As described in Chapter 5, TGF-0 counteracted the effects of IL-1 on PG synthesis 
and content. In contrast to TGF-/3, BMP-2 did not show any effect on chondrocyte PG 
metabolism in the presence of IL-1. 
Subsequently, the ability of TGF-/3 and BMP-2 to stimulate articular cartilage repair in 
established arthritis was studied (Chapter 6). Local administration of BMP-2 in arthritic joints 
did not show any effect on cartilage PG synthesis or content. In contrast, intra-articular injection 
of TGF-/3 clearly stimulated articular cartilage repair. TGF-/3 did not affect inflammation but 
stimulated chondrogenesis in the joints. 
To elucidate the significance of possible side-effects, long-term effects of local 
administration of TGF-/J into normal murine knee joints were studied (Chapter 7). One month 
after three intra-articular injections of TGF-/J pathological changes, similar to changes found in 
early stages of murine OA (102,147), were found. These data indicate that care must be taken 
with application of TGF-0 and that TGF-/3 might play a role in the induction of OA. 
To further investigate the role of endogenous TGF-/J in arthritis and osteoarthritis potent 
inhibitors for TGF-/3 are required. The type II TGF-0 receptor has a high affinity for TGF-0 
(94,95,148). Therefore a soluble type Π receptor was expressed in Escherichia coli and Pichia 
pastoris. In Chapter 8 the expression, purification and characterization of this protein is 
described. 
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ABSTRACT 
Objective Transforming growth factor ß (TGF-ß) is a multipotent regulator of cell 
proliferation and extracellular matrix production. The effect of TGF-ß on 
chondrocyte matrix production was studied in relation to expression of TGF-ß 
binding proteins. The effect of TGF-ß on proteoglycan (PG) synthesis of isolated 
articular chondrocytes depended on the culture period. PG synthesis of 
chondrocytes which were cultured for one day was inhibited by TGF-ß whereas PG 
synthesis of chondrocytes, cultured in monolayer for seven days or longer, was 
stimulated by TGF-ß. To investigate if this differential response is related to a 
distinct expression of TGF-ß receptors, this parameter was studied by affinity 
labeling. 
Methods Chondrocytes were incubated with 100 pM TGF-ß labeled with iodine-
125. Crosslinking was performed using 0.25 raM disuccinimidyl suberate (DSS). 
Membrane proteins were extracted and analysed by denaturating sodium 
dodecylsulphate Polyacrylamide gel electrophoresis (SDS-PAGE) and 
autoradiography. 
Results Freshly isolated and cultured chondrocytes expressed types I, II and III 
TGF-ß receptors. The type II TGF-ß receptor of cultured chondrocytes appeared to 
be about 15 KDa smaller than the type II TGF-ß receptor expressed on freshly 
isolated chondrocytes, however. 
Conclusions As the type II TGF-ß receptor appears to be involved in signal 
transduction, this change in size of the type II TGF-ß receptor might be related to 
the differential effect of TGF-ß on PG synthesis of freshly isolated and cultured 
bovine articular chondrocytes. 
Correlation of the size of type II TGF-/S receptor with TGF-/S responses of chondrocytes 2 9 
INTRODUCTION 
Transforming growth factor ß (TGF-ß) is a multipotent regulator of cell 
proliferation and extracellular matrix synthesis (1,2). It is produced as a latent, 
high molecular weight complex (2,3) which can be activated by proteolytic 
cleavage or extremes of pH (2). Active TGF-ß is a 25 kDa polypeptide, consisting 
of two identical subunits of 112 amino-acids, linked by disulfide bonds (1,2). TGF-
ß might be an important regulator of articular chondrocyte metabolism during joint 
diseases, as high concentrations of latent TGF-ß (300 ng/g) are present in articular 
cartilage (4) and active TGF-ß is found in the synovial fluid of patients with 
rheumatoid arthritis or osteoarthritis (5). 
The reported effects of TGF-ß on chondrocyte metabolism are contradictory. 
Stimulating and inhibitory effects of TGF-ß on proteoglycan (PG) and DNA 
synthesis of articular chondrocytes have been described (6-9). We have shown that 
effects of TGF-ß on PG and DNA synthesis of isolated bovine articular 
chondrocytes are related to differences in culture time (10). TGF-ß inhibits PG and 
DNA synthesis of isolated bovine articular chondrocytes which were cultured for 
one day ('freshly isolated chondrocytes'), whereas TGF-ß stimulates PG and DNA 
synthesis of bovine articular chondrocytes cultured for seven days or longer 
('cultured chondrocytes'). This effect appeared to be the result of phenotypical 
changes between freshly isolated and cultured chondrocytes. 
Effects of TGF-ß are mediated by cell surface receptors. Articular chondrocytes 
express at least four distinct types of TGF-ß binding proteins: type I (53 KDa), 
type II (70-100 KDa), type III (250-350 KDa) and type V (400 KDa)(l,ll). Other 
types of TGF-ß binding proteins, like the type VI TGF-ß receptor, are described on 
several cell types (12-14), but it is not known if these are also present on 
chondrocytes. Little is known about the function of these different binding proteins, 
though on a large variety of cell types it was demonstrated that the type I and Π 
receptors are important in signal transduction (15-21). Involvement of the type II 
TGF-ß receptor in signal transduction is also suggested by the presence of a 
serine/threonine kinase domain (22). The type V receptor might also have a 
function in signal transduction since it contains a serine/threonine kinase domain 
(23) and TGF-ß resistant tumor cell lines have been described which have no 
expression of type V receptors but a normal expression of the other TGF-ß 
receptors (11). The type III receptor, also called betaglycan, probably does not 
have a role in signal transduction as it has a small intracellular domain (24,25) and 
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cells are described which lack betaglycan but have a normal response on TGF-ß 
(26,27). 
The aim of this study was to investigate if the differential effect of TGF-ß 
on PG synthesis of freshly isolated and cultured articular chondrocytes is related to 
differences in TGF-ß receptor expression. 
MATERIALS AND METHODS 
Isolation of bovine articular chondrocytes 
Articular cartilage chondrocytes were isolated from bovine 
metacarpophalangeal joints. Cartilage slices were incubated for 48 hours in RPMI 
DM (Flow Laboratories) supplemented with 1 mg/ml Clostridium collagenase (371 
Units/mg, Worthington Biochemical Corp.) at 37 °C in a humidified 5% C02 
atmosphere. After incubation with collagenase, chondrocytes were washed three 
times with collagenase free medium. Cells were seeded at a density of 5 χ IO5 
cells/ml in 24 well cluster dishes (lml/cluster, Costar) and grown for 1 day 
('freshly isolated chondrocytes') or 14 days ('cultured chondrocytes') in medium 
supplemented with 20% fetal calf serum (FCS)(Flow Laboratories). Culture 
medium was changed every other day. The cell number doubled during culture in 
approximately one week after which confluence was reached. 
Effect of TGF-ß on proteoglycan synthesis 
Recombinant TGF-ß 1 (Serva) was solubilized in 4 mM HCl with 0.1% 
bovine serum albumin (Sigma). Freshly isolated and cultured chondrocytes were 
incubated for 24 hours in the presence of TGF-ß (5 ng/ml, 200 pM). Four hours 
before the end of the incubation period, 10 /¿Ci 35S-sulfate (Du Pont de Nemours) 
was added. After the incubation period, the culture medium was treated with 
papain (lmg/ml papain, (Sigma), 0.2 M NaCl, 0.1 M Na-acetate, 10 mM L-
cysteine hydrochloride (Sigma), 50 mM Na2EDTA, 50 μζ/τηΐ chondroitin sulfate 
carrier (Sigma), pH 6.0) for 2 hours at 60 °C. The glycosaminoglycans (GAG) 
were precipitated by incubation (2 hours, 37 °C) with 0.1% cetylpiridinium 
chloride (CPC, Sigma). After centrifugation (15 minutes, room temperature, 
10.000 g) the pellet was washed three times with 0.05% CPC. The pellet was 
solubilized for 2 h at 60° С with lumasolve (Perstorp Analytical) and after addition 
of scintillation fluid counted in a liquid scintillation counter. 
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The Wilcoxon's Rank Sum test was used to test statistical significance. 
Differences were significant when the Ρ value was less than 0.05. 
Collagenase treatment of cultured chondrocytes 
Chondrocytes, cultured for 14 days in medium supplemented with 20% fetal 
calf serum (FCS), were incubated for 48 hours in RPMI DM supplemented with 1 
mg/ml Clostridium collagenase (371 Units/mg, Worthington Biochemical Corp.) at 
37 °C in a humidified 5% C02 atmosphere. After incubation with collagenase, 
chondrocytes were washed three times with collagenase free medium. Cells were 
seeded at a density of 5 χ 10s cells/ml in 24 well cluster dishes (lml/cluster) and 
grown for one day, after which the effect of TGF-ß on the PG synthesis was 
measured. 
1251 Labeling of TGF-ß 
TGF-ßl was labeled with iodine-125 using the oxidizing agent 1,3,4,6-
tetrachloro-3a,6a-diphenyl glycoluril (Iodogen; Pierce) according to the method 
described by Salacinski et al (28). 5 μg TGF-ß in 100 μΐ sodium phosphate buffer 
(0.05M, pH 7.4) was incubated in the presence of 0.5 mCi carrier free Na125I 
(Amersham) in a reaction vial coated with 2 μg Iodogen. After an incubation of 15 
minutes at room temperature, the reaction was terminated by addition of 1 Μ ΚΙ. 
Radiolabeled TGF-ß was separated from free iodine using a Sephadex G25 column 
which was equilibrated with 4 mM HCL containing BSA (0.1% w/v). 
Affinity labeling 
Affinity labeling was performed according to the method of Massagué and 
Like (29). Chondrocytes were washed with binding buffer (128 mM NaCl, 5 mM 
KCl, 1.2 mM CaCl2, 1.2 mM MgSO, ¿0 mM 4-(2-hydroxyethyl)-l-
piperazineethanesulfonate, pH 7.5) after which they were incubated with 100 pM 
125I-TGF-ß in binding buffer, supplemented with 5 mg/ml BSA, for 3 hours at 4 
°C. Competition studies were performed in the presence of 4 nM non-radiolabeled 
TGF-ß. After the incubation period the buffer was discarded and the crosslink 
reaction was performed in binding medium supplemented with 0.25 mM 
disuccinimidyl suberate (Pierce) for 30 minutes at 4CC. After washing cells with 
binding buffer the cells were incubated (16 hours, 4 °C) with extraction buffer (1% 
v/v Triton X-100, 1 mM EDTA, 10 mM Tris, and 1 mM p-methyl sulphonyl 
fluoride (PMSF). Detergent soluble material was analysed by denaturating SDS-
polyacrylamide gel electrophoresis, using prefababricated 5-20% gradient gels (Bio-
Rad), and autoradiography. Autoradiograms were scanned using an automatic gel 
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scanner (LKB Ultroscan XL). Sizes of binding proteins were determined using pre-
stained molecular weight markers (Bio-Rad). 
RESULTS 
As shown previously (10), TGF-ß inhibited PG synthesis of freshly isolated 
chondrocytes whereas PG synthesis of cultured chondrocytes was stimulated by 
TGF-ß (Figure 1). It was suggested that this phenomenon is the result of 
phenotypical changes occurring during culture. However, the possibility that the 
lack of stimulation on freshly isolated chondrocytes was a result of the collagenase 
treatment, which was used to isolate chondrocytes from cartilage, still remained. 
To exclude this possibility, cultured chondrocytes were treated with collagenase, 
seeded in the original density of 5 χ IO5 cell/ml and cultured for 24 hours after 
which the effect of TGF-ß on the PG synthesis was measured. As shown in figure 
1, collagenase treatment of cultured chondrocytes did not alter the effect of TGF-ß, 
showing that the differential effect of TGF-ß was indeed a result of phenotypical 
changes. 
Figure 1 Effect of TGF-ß on the PG synthesis of freshly isolated articular chondrocytes (A), 
cultured chondrocytes (B) and cultured chondrocytes after collagenase treatment (C). 
Chondrocytes were incubated with (hatched bar) or without (solid bar) 200 pM TGF-ß for 24 
hours. During the last 4 hours the culture medium was supplemented with 10 μΟ "S-sulfate. After 
incubation PGs were precipitated and 35S content was measured. Experiments were performed in 
quintuple. Without a TGF-ß incubation the 15S incorporation of cultured chondrocytes and cultured 
chondrocytes after collagenase treatment, were comparable to the 3SS incorporation of freshly 
isolated chondrocytes. Shown are the means (+SD) of a representative experiment of four. 
Significant differences are indicated with asterisk. 
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To investigate if this effect was related to alterations in TGF-ß receptor 
expression, affinity labeling was performed. After SDS-PAGE and 
autoradiography, several bands were demonstrated. The sizes of these bands 
correspond with sizes of the affinity-labeled type I (65 kDa), type II (85 kDa) and 
type III (diffuse high molecular band 250-350 kDa) TGF-ß receptors (Figure 2). It 
might be possible that the diffuse high molecular band also includes the affinity-
labeled types V (400 kDa) and VI (180 kDa) binding proteins, but that the 
separation capacity in this region of the gel was not enough to distinguish them 
from the type III receptor. Studies in which affinity labeling was performed in the 
presence of 4 nM non-radiolabeled TGF-ß showed that these affinity-labeled 
proteins are specific TGF-ß binding proteins as competition between 125I-TGF-ß and 
non-radiolabeled TGF-ß for binding to these receptors was demonstrated (Figure 
2). In addition to the types I, II and III TGF-ß receptors, we showed a band of 
about 30 kDa, corresponding to a binding protein of 18 kDa. This binding protein 
appears not to be a specific TGF-ß binding protein, as we could not show 
competition between radiolabeled and non-radiolabeled TGF-ß for binding to this 
Figure 2 Affinity labeling of cultured 
chondrocytes without (A) and in the 
presence (B) of 4 nM non-radiolabeled 
TGF-ß. Chondrocytes were incubated with 
100 pM '"I-TGF-ß. Crosslinking was 
performed using 0.25 mM disuccinimidyl 
suberate. Membrane proteins were 
extracted and analyzed by denaturating 
SDS-PAGE and autoradiography. 
Molecular weight markers and bands 
corresponding with the affinity-labeled type 
I, type II and type III TGF-ß receptors are 
indicated. 
A В 
protein (Figure 2). 
2 0 5 -
1 0 6 -
8 0 -
4 9 -
- type 
type 
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Although isolated and cultured chondrocytes expressed the 18 kDa binding 
protein and types I, II and III TGF-ß receptors, a difference in TGF-ß receptor 
expression was demonstrated between these chondrocytes. A small, but significant 
difference was observed in the size of the type II TGF-ß receptors, whereas no 
other reproducible differences were observed in TGF-ß receptor expression. The 
type II TGF-ß receptor of freshly isolated chondrocytes appears to be about 15 kDa 
larger than the type II receptor of cultured chondrocytes (Figure 3). The variation 
in size of the type II receptor was also demonstrated after scanning autoradiograms 
with an automatic gel scanner (Figure 4). The ratio between the intensities of bands 
showed variation between experiments. We could not show a correlation between 
the ratio of the intensities of the type I and type II receptors and the effects of 
TGF-ß on chondrocytes, however. The TGF-ß receptor expression of cultured 
chondrocytes which were treated with collagenase was also analysed. We were not 
able to show differences between TGF-ß receptor expression of cultured 
chondrocytes and cultured chondrocytes which were treated with collagenase (data 
not shown). 
2 0 5 -
1 0 6 -
8 0 -
4 9 -
- type III 
- type II 
- type I 
Figure 3 Affinity labeling of freshly 
isolated (A) and cultured (B) chondrocytes. 
Chondrocytes were incubated with 100 pM 
'
25I-TGF-ß. Crosslinking was performed 
using 0.25 mM disuccinimidyl suberate. 
Membrane proteins were extracted and 
analyzed by denaturating SDS-PAGE and 
autoradiography. Molecular weight 
markers and bands corresponding with the 
affinity labeled type I, type II and type III 
TGF-ß receptors are indicated. Shown is a 
representative autoradiogram of three. 
3 2 -
2 7 -
A В 
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optloal danalty 
dittano· of migration 
Figure 4 Scan of autoradiogram. 
Autoradiograms were scanned using an 
automatic gelscanner. Absorbtion units 
were normalized for background. The 
relative positions of the type I and type II 
TGF-ß receptors of freshly isolated ( О ) 
and cultured ( * ) chondrocytes are 
shown. 
DISCUSSION 
Proteoglycan synthesis of isolated articular chondrocytes has been reported 
to be both stimulated and inhibited by TGF-ß (6-9). We have shown before that 
these differential findings may be the result of differences in culture period (10). 
PG synthesis of bovine articular chondrocytes which were cultured for one day 
('freshly isolated chondrocytes'), was inhibited, whereas the PG synthesis of 
chondrocytes cultured for seven or more days ('cultured chondrocytes') was 
stimulated by TGF-ß. In this study we excluded the possibility that this was an 
effect of the collagenase treatment used to isolate chondrocytes from cartilage, 
suggesting that the differential effect of TGF-ß on freshly isolated and cultured 
chondrocytes is a result of phenotypical changes occurring during culture. We 
showed before that freshly isolated chondrocytes are normal differentiated 
chondrocytes since they exhibited the typical polygonal morphology of 
differentiated chondrocytes and produced predominantly large proteoglycans, both 
characteristics of differentiated chondrocytes (10). During culture, phenotypical 
changes occur as monolayer cultured chondrocytes had an altered morphology and 
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synthesized besides large proteoglycans, a considerable quantity of smaller 
proteoglycans. 
The observation that PG synthesis of normal differentiated chondrocytes is 
inhibited by TGF-ß is in agreement with earlier observations (6,30). PG synthesis 
of articular chondrocytes cultured in agarose, a system in which chondrocytes 
maintain their differentiated phenotype, was inhibited by TGF-ß (6). Moreover, PG 
synthesis of intact murine articular cartilage, cultured for one day, was also 
inhibited by TGF-ß (30). Since effects of TGF-ß are mediated by its cell surface 
receptors, we investigated whether the dissimilar effect of TGF-ß on PG synthesis 
of freshly isolated and cultured chondrocytes could be the result of differences in 
TGF-ß receptor expression. 
Using affinity labeling we were able to show that the type II TGF-ß receptor 
of cultured chondrocytes is about 15 kDa smaller than the type II TGF-ß receptor 
of freshly isolated chondrocytes. No other reproducible variations in TGF-ß 
receptor expression were found. This observation suggests a relation between the 
size of the TGF-ß type Π receptor and the effect of TGF-ß on the PG synthesis of 
articular chondrocytes. As the type II TGF-ß receptor has been shown to play a 
part in mediating inhibition of PG synthesis on chondrocytes (31,32), we postulate 
that the small-sized type II TGF-ß receptor on cultured chondrocytes is non-
functional, leading to stimulating effects of TGF-ß by way of the type I or other 
TGF-ß receptors. The existence of comparable non-functional, small-sized type II 
TGF-ß receptors on other cell types has been reported earlier. Resistance to growth 
inhibition by TGF-ß was correlated with the expression of non-functional small-
sized type II TGF-ß receptors on mutant bovine endothelial cells (33), mutant mink 
lung epithelial cells (19) and human colon carcinoma cells (34). As the TGF-ß type 
Π receptor is a glycoprotein, with about 15 kDa of N-linked carbohydrate (1,35), it 
is possible that the difference in molecular weight between normal and small-sized 
type II receptors is a result of alterations in glycosylation. Normal glycosylation 
was demonstrated on the altered type II TGF-ß receptors on mink lung epithelial 
cells (35), however, suggesting that other mechanisms may be involved. The 
difference between normal and small-sized type II receptors might also be the result 
of alternative splicing. Alternative splicing is described for the type II activin 
receptor (36), a receptor like the type II TGF-ß receptor, belonging to the 
serine/threonine kinase family (13). 
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In this study we demonstrated a small-sized type Π TGF-ß receptor on 
phenotypically altered chondrocytes. Stimulation of the PG synthesis of these 
chondrocytes appears to be correlated with the expression of this small-sized 
receptor. Because phenotypically changed chondrocytes are also present in 
osteoarthritic (OA) cartilage (37-39) and the PG synthesis of human OA cartilage is 
stimulated by TGF-ß, whereas under the same conditions TGF-ß had no effect on 
the PG synthesis of normal human cartilage (40), non-functional, small-sized type 
II TGF-ß receptors might be expected in OA cartilage. The increased PG synthesis, 
characteristic of OA cartilage (41,42), might be the result of the expression of non-
functional, small-sized type II TGF-ß receptors in combination with functional type 
I TGF-ß receptors. Alteration of expression and function of TGF-ß receptors could 
be a mechanism of chondrocytes in pathological cartilage to initiate the repair 
process. Interference with cellular physiology by pharmacological modulation of 
TGF-ß receptor expression might provide new directions for stimulation of tissue 
repair. 
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ABSTRACT 
Recently a new isoform of the type II TGF-ß receptor (TGFßRII) was 
identified. This isoform (TGFßRII2) contains an insertion of 25 aminoacids in the 
extracellular domain of the receptor. Using RT-PCR we demonstrated that both 
TGFßRII, and TGFßRII2 are expressed by chondrocytes in murine and human 
articular cartilage. Bovine articular chondrocytes did express TGFßRII! mRNA but 
did not express detectable levels of TGFßRII2 mRNA suggesting that the new 
isoform does not play an important role in normal bovine cartilage physiology. 
Because TGF-ß responses seem to be age-related and differential TGF-ß responses 
have been described between normal cartilage and cartilage undergoing repair we 
studied if the relative mRNA expression between these isoforms is altered during 
cartilage repair and aging. No differences in the relative mRNA expression of the 
two isoforms of the type II TGF-ß receptor could be demonstrated in murine 
cartilage during aging or during the repair phase after mild PG depletion indicating 
that it is unlikely that age-related TGF-ß responses and differential TGF-ß 
responses between normal cartilage and cartilage undergoing repair are the result of 
differences in the relative expression of the two TGFßRII isoforms. 
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INTRODUCTION 
Transforming growth factor beta (TGF-ß) is a potent regulator of cell 
metabolism (1,2). A role of TGF-ß in cartilage physiology is suggested by the 
presence of high concentrations of TGF-ß in normal articular cartilage (3) and its 
regulatory role in chondrocyte proliferation, differentiation and extracellular matrix 
production (4-11). Since TGF-ß expression in the joint is enhanced in patients with 
rheumatoid arthritis (12,13) and active TGF-ß is present in the synovial fluid of 
patients with rheumatoid arthritis or osteoarthritis (14) it is assumed that TGF-ß 
also plays a role in the regulation of chondrocyte metabolism during these joint 
diseases. 
TGF-ß responses are mediated by specific cell surface receptors. Articular 
chondrocytes express at least four distinct types of TGF-ß receptors: type I, type 
II, type III and type V TGF-ß receptors (1,15). The type I and type II TGF-ß 
receptors seem to be the most important TGF-ß receptors since they are directly 
involved in signal transduction (16-20). 
Recently a new isoform of the type II TGF-ß receptor was isolated from a 
mouse brain cDNA bank (21), a human glioblastoma cDNA bank (22) and from a 
human endothelial cell cDNA bank (23). This new isoform (TGFßRII2) contains an 
insertion of 25 amino acids in the extracellular domain of the receptor. It is most 
likely that this isoform is generated by differential splicing of mRNA that is 
transcribed from the original type II TGF-ß receptor gene. An important role of 
this isoform is suggested because the insertion of the human isoform and the 
murine isoform are localized at the same site and the amino acid sequence of the 
insertion is highly conserved between these species (76 % identical) (23). It has 
been shown that TGFßRII2 mRNA is expressed in different murine tissues like 
stomach, intestine, kidney, lung and brain (21). In addition, TGFßRII2 mRNA is 
expressed in several human cell-types like glioblastoma cells, vein endothelial cells, 
embryonal lung fibroblasts, omental microvascular endothelial cells and lung 
carcinoma cells (23). However, no data are available about the expression of 
TGFßRII2 mRNA in articular cartilage. Therefore we studied the expression of this 
isoform in normal articular cartilage of different species. Because TGF-ß responses 
on articular cartilage seem to be age-related (24-27) and differential TGF-ß 
responses have been described between normal cartilage and cartilage undergoing 
repair (28-30) we also studied if the relative expression of TGFßRII, and TGFßRII2 
is altered during aging or during matrix repair after PG depletion. 
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MATERIALS AND METHODS 
Animals 
Male C57B1/10 mice were used to study age-related differences. Male 
C57B1/6 mice were used in experiments in which cartilage depletion was induced. 
Mice were kept in cages with a wood chip bedding in a room kept at constant 
temperature. They were fed a standard diet and tap water ad libitum. 
Isolation of cartilage 
Murine articular cartilage was isolated from patellae. Patellae were 
decalcified in 3.5% EDTA for 4 hours at 4 °C whereafter the whole cartilage layer 
was stripped off. Because old cartilage is more calcified, decalcification of patellae 
of old mice (>3 month) was performed over night at 4 °C. In control experiments 
it was demonstrated that decalcification by EDTA does not affect efficiency of 
RNA isolation or RT-PCR (data not shown). Bovine cartilage was isolated from 
metacarpophalangeal joints within 8 hours after death of the animals. Human 
cartilage was isolated from femoral knee condyles within 18 hours after death of 
the donor. Only cartilage samples which were histologically defined as normal 
were used. Isolated human and bovine articular cartilage was immediately frozen in 
liquid nitrogen. 
RNA isolation and RT-PCR 
Total RNA was isolated using TRIzol Reagent (Life Technologies). Human 
and bovine articular cartilage was grinded to powder in a freeze mill and defrosted 
in TRIzol. Murine articular cartilage was directly after isolation extracted with 
TRIzol. Before reverse transcription total RNA was treated with DNase (Life 
Technologies). Reverse transcription was performed with M-MLV Reverse 
Transcriptase (Life Technologies) using the 3' PCR primer. Taq DNA Polymerase 
(Life Technologies) was used in the PCR reaction. cDNA was cycled 35 times at 
92 °C for 1 min, 55 °C for 1 min and 72 °C for 1 min. The amplified products 
were separated on an 1.6% agarose gel and visualized by chemoluminescense using 
the Digoxigenin (DIG) System (Boehringer Mannheim). The PCR primers used for 
amplification of TGFßRIl! and TGFßRII
 2 mRNA are described by Suzuki et al 
(21). Since these primers are located on both sides of the insertion, the PCR 
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products of TGFßRIl! or TGFßRII2 differ in size (525 bp and 601 bp respectively) 
and show different mobility on an 1.6% agarose gel. 
Induction of mild proteoglycan depletion 
Mild PG depletion was induced in 10 weeks old male C57B1/6 mice by 
intra-articular injection of papain as described by van der Kraan et al (31). In 
short, the right knee-joints of the mice were injected once with 6 μΐ 0.5% papain 
(Type IV, 15 units/mg, Sigma in 0.03 M L-cysteine.HCL, Sigma). The left control 
knees were injected with saline. At several points of time after the injection 
patellae were isolated and used for determination of patellar PG synthesis and RNA 
extraction for RT-PCR. 
Determination of patellar cartilage proteoglycan synthesis 
Proteoglycan synthesis was measured ex vivo. Whole patellae, with a 
standard amount of surrounding tissue, were dissected from the knee joints. 
Patellae were pulse-labeled (2h, 37 °C) with 35S-sulphate (1.1 MBq/ml), After 
labeling the patellae were washed, fixed, decalcified, punched out of the 
surrounding tissue, dissolved and counted by liquid scintillation counting as 
described before (34). 
RESULTS 
TGFßRIIi and TGFßRII2 mRNA expression in normal cartilage 
RT-PCR on isolated RNA from human and murine articular cartilage using 
TGFßRIl specific primers resulted in two PCR products. The sizes of the PCR 
products corresponded with the expected size of amplified TGFßRIl! mRNA (525 
bp) and TGFßRII2 mRNA (601 bp) demonstrating that both TGFßRIl , and 
TGFßRIIj mRNA are expressed in normal articular cartilage. However, there were 
striking differences in the relative expression of the two isoforms between species. 
Murine articular chondrocytes expressed almost equal amounts of TGFßRIl! and 
TGFßRII2 mRNA while human articular chondrocytes expressed about 3 times 
more TGFßRIIi mRNA than TGFßRII2 mRNA. When RNA from bovine articular 
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chondrocytes was used only TGFßRII, mRNA was detected demonstrating that the 
expression of the TGFßRII2 isoform is very low or absent (Figure 1). 
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Figure 1 Expression of TGFßRII, and TGFßRII2 mRNA in normal bovine (B), murine (M) and 
human (H) articular cartilage. Total RNA was isolated from normal articular cartilage and RT-
PCR was performed. PCR products are separated on a 1.6% agarose gel. Each lane shows the 
products of RT-PCR using RNA from different donors. RNA from human and bovine cartilage was 
isolated form individual donors while RNA of murine cartilage was isolated from pooled patellar 
cartilage of 5 mice. 
TGFßRII, and TGFßRII2 mRNA expression in cartilage of different age 
It has been reported that TGF-ß has different effects on old cartilage 
compared to young cartilage (24-27). To investigate if these age-related TGF-ß 
responses are the result of differences in the relative expression of the two isoforms 
of the TGF-ß type II receptor we determined the relative mRNA expression of 
TGFßRII! and TGFßRII2 in murine articular cartilage of different ages. RNA was 
isolated from patellar cartilage of 3, 6, 12, 18 and 24 months of age whereafter 
RT-PCR was performed. As shown in figure 2, articular cartilage from mice of all 
ages express both TGFßRII, and TGFßRIL, mRNA. No differences could be 
demonstrated in the relative expression of TGFßRII, and TGFßRII2 mRNA between 
3 months old (young adult) cartilage and cartilage up to 24 months of age (very 
old). 
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Figure 2 Expression of TGFßRII, and TGFßRII2 mRNA in murine articular cartilage between 3 
and 24 month of age. RT-PCR was performed using RNA isolated from patellar articular cartilage 
of different age. RNA was isolated from pooled patellar cartilage of 5 mice. Shown is a 
representative experiment of three. 
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TGFßRII, and TGFßRII2 mRNA expression in cartilage during a repair phase 
Because differential TGF-ß responses have also been described between 
normal cartilage and cartilage undergoing repair after cartilage injury (11,28,29) 
we investigated whether the relative expression of TGFßRII! and TGFßRII
 2 mRNA 
is altered during the repair phase after mild PG depletion. A murine cartilage 
repair model was used in which 0.5% papain was injected in the murine knee joint. 
Intra-articular injection of papain results in PG depletion (31) and an inhibition of 
the PG synthesis up to 50% at one day after injection (Figure 3). The PG synthesis 
is normalized between three and four days after injection whereafter the PG 
synthesis is supranormal up to 14 days with a maximal stimulation at 7 days after 
injection. 
% 35S-SULPHATE INCORPORATION 
Figure 3 Effect of intra-articular 
injection of 0.5% papain on the PG 
synthesis of patellar cartilage. 
Glycosaminoglycan synthesis was 
measured ex-vivo by 35S-sulphate 
incorporation using 5 patellae at 
each point of time. The results are 
expressed as percentage of "S-
sulphate incorporation of patellar 
cartilage from joints which were 
intra-articular injected with saline. 
Shown is a representative 
experiment of three. 
DAYS AFTER INJECTION 
The relative TGFßRII, and TGFßRII
 2 mRNA expression in cartilage was 
determined by RT-PCR at different points of time after injection of papain. No 
differences in the relative mRNA expression of the two isoforms could be 
demonstrated between normal articular cartilage and cartilage after papain treatment 
on any point of time (Figure 4). 
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Figure 4 Expression of TGFßRII, and TGFßRII2 mRNA in patellar cartilage after PG depletion. 
Murine patellae were dissected at several points of time after intraarticular injection of 0.5% 
papain (P) or saline (C). RNA was isolated from pooled patellar cartilage of 5 mice. RT-PCR was 
performed and the PCR products are separated on a 1.6% agarose gel. Shown is a representative 
experiment of three. 
DISCUSSION 
Recently a new isoform of the type II TGF-ß receptor was identified (21-
23). This new isoform (TGFßRII2) contains an insertion of 25 amino acids in the 
extracellular domain of the receptor. An important role of this isoform is suggested 
by the high conservation of this insertion between species. Since the original type II 
receptor (TGFßRII,) has a low affinity for TGF-A2 (32,33) it was investigated 
whether the new isoform was a TGF-ß2 specific receptor. However, binding 
studies using transfected cells showed that TGFßRII2 also had a much higher 
affinity for TGF-ß 1 than for TGF-ß2 (21,23). These results indicate that the new 
isoform is not a TGF-ß2 specific receptor. Transfection studies using a TGF-ß 
resistant cell line which lacks endogenous TGFßRII demonstrated that TGFßRII, 
and TGFßRII2 where indistinguishable in their biological functions (23). However, 
these studies are non physiological and limited to only a few specific TGF-ß 
responses. 
Using RT-PCR we now demonstrated for the first time that both TGFßRII, 
and TGFßRII2 mRNA are expressed in normal human and murine articular 
cartilage. We were not able to detect TGFßRII2 mRNA in bovine articular 
chondrocytes. Although murine primers were used in these studies we can exclude 
the possibility that the inability to detect TGFßRII2 mRNA in bovine articular 
chondrocytes is an artefact due to differences in the primer-annealing sequences. 
Both TGFßRII, and TGFßRII2 mRNA were amplified in the same tube, using the 
same primers and under the same conditions so the isoforms are internal controls 
for each other. Since TGFßRII, mRNA could be detected in bovine chondrocytes 
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we can conclude that bovine articular chondrocytes do not express TGFßRII2 
mRNA or express this isoform at a very low level. This implicates that it is 
unlikely that TGFßRII2 plays an essential role in the metabolism of normal bovine 
articular cartilage. 
TGF-ß responses on articular chondrocytes are shown to be age-related (24-
27). For example, articular cartilage from old adult pigs is more sensitive to TGF-ß 
induced elaboration of extracellular inorganic pyrophosphate (ePPi) than cartilage 
from juvenile and young adult pigs (26). Young murine articular cartilage appears 
to be more sensitive to TGF-ß induced stimulation of PG synthesis than old murine 
articular cartilage (25). Because various TGF-ß responses are age-related we 
investigated if one of the isoforms is selectively unregulated during aging. 
However, we demonstrated that the ratio between TGFßRII, and TGFßRII2 mRNA 
does not differ in murine articular cartilage between 3 month and 24 month of age. 
These results suggest that the described differential TGF-ß responses between old 
and young articular cartilage are not mediated by differences in the relative 
expression of the two isoforms of TGFßRII. 
It has also been demonstrated that TGF-ß has different effects on normal 
articular cartilage and cartilage during a repair phase. For example, TGF-ß 
stimulated PG synthesis of human osteoarthritic cartilage while under the same 
conditions TGF-ß did not have a significant effect on the PG synthesis of normal 
human cartilage (29). In addition, TGF-ß enhanced the PG synthesis of interleukin-
1 (IL-1) treated cartilage but the effects of TGF-ß on normal cartilage PG synthesis 
were minimal(28,30). We investigated the relative expression of TGFßRII, and 
TGFßRII2 mRNA in the repair phase after mild PG depletion. Mild PG depletion 
in murine articular cartilage was induced by injection of 0.5% papain in the murine 
knee joint. No differences in the relative expression of TGFßRII! and TGFßRII2 
mRNA could be demonstrated between normal cartilage and cartilage undergoing 
repair after mild PG depletion. This indicates that the supranormal PG synthesis 
after PG depletion by papain is not mediated by selective upregulation of mRNA of 
one of the two isoforms. This also suggests that the described differential TGF-ß 
responses between normal cartilage and cartilage undergoing repair (28-30) are not 
the result of differences in the relative expression of TGFßRII! and TGFßRII
 2 
mRNA. 
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In summary, this study demonstrates that the newly identified isoform of the 
type II TGF-ß receptor (TGFßRII2) is expressed in normal human and murine 
articular cartilage. TGFßRII2 mRNA was not detectable in bovine articular cartilage 
indicating that it is unlikely that TGFßRII2 plays an important role in the 
physiology of normal bovine articular cartilage. No differences in the relative 
mRNA expression of the two isoforms of the type II TGF-ß receptor could be 
demonstrated in murine cartilage during aging or during the repair phase after mild 
PG depletion indicating that it is unlikely that age-related TGF-ß responses and 
differential TGF-ß responses between normal cartilage and cartilage undergoing 
repair are the result of differences in the relative expression of the two TGFßRII 
isoforms. 
Expression of type II TGF-0 receptor isoforms in articular cartilage 5 1 
REFERENCES 
1 Massague J The transforming growth factor beta family Annu Rev Cell Biol 6 597-641, 1990 
2 Barnard JA, Lyons RM, Moses HL The cell biology of transforming growth factor beta 
Biochimica et Biophysica Acta 1032 79-87, 1990 
3 Morales TI, Joyce ME, Sobel ME, Damelpour D, Roberts AB Transforming growth factor-beta 
in calf articular cartilage organ cultures synthesis and distribution Arch Biochem Biophys 
288 397-405, 1991 
4 van der Kraan PM, Vitters EL, van den Berg WB Differential effect of transforming growth 
factor beta on freshly isolated and cultured articular chondrocytes J Rheumatol 19 140 145, 1992 
5 Roughley PJ, Meldung LI, Recklies AD Changes in the expression of deconn and biglycan in 
human articular cartilage with age and regulation by TGF-beta Matrix Biol 14 51-59, 1994 
6 Morales TI Transforming growth factor-beta and insulin-like growth factor-1 restore 
proteoglycan metabolism of bovine articular cartilage after depletion by retinole acid Arch 
Biochem Biophys 315 190-198, 1994 
7 Luyten FP, Chen P, Paralkar V, Reddi AH Recombinant bone morphogenetic protein-4, 
transforming growth factor-beta 1, and activin A enhance the cartilage phenotype of articular 
chondrocytes in vitro Exp Cell Res 210 224-229, 1994 
8 Inoue H, Kato Y, Iwamoto M, Hiraki Y, Sakuda M, Suzuki F Stimulation of cartilage-matnx 
proteoglycan synthesis by morphologically transformed chondrocytes grown in the presence of 
fibroblast growth factor and transforming growth factor-beta J Cell Physiol 138 329-337, 1989 
9 Morales TI Transforming growth factor-beta 1 stimulates synthesis of proteoglycan aggregates m 
calf articular cartilage organ cultures Arch Biochem Biophys 286 99-106, 1991 
10 Benya PD, Padilla SR Dihydrocytochalasin В enhances transforming growth factor-beta-induced 
reexpression of the differentiated chondrocyte phenotype without stimulation of collagen synthesis 
Exp Cell Res 204 268-277, 1993 
11 van Beuningen HM, van der Kraan PM, Arntz OJ, van den Berg WB Transforming growth 
factor-beta 1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte 
formation m the murine knee joint Lab Invest 71 279-290, 1994 
12 Taketazu F, Kato M, Gobi A, Ichijo H, ten Dyke P, Itoh J, Kyogoku M, Ronnehd J, Miyazono 
K, Heldin CH, et al Enhanced expression of transforming growth factor-beta s and transforming 
growth factor-beta type II receptor in the synovial tissues of patients with rheumatoid arthritis 
Lab Invest 70 620-630, 1994 
13 Miossec P, Navihat M, Dupuy A, Sany J, Banchereau J Low levels of interleukin-4 and high 
levels of transforming growth factor beta in rheumatoid synovitis Arthritis Rheum 33 1180-1187, 
1990 
14 Fava R, Olsen Ν, Keski Oja J, Moses H, Pincus Τ Active and latent forms of transforming 
growth factor beta activity m synovial effusions J Exp Med 169 291-296, 1989 
15 O'Grady P, Huang SS, Huang JS Expression of a new type high molecular weight receptor (type 
V receptor) of transforming growth factor beta in normal and transformed cells Biochem Biophys 
Res Commun 179 378-385, 1991 
16 ten Dijke P, Yamashita H, Ichijo H, Franzen P, Laiho M, Miyazono K, Heldin CH 
Characterization of type I receptors for transforming growth factor-beta and activin Science 
264 101-104, 1994 
17 Wrana JL, Attisano L, Cárcamo J, Zentella A, Doody J, Laiho M, Wang XF, Massague J TGF 
beta signals through a heteromenc protein kinase receptor complex Cell 71 1003-1014, 1992 
52 CHAPTER 3 
18 Inagaki M, Moustakas A, Lin HY, Lodish HF, Carr BI Growth inhibition by transforming 
growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after 
expression of TGF-beta receptor type II cDNA Proc Natl Acad Sci U S A 90 5359-5363, 1993 
19 Cárcamo J, Zentella A, Massague J Disruption of transforming growth factor beta signaling by a 
mutation that prevents transphosphorylation within the receptor complex Mol Cell Biol 
15 1573-1581, 1995 
20 Bassmg CH, Howe DJ, Segarmi PR, Donahoe PK, Wang XF A single heteromenc receptor 
complex is sufficient to mediate biological effects of transforming growth factor-beta ligands J 
Biol Chem 269 14861-14864, 1994 
21 Suzuki A, Sluoda N, Maeda T, Tada M, Ueno N Cloning of an isoform of mouse TGF-beta type 
II receptor gene FEBS Lett 355 19-22, 1994 
22 Nikawa J A cDNA encoding the human transforming growth factor beta receptor suppresses the 
growth defect of a yeast mutant Gene 149 367-372, 1994 
23 Hirai R, Fuji ta Τ A human transforming growth factor-beta type II receptor that contains an 
insertion in the extracellular domain Exp Cell Res 223 135-141, 1996 
24 Guerne PA, Blanco F, Kaelin A, Desgeorges A, Lotz M Growth factor responsiveness of human 
articular chondrocytes in aging and development Arthritis Rheum 38 960-968, 1995 
25 van Beuningen HM, van der Kraan PM, Amtz OJ, van den Berg WB In vivo protection against 
interleukin-1-induced articular cartilage damage by transforming growth factor-beta 1 age-related 
differences Ann Rheum Dis 53 593-600, 1994 
26 Rosenthal AK, Ryan LM Ageing increases growht factor induced inorganic pyrophosphate 
elaboration by articular cartilage Mech Ageing Dev 75 35-44, 1994 
27 Recklies AD, Roughley PJ, Bilimora KM Differential response of young and old human articular 
chondrocytes to IGF-1 and TGF-/3 Trans Orthop Res Soc 14 281, 1989 
28 Rayan V, Hardingham Τ The recovery of articular cartilage in expiant culture from mterleukin-1 
alpha effects on proteoglycan synthesis and degradation Matrix Biol 14 263-271, 1994 
29 Lafeber FP, van der Kraan PM, Huber Brumng О, van den Berg WB, Bijlsma JW Osteoarthntic 
human cartilage is more sensitive to transforming growth factor beta than is normal cartilage Br J 
Rheumatol 32 281-286, 1993 
30 van Beuningen HM, van der Kraan PM, Amtz OJ, van den Berg WB Protection from interleukin 
1 induced destruction of articular cartilage by transforming growth factor beta studies m 
anatomically intact cartilage in vitro and in vivo Ann Rheum Dis 52 185-191, 1993 
31 van der Kraan PM, Vitters EL, van de Putte LB, van den Berg WB Development of 
osteoarthntic lesions in mice by "metabolic" and "mechanical" alterations in the knee joints Am J 
Pathol 135 1001-1014, 1989 
32 Tsang ML, Zhou L, Zheng BL, Wenker J, Fransen G, Humphrey J, Smith JM, O'Connor 
McCourt M, Lucas R, Weatherbee JA Characterization of recombinant soluble human 
transforming growth factor-beta receptor type II (rhTGF-beta sRII) Cytokine 7 389 397, 1995 
33 López-Casillas F, Wrana JL, Massagué J Betaglycan presents ligand to the TGF/9 signaling 
receptor Cell 73 1435-1444, 1993 
34 van den Berg WB, Kruysen MWM, van de Putte LBA The mouse patella assay An easy method 
of quantitating articular cartilage chondrocyte function in vivo and in vitro Rheumatol Int 
1 165-169, 1982 
ДАІИПШК é\ 
BMP-2 AND TGF-01 BOTH STIMULATE ARTICULAR CARTILAGE 
PROTEOGLYCAN SYNTHESIS AND INDUCE CHONDROGENESIS IN 
VIVO, BUT SHOW QUANTITATIVE AND QUALITATIVE DIFFERENCES 
Henk M. van Beuningen, Harrie L. Glansbeek, Elisabeth A. Morris', 
Peter M. van der Kraan and Wim В. van den Berg 
Department of Rheumatology, University Hospital Nijmegen, Nijmegen, the Netherlands 
'Cartilage Metabolism Laboratory, Genetics Institute Inc., Cambridge, MA, USA 
54 CHAPTER 4 
ABSTRACT 
The related molecules bone morphogenetic protein-2 (BMP-2) and trans-
forming growth factor beta-1 (TGF-ßl) have both been shown to stimulate 
chondrocyte proteoglycan (PG) synthesis in vitro. The objective of this study was 
to determine the in vivo effects of these factors on articular cartilage PG 
metabolism. Several dosages of BMP-2 or TGF-ßl were injected into the murine 
knee joint, once or repeatedly. Patellar cartilage PG synthesis was measured by 35S-
sulfate incorporation and PG content was analyzed by measuring safranin О 
staining intensity on histologic sections. A single injection of 200 ng BMP-2 
induced a much earlier and more impressive stimulation of articular cartilage PG 
synthesis, than 200 ng TGF-ßl. RT-PCR revealed that both factors upregulated 
mRNA of aggrecan more than that of biglycan and decorni. However, 21 days 
after a single injection of 200 ng TGF-ßl PG synthesis still was significantly 
increased, while stimulation by BMP-2 only lasted for 3 to 4 days. Stimulation by 
BMP-2 could be prolonged to at least 2 weeks by triple injections of 200 ng each, 
at alternate days. Remarkably, even after this intense exposure to BMP-2, stimula-
tion of PG synthesis was not reflected in long-lasting enhancement of PG content of 
articular cartilage. In contrast, even a single injection with 200 ng of TGF-ßl 
induced prolonged enhancement of PG content. 
After repeated injections, both BMP-2 and TGF-ßl induced chondrogenesis at 
specific sites. "Chondrophytes" induced by BMP-2 were found predominantly in 
the region where the growth plates meet the joint space, while those triggered by 
TGF-ß originated from the periosteum also at sites remote from the growth plates. 
We conclude that BMP-2 and TGF-ß stimulate PG synthesis and PG content with 
different kinetics, and that these factors have different chondro-inductive 
properties. 
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INTRODUCTION 
Loss of proteoglycans (PGs) from articular cartilage is a feature of several 
joint diseases. Depletion of these highly sulfated and hydrated molecules decreases 
the resistance of cartilage to mechanical forces and to extended enzymatic 
degradation and could therefore be the first step in cartilage degeneration. Factors 
which are able to stimulate PG synthesis and to accelerate replenishment of PGs in 
depleted cartilage could be of significant therapeutic value. Transforming growth 
factor beta-1 TGF-ßl) and bone morphogenetic protein-2 (BMP-2) have been 
shown to stimulate chondrocyte PG synthesis in vitro (1-5). Therefore, they are 
possible candidates in the search for factors that improve restoration of articular 
cartilage. 
Transforming growth factors (TGF-ßs) and bone morphogenetic proteins (BMPs) 
belong to the TGF-ß superfamily (6,7). This superfamily consists of dimeric 
molecules of which each monomer contains at least seven conserved cysteine 
residues (8). The proteins signal by serine/threonine kinases (6,9). In earlier studies 
(10) we showed that intra-articular injection of 200 ng TGF-ßl into the knee joint 
of C57B1/6 mice induces long-lasting stimulation of patellar cartilage PG synthesis. 
However, we also found that multiple injection induces fibrosis (thickening of 
synovium and ligaments) and formation of "chondrophytes", originating from the 
periosteum, and developing into osteophytes. In the present study we tried to 
identify dose regimens which might preserve the anabolic effect on cartilage 
without pronounced side effects on synovial tissue and periosteal tissue. Moreover, 
we made a comparison with BMP-2. The latter factor belongs to the BMP family 
and has been shown to possess strong chondrocyte PG synthesis stimulatory 
activity, in vitro (3,4), whereas information on in vivo effects on cartilage 
metabolism is lacking. It was found that both factors stimulate chondrocyte PG 
synthesis, but with markedly different kinetic profiles. Moreover, both factors 
induced chondrophytes, but at different, characteristic, regions of the joint. 
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MATERIALS AND METHODS 
Animals 
Male C57B1/6 mice aged 12 weeks were used. They were fed a standard diet 
and tap water ad libitum. 
Growth Factors 
Recombinant human BMP-2, rhTGF-ßl, and rhTGF-ß2 were kindly 
provided by Genetics Institute Ine (Cambridge, MA, USA), Genentech Ine (San 
Francisco, CA, USA), and Novartis (Basel, Switzerland), respectively. 
lntra-articular injections 
BMP-2 and TGF-ßs were dissolved in saline + 0.1% ultrapure bovine 
serum albumin (Sigma, St Louis, MO, USA). Six μΐ volumes were injected into 
the joint cavity of the right knee. BMP-2 and TGF-ß were administered in 2, 20, 
200, or 400 ng dosi. Simultaneously, the contralateral joint received an equal 
volume of vehicle (saline + 0.1% bovine serum albumin). Each joint was injected 
once or three times at alternate days. 
Histology 
Whole knee joints were dissected and processed as previously described 
(11). Semiserial frontal sections were stained by hematoxylin/eosin or safranin 
O/fast green for examination of cells and cartilage matrix, respectively. For 
autoradiographic analysis of 35S-sulfate incorporation (11), radiolabeled sulfate 
(75/*Ci) was injected intraperitoneally 6 hours before dissection of the knee joints. 
After histologic processing, б-μπι sections were prepared and mounted on gelatin-
coated slides. These were dipped in K3 emulsion (Ilford, Basildon, Essex, UK) and 
exposed for 3 to 5 weeks. After this period, the slides were developed and stained 
with hematoxylin and eosin. 
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Determination of patellar cartilage proteoglycan synthesis 
Proteoglycan synthesis was measured ex vivo according to the method of 
van den Berg et al. (12). Patellae with a standard amount of surrounding tissue 
were dissected from the knee joints. Patellae were then pulse-labeled (2 hours, at 
37°C) with 35S-sulfate. Subsequently, they were washed, fixated in ethanol, and 
decalcified in formic acid. After decalcification the entire cartilage was stripped 
off, dissolved in lumasolve and radioactivity was measured by liquid scintillation 
counting. In some experiments a piece of 0.2 mm2 was punched out of the patellar 
cartilage for study of the homogeneity (central part relative to peripheral part) of 
growth factor effects (13). 
Determination of patellar cartilage proteoglycan content 
Articular cartilage PG content is reflected in safranin О staining intensity in 
histological sections. This was measured using an automated image analysis system 
as described before (14). Fast green staining was neutralized by use of a green 
filter. Optical density was examined in the non-calcified cartilage. Measurements 
were corrected for chondrocyte lacunae and for background measured in PG 
depleted cartilage in which no red stain was visible any more. 
RNA extraction and RT-PCR 
Patellae were dissected and immediately decalcified in 3.5% EDTA for 4 
hours at 4°C. Following decalcification the complete articular cartilage layer was 
stripped from the underlying bone. The isolated cartilage was instantly put in 
TRIzol reagent (Life Technologies) for RNA extraction. In control experiments it 
was shown that this procedure did not affect the RNA isolation or RT-PCR 
negatively (15). RNA was directly extracted from cartilage, without homogeniza-
tion of tissue. Cartilage of 10 patellae was pooled. Before reverse transcription the 
isolated RNA was treated with DNAse 1 (Life Technologies). The reverse tran­
scription reaction was performed with moloney-murine leukemia virus (M-MLV) 
reverse transcriptase (Life Technologies), using an oligo(dT)15 primer (Eurogentec, 
Liege, Belgium). Amplification of DNA was accomplished by using Taq DNA 
polymerase (Life Technologies) up to a cycle number of 40. To estimate the 
relative mRNA levels, 5 μΐ samples were taken at increasing cycle numbers. The 
PCR products were electrophorised in 1.6% agarose gels containing ethidium 
bromide. The cycle number at which the product was-first detected on the gel was 
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taken as a measure for the amount of specific mRNA present in the originally 
isolated RNA. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA levels 
were used as an internal control. This method was validated by van Meurs et al. 
(15). All RT-PCR reactions were performed in duplicate.The following primers 
were used in the amplification reactions. 
GAPDH: 5'AACTCCCTCAAGATTGTCAGCA-3'(upper),5'-TCCACCACCCTGT 
TGCTGTA-3', resulting in a 553 bp product. Biglycan: 5'-AGAAGGCCTTTAGC 
CCTCCTG-3' (upper), 5'-ACTTTGCGGATACGGTTGTC-3' (130 bp product). 
Aggrecan primers were used as described by Grover and Roughly (16) resulting in 
a 501 bp product, while decorin primers were used according to Asundi and 
Dreher (17)(400 bp). Primers detecting murine collagen type X had the following 
sequences: 5'-ATACCCTTTCTGCTGCTAATGTTCTTGACC-3' (upper), 5'-
TGATATTCCTGGTGGTCCTGGCAAC-3' (lower), resulting in a 387 bp product. 
Statistical analysis 
Differences between experimental groups were tested using the Student's t-
test. Differences were considered significant if Ρ < 0.05. 
RESULTS 
Stimulation of articular cartilage PG synthesis 
Dose-response studies over a one-week period showed that one intra-ar-
ticular injection of 200 ng BMP-2 increased patellar cartilage PG synthesis up to 
three times the normal level within 2 days (Figure la). Thereafter PG synthesis 
declined and reached nearly basal levels at day 5 after injection. The stimulation of 
PG synthesis could not be increased beyond the level reached with 200 ng by using 
a higher BMP-2 dosage (400 ng, not shown). One injection with 20 ng BMP-2 
stimulated PG synthesis to 150% of basal level, but this stimulation was lost within 
3 days, while 2 ng was without significant effects. A single injection of TGF-ßl 
also stimulated PG synthesis but the maximum level reached was lower; only twice 
the normal synthesis rate (Figure lb). Moreover, this level was reached later (after 
four days) and stimulation of PG synthesis lasted longer as compared to BMP-2 
injection. Significant stimulation was found up to one month after injection of 200 
ng TGF-ß (Figure 2). Even the 2 ng TGF-ßl dose stimulated PG synthesis for at 
least 7 days. Triple injections did not further increase or prolong TGF-ßl-induced 
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stimulation of PG synthesis (Figure 3). In contrast, prolonged stimulation was 
found after triple injections of 200 ng BMP-2. Autoradiography showed that 35S-
sulfate incorporation was stimulated homogeneously throughout the articular 
cartilage both after BMP-2 and TGF-ßl injections (Figure 4). Using scintillation 
counting we confirmed that effects on 35S-incorporation were similar in the central 
and peripheral parts of patellar cartilage (data not shown). Effects of TGF-ßl and 
TGF-B2 on proteoglycan synthesis appeared to be comparable (data not shown) 
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A 
*/ 
* 
\ * 
\ * 
-»--
* 200 ng BMP-2 
* 20 ng BMP-2 
* 2 ng BMP-2 
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tr^~ · 1 - ^ ч 
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days after Injection 
% 35S-sulphate Incorporation 
2 3 4 5 
days after injection 
Figure 1 Dose-dependent stimulation of patellar cartilage PG synthesis after a single injection of 
BMP-2 (A) or TGF-ßl (В). Even the lowest dose of TGF-ßl still had significant effect (p < 0.05) 
at day 7. "S-sulfate incorporation is expressed as 7c of the vehicle-injected control. Each value 
represents the mean of at least 12 animals. *= significant increase <p< 0.05). 
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Figure 2 Duration of stimulation of 
PG synthesis after a single injection 
of 200 ng BMP-2 or TGF-ßl The 
effect of BMP-2 was lost after 5 
days, while TGF-ßl still had 
significant effect (p <005) on day 
21 35S-sulfate incorporation is ex-
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mean of at least 12 animals *= 
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Figure 3 Duration of stimulation 
patellar cartilage PG synthesis 
after triple injections of 200 ng 
BMP-2 or TGF-ßl By giving mul-
tiple injections the effect of BMP-2 
was prolonged to 14 days (p < 
0 05), while stimulation by TGF-ßl 
was comparable to the effect of a 
single injection 31S-sulfate incorpo-
ration is expressed as % of the 
vehicle-injected control Each value 
represents the mean of at least 12 
animals *=significant increase 
(p<0 05). 
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Figure 4 Autoradiographs showing in vivo "S-sulfate incorporation in cartilage and chondrophytes 
(arrows) after BMP-2 or TGF-ß triple injections (200 ng each); hematoxylin/'eosin stained frontal 
sections of murine knee joint. A) vehicle-injected control joint of B, B) contralateral joint of the 
same animal as A at day 4 after the last BMP-2 injection, C) vehicle-injected control joint of D, 
D) contralateral joint of the same animal as С at day 4 after the last TGF-ß injection, ρ = 
patella, ƒ = femur, с = articular cartilage, e = epiphyseal cartilage (original magnification χ 
100) 
Upregulation of mRNA of different PG types and of collagen X 
Overall PG synthesis can be determined by measurement of 35S-sulfate 
incorporation, but this reflects mainly aggrecan synthesis. To get insight in 
potential effects of BMP-2 and TGF-ß 1 on mRNA expression of different PG types 
we used RT-PCR. Messenger RNA levels were determined of three abundant PG 
types in articular cartilage; aggrecan, biglycan and decorin. At the time point of 
highest PG synthesis after the last of three BMP-2 injections, day 2, the mRNA 
levels of aggrecan, biglycan, and decorin were increased to 8, 4 and 2 times basal 
values, respectively. A single injection of 200 ng BMP-2 had less, but still signifi-
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cant effect; At day 2 after one BMP-2 injection, the amount of mRNA of decorin 
was unchanged, while that of aggrecan and biglycan had increased to 4 times basal 
values In contrast, TGF-ß injections induced upregulation of only aggrecan mRNA 
(2-4-fold) one day after the last of three 200 ng injections. However, this was 
already normalized one day later. Interestingly, the amount of mRNA encoding for 
collagen type X, indicative for chondrocyte hypertrophy, was unchanged after 
TGF-ß exposure, but highly upregulated after BMP-2 injections (± 16 times 
normal values at day 2 after third injection). 
Elevation of articular cartilage PG content 
In order to elucidate whether the stimulation of PG synthesis was reflected 
in an increase in articular cartilage PG content, intensity of safranin О staining in 
histological sections was measured. BMP-2 injections (3 χ 200 ng) appeared to 
induce only a small, short-lived increase of patellar cartilage PG content (table 1), 
while TGF-ß 1 injections (3 χ 200 ng) induced prolonged enhancement of the PG 
content, lasting at least 2 weeks after the third injection. A single injection of 200 
ng TGF-ß 1 was almost as effective in this respect as triple injections. Effects of 
TGF-ß 1 and TGF-B2 on PG content appeared to be comparable (data not shown). 
Table 1 Effect of intra-articular injections on patellar cartilage proteoglycan content 
Injected substance days" % increase of proteoglycan content* 
1 χ TGF-ß 7 
1 χ TGF-ß 14 
3 χ TGF-ß 1 
3 χ TGF-ß 4 
3 χ TGF-ß 7 
3 χ TGF-ß 14 
3 χ BMP-2 1 
3 χ BMP-2 2 
3 χ BMP-2 4 
" days after the last injection, in the triple injection protocol three injections (200 ng each) were 
given, at alternate days, meaning that in this protocol day 1 after the last injection = 5 days from 
start 
* safranin О staining intensity of histological sections measured using an automated image 
analyzer Staining intensity of patella cartilage in vehicle-injected knee joints was stated 100% 
Each experimental group consisted of at least 10 mice, and of each joint at least 4 sections were 
analyzed * ρ < 0 01, significantly different from vehicle-injected joints 
16 ± 7' 
17 ± 8' 
27 ± 13' 
25 + 11' 
22 ± 8' 
15 ± 6 ' 
26 ± 15' 
10 ± 10 
9 ± 7 
not significant 
not significant 
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Induction of osteophytes 
Histologic sections of knee joints demonstrated that intra-articular injection 
of TGF-ß and BMP-2 resulted in formation of new chondroid tissues (Figure 5). 
Interestingly, these new structures show different characteristics. BMP-2 induced 
outgrowth of epiphyseal cartilage, especially in the femur, at the level where the 
growth plate approaches the articular cartilage of the patellar groove. This chondro-
genic activity appeared to be restricted to those regions in the growth plate adjacent 
to the joint space, in close contact with the periosteum. Autoradiography (Figure 4) 
showed no effect of BMP-2 on 35S-sulphate incorporation in the epiphyseal cartila-
ge, indicating local activation of only the area where the growth plate meets the 
joint space. Besides in the described regions, BMP-2 did not induce notable deve-
lopment of chondroid tissue. In contrast, TGF-ß induced chondrogenesis originating 
from the periosteum with apparently no need for direct contact with epiphyseal 
cartilage. The TGF-ß-induced 'chondrophytes' developed close to the margins of 
articular cartilage, at the insertion sites of ligaments, and at the base of menisci. 
They were found also on the patella, which has no growth plate in mice, and in 
superficial frontal sections of the knee, which did not include epiphyseal cartilage 
(Figure 5). Chondro-inductive effects of TGF-ß 1 and TGF-B2 appeared to be 
comparable (not shown). Injection of TGF-ß 1 and BMP-2 together showed clear 
synergism of these two factors in chondrogenesis (Figure 5). At later time points 
chondrophytes lost their PGs (no safranin О staining) and developed into osteo­
phytes, containing bone marrow (Figure 5). Mature osteophytes induced by BMP-2 
and TGF-ß looked very much alike, except for their localization. 
In search for treatments that stimulate articular cartilage PG synthesis for at least a 
week, without inducing chondrophytes, dose-response studies were performed 
(table 2). These studies indicated that in the triple injection protocol chondro-in-
duction and longterm stimulation of PG synthesis by TGF-ß or BMP-2 could not be 
uncoupled. TGF-ß was more potent than BMP-2 in both effects. The only protocol 
that met the above-mentioned requirements, was a single injection of TGF-ß. Even 
the 200 ng dose did not induce chondrophytes in this protocol, and as has been 
shown in figure IB a single injection of all tested TGF-ß dosages (2, 20, 200 ng) 
induced long-term stimulation of PG synthesis. 
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Figure 5 Safranin О stained frontal sections of 
murine knee joint showing chondrophyte and 
osteophyte development (arrows) after triple intra­
articular injections of 200 ng BMP-2 or TGF-ßl. 
A) normal joint, B) superficial section, 4 days after 
last BMP-2 injection, showing that remote from the 
growth plates no signs of chondrophyte formation 
were visible, C) deeper section, at the same time-
point after the last BMP-2 injection, showing 
chondrophytes (stained red) at the sites where 
growth plates meet the joint space, D) 4 days after last TGF-ßl injection, chondrophyte 
development more independent of growth plate (also chondrophytes on the patella) was found; also 
note synovial hyperplasia, E) 21 days after last BMP-2 injection chondrophytes had developed into 
osteophytes, not stained with safranin О and containing bone marrow, F) 21 days after the last 
TGF-ßl injection, osteophytes had developed that looked very similar compared to those induced 
by BMP-2, G) synergism of TGF-ßl and BMP-2 chondroinductive (and flbrotic) actions, 4 days 
after the last injection of BMP-2 + TGF-ßl . (original magnificatten χ 100) 
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Table 2 Correlation between long-term stimulation of PG synthesis and induction of chondrophytes 
by BMP-2 and TGF-ß. 
injected substance chondrophytes stimulation of PG synthesis ( > 1 week) 
1 χ 200 ng TGF-ß - + 
3 χ 200 ng TGF-ß + 
3 χ 20 ng TGF-ß + 
3 χ 2 ng TGF-ß 
+ + 
+ 
1 χ 200 ng BMP-2 
3 χ 200 ng BMP-2 
3 χ 20 ng BMP-2 
Induction of fibrosis 
TGF-ß was much more potent than BMP-2 in inducing fibrosis. Triple 
injections with 200 ng TGF-ß increased the amount of fibroblasts in the synovial 
sublining, and also the diameter of collateral ligaments clearly increased (Figure 6). 
BMP-2 injections had only very little effect in this respect, but in some cases a 
granulous tissue developed at the extraarticular side of collateral ligaments. Similar 
structures, but larger, were found after injections of BMP-2 + TGF-ß 1. 
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Figure 6 Safranin О stained frontal 
sections of murine knee joint 
showing effects on collateral 
ligaments induced by triple intra­
articular injections of 200 ng BMP-
2 or TGF-ßl. A) normal joint B) 4 
days after the last BMP-2 injection 
there is no fibrosis of ligaments, 
but in some cases a new granulous 
structure, hardly stained, has 
developed at the extraarticular side 
of the ligament, and a 
chondrophyte is present at the end 
of the growth plate (arrows) C) 4 
days after the last TGF-ßl injection 
the collateral ligaments are thicker 
and in some cases they stain red 
instead of green, indicating 
enhanced PG content, presumably 
a sign of chondrogenesis D) 4 days 
after the last coinjection of TGF-ßl 
and BMP-2, with large 
chondrophyte at the extra-articular 
side of the ligament (arrows), 
(original magnification χ 100) 
DISCUSSION 
In vitro, members of the BMP family like BMP-2, BMP-4, BMP-7, and 
BMP-9 have been demonstrated to stimulate articular chondrocyte PG synthesis 
(3,4,18,19), but until now no in vivo data were available. We reported earlier that 
TGF-ßl is a potent stimulator of articular cartilage PG synthesis and content in 
vivo (10). In the present study, we focused on the comparison of effects of intra-
articular injections of TGF-ßl and BMP-2 on articular cartilage PG synthesis and 
content in vivo. 
BMP-2, like TGF-ßl, appeared to be a potent stimulator of articular cartilage PG 
synthesis in vivo. PG synthesis was stimulated homogeneously throughout the 
articular cartilage. Interestingly, stimulation of PG synthesis by BMP-2 and TGF-
ßl showed different kinetics. Stimulation of PG synthesis by BMP-2 was much 
earlier and stronger, but also of shorter duration than stimulation by TGF-ß. The 
retarded stimulation of PG synthesis by TGF-ß could indicate that the first event is 
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production of a second mediator, or a change in chondrocyte phenotype. An 
explanation of the prolonged stimulation of PG synthesis seen after TGF-ß injection 
could be TGF-ß autoinduction (20), but also changes in mechanical forces on 
articular cartilage due to TGF-ß-induced fibrosis and chondrophyte development 
could be responsible. In contrast to the long-term disturbance of overall PG 
synthesis, TGF-ß induced only slight, transient changes in mRNA levels of 
aggrecan and did not change message of the two small PGs. Thus, on the mRNA 
level we found no indication of changes in the balance between large and small 
PGs during TGF-ß-induced PG overproduction. Substantial shifts in favour of the 
smaller PG classes were described in the literature, but this always concerned 
TGF-ß effects on other cell types and in vitro (21-23). Reported TGF-ß effects on 
human articular chondrocyte PG gene expression in vitro (24,25) are much smaller 
(biglycan χ 2, decorin χ 0.5, aggrecan χ 4). This is more in line with our findings 
in murine articular cartilage in vivo, especially if we take into account that with 
RT-PCR it is not easy to pick up a shift of one cycle. BMP-2 effects on PG 
message were larger than those of TGF-ß, and resulted in a shift in favour of 
aggrecan. Because of the short duration of BMP-2 effects on PG synthesis, and 
content, we suppose this will not have too much influence on the composition of 
the cartilage extracellular matrix. BMP-2 also strongly stimulated collagen type X 
mRNA expression. As type X collagen is synthesized primarily by hypertrophic 
chondrocytes (26,27), this finding indicates that BMP-2 may be involved in 
induction of the hypertrophic phenotype. 
Stimulation of PG synthesis was reflected in increased PG content after TGF-ß, but 
not after BMP-2 injections. This might be caused by the short duration of BMP-2 
induced stimulation of PG synthesis, but also TGF-ß could promote PG binding to 
matrix or chondrocytes by inducing HA production (28) or by stimulation of 
integrin expression on chondrocytes (29). Moreover, TGF-ß might enhance PG 
content by suppressing PG degradation (1,24,30). However, also members of the 
BMP family seem to have, at least in vitro, the potential to inhibit PG breakdown 
(19,31). 
Apart from its strong effects on cartilage PG metabolism, TGF-ß was also much 
more potent than BMP-2 in induction of fibrosis. This was seen in the synovium, 
but also ligaments increased in diameter after TGF-ß injections. The difference in 
fibrogenic properties of BMP-2 and TGF-ß 1 we showed is in line with a study that 
compared BMP-7 and TGF-ß 1 effects on fibroblast proliferation and matrix 
synthesis (32). Another periarticular change we observed was the induction of 
chondrophytes, which eventually developed into osteophytes. Intra-articular 
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injections of BMP-2 resulted in the formation of new chondroid tissue, especially 
in the femoro-patellar area. The ability of BMP-2 to induce the formation of new 
cartilage and bone has been demonstrated before, using the rat ectopic bone 
formation assay (7,33). Other members of the BMP family, like BMP-3, BMP-4, 
BMP-5, and BMP-7 are also able to induce new cartilage and bone in vivo 
(7,33,34). As we demonstrated before, intra-articular injections of TGF-ßl induced 
chondrophytes which develop into osteophytes (10). Interestingly, the BMP-2-
induced chondrophytes are quite different as compared to those induced by TGF-ß. 
The ВМР-2-induced chondrophytes are always growing in close contact with the 
area where growth plates meet the joint space, while those induced by TGF-ß seem 
to develop more independently of these sites. Also the observation that the most 
pronounced TGF-ß-induced chondrophyte development was on the patella (lacking 
a growth plate), while after BMP-2 injections chondrophytes were rarely seen on 
the patella, but predominantly on the femur, points in this direction. Autoradio-
graphy did not show BMP-induced activation, at the level of proteoglycan 
synthesis, of the growth plates themselves. This indicates that the chondroid tissue 
had originated from the periosteum, or from the surface of the growth plate 
adjacent to the joint space. Several studies performed in other systems also show 
that BMP-2 and TGF-ß act different in inducing cartilage and bone production 
(35-37). This could indicate that BMP-2 and TGF-ß may act by different 
mechanisms, or that because of variable receptor expression they activate different 
cell populations. Additional evidence for the existence of differential activation 
pathways is the synergism in chondrophyte induction that we found after injecting 
BMP-2 and TGF-ß into the same joint. Because of the characteristic appearance 
and localization of early ВМР-2-induced chondrophytes, we can speculate about the 
relative contribution of BMP and TGF-ß in osteophyte induction during natural 
processes in mice. From the appearance of arthritis-induced chondrophytes we 
conclude that there is no physiological role for BMP in this process. Moreover, the 
localization of osteophytes in naturally occurring and experimental osteoarthritis in 
mice also is more similar to that induced by TGF-ß than BMP-2 injections, but we 
do not know what early chondrophytes in these conditions look like. 
A single injection of 200 ng TGF-ß appeared to induce long-term enhancement of 
articular cartilage PG synthesis and content, with only moderate fibrosis and no 
chondrophytes. For induction of chondrophyte formation repeated injections were 
needed. Three injections of a 10 times lower dose still induced chondrophyte 
formation. BMP-2 was less potent also in this respect, because three injections of 
20 ng BMP-2 appeared to have no chondroinductive capacity. In the triple injection 
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protocol we did not succeed in finding dosages that had significant effects on 
cartilage PG metabolism, without inducing chondrophytes. There is evidence that 
periosteum of rodents is more responsive to chondrophyte-inducing factors as 
compared to primates (38,39), indicating that BMP- or TGF-ß-induced formation of 
chondrophytes and osteophytes might be less of a problem in humans. 
In summary, this study demonstrates that local administration of BMP-2 or TGF-ß 
into normal joints stimulates articular cartilage PG synthesis. TGF-ß has the highest 
impact, because of its long-lasting enhancement of both PG synthesis and PG 
content, and seems to be the most promising factor for replenishment of PG in 
depleted cartilage in pathological conditions. However, formation of chondrophytes 
might limit the therapeutic applications of TGF-ß and BMP-2. 
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ABSTRACT 
Objective. To study effect of bone morphogenetic protein-2 (BMP-2) on articular 
cartilage proteoglycan (PG) synthesis in vivo and to investigate if BMP-2 is able to 
counteract the effects of interleukin-1 (IL-1) on articular cartilage PG synthesis and 
content. 
Methods. BMP-2 alone or in combination with IL-la was injected into murine 
knee joints. PG synthesis was measured by 35S-sulfate incorporation using an ex 
vivo method or autoradiography. Cartilage PG content was analyzed by measuring 
safranin О staining intensity on histologic sections. 
Results. BMP-2 appeared to be a potent stimulator of articular cartilage PG 
synthesis in vivo. However, BMP-2 was not able to counteract the deleterious 
effects of IL-la on articular cartilage PG synthesis and content. In addition, intra­
articular injections of BMP-2 induced chondrophytes. 
Conclusion. Although BMP-2 is a very potent stimulator of cartilage PG synthesis 
in vivo, the therapeutic applications of BMP-2 are limited due to the inability of 
BMP-2 to counteract the effects of IL-1 and the induction of chondrophytes. 
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INTRODUCTION 
Rheumatoid arthritis is a disease characterized by chronic inflammation of 
the joints. The disease causes cartilage degradation which results in the loss of joint 
function. An early event in the process of cartilage degradation is depletion of 
proteoglycans (PG) from articular cartilage. Interleukin 1 (IL-1) is an important 
mediator in this process. IL-1 is able to enhance PG degradation and to suppress 
PG synthesis (1-4). Moreover, studies in which IL-1 was neutralized during 
experimental arthritides demonstrated that IL-1 is directly involved in the inhibition 
of articular cartilage PG synthesis (4-7). 
Factors which are able to counteract the effects of IL-1 on chondrocyte 
metabolism or which are able to stimulate the replenishment of proteoglycans in the 
depleted matrix could be of significant therapeutic value. In this respect bone 
morphogenetic proteins (BMPs) seem promising. BMPs belong to the transforming 
growth factor ß (TGF-ß) superfamily (8,9). This superfamily consist of dimeric 
molecules, each of which contains 7 conserved cysteine residues (10). The proteins 
signal by serine/threonine kinases (8,11). One of the members of the BMP family 
with potential therapeutic value is bone morphogenetic protein-2 (BMP-2). BMP-2 
has been demonstrated to be a potent stimulator of chondrocyte metabolism and 
differentiation (12-15). BMP-2 is a potent stimulator of PG synthesis of articular 
cartilage expiants in vitro (12) but until now no in vivo data about the effects of 
BMP-2 on articular cartilage PG synthesis have been available. Neither have any 
data been published about the ability of BMP-2 to counteract the effects of IL-1 on 
articular cartilage. We therefore studied the effect of BMP-2 on murine articular 
cartilage PG synthesis in vivo and investigated the ability of BMP-2 to counteract 
the effects of IL-1 on articular cartilage PG synthesis and content. 
MATERIALS AND METHODS 
Animals 
Male C57B1/6 mice between 8 and 12 weeks of age were used. They were 
fed a standard diet and tap water ad libitum. 
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Growth factors and cytokines 
Recombinant murine IL-la (0.48 mg/ml in PBS pH 7.4) and recombinant 
human TGF-ßl (0.1 mg/ml in 20 mM NaOAc pH 5.0) were kindly provided by 
respectively Pfizer Central Research (Groton, CT, USA) and Genentech Ine (South 
San Francisco, CA, USA). Recombinant human BMP-2 (2.27 mg/ml in 0.5M 
Arginine, 10 mM Histidine pH 6.5) was supplied by Genetics Institute Ine 
(Cambridge, MA, USA). To prevent loss of protein due to adherence to plastic 
only siliconized tubes and tips were used. 
Intra-articular injections 
To study the effect of BMP-2 on articular cartilage PG synthesis in vivo 6 μ\ 
physiological saline + 0.1 % bovine serum albumin including rhBMP-2 (2-1000 
ng) was injected into the joint cavity of the right knee. The ability of BMP-2 to 
counteract the effects of IL-1 on articular cartilage PG synthesis and content was 
studied by injecting IL-la (10 ng), either alone or in the presence of BMP-2 (200-
1000 ng). The dose of 10 ng IL-la has been demonstrated to suppress articular 
cartilage PG synthesis after a single injection and to induce significant PG depletion 
in multiple injection protocols (2). One single injection or 3 injections were given 
on alternate days. Since we have previously demonstrated that TGF-ßl is able to 
counteract the effects of IL-1 on articular cartilage PG synthesis and content 
(16,17) we used coinjections of IL-la (10 ng) and TGF-ßl (200 ng) as positive 
controls. 
Histology 
Whole knee joints were dissected and fixed for 7 days in phosphate-buffered 
formalin. The fixed knee joints were decalcified (5 % formic acid) and dehydrated 
by an automated tissue processing apparatus (VIP, Miles Scientific, Naperville, IL, 
USA). After embedding in paraffin wax semiserial frontal knee sections (6 μπι) 
were prepared and mounted on gelatin-coated slides. Paraffin was removed by 
xylol and ethanol and sections were stained with safranin О and fast green (18). 
Safranin О staining, a semiquantitative marker of PG depletion, was measured 
using an automated image analysis system (VIDAS, Kontron Electronics, Munich, 
Germany) (19). Fast green staining was neutralized by use of a green filter. Optical 
density was examined in the noncalcified cartilage of the patella. Measurements 
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were corrected for chondrocyte lacunae. Staining values were corrected for 
background staining as measured in PG-depleted patellar cartilage in which red 
stain was no longer visible. PG depletion was induced by intra-articular injection of 
papain (19). Each experimental group contained at least 8 knee joints, of which 3 
semiserial sections were analyzed. 
Autoradiographic analysis of 35S-sulfate incorporation was performed as 
described (18). Radiolabeled sulfate (75 ¿iCi) was injected intraperitoneally 6 hours 
before dissection of the knee joints. After histologic processing, 6 μπι sections 
were prepared and mounted on gelatin coated slides. These were dipped in K5 
emulsion (Illford Basildon, Essex, UK) and exposed for 3 or 5 weeks. After this 
period the slides were developed and stained with hematoxylin and eosin. 
Determination of patellar cartilage proteoglycan synthesis 
Proteoglycan synthesis was measured ex vivo according to the method of 
van den Berg et al (20). Whole patellae were dissected from the knee joints and 
pulse-labeled (3 hours at 37 °C) with 35S-sulfate (30 μΟί/πύ). Subsequently, they 
were washed, fixed in ethanol and decalcified in formic acid. After decalcification 
of the patellae, the entire cartilage was stripped off, and a 0.2 mm2 round section 
was punched out of the center (central part) remaining the peripheral part (21). The 
central and peripheral areas of the patellar cartilage were dissolved and 35S-
incorporation was counted by liquid scintillation counting. Each experimental group 
contained at least 6 patellae. 
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RESULTS 
Effect of BMP-2 on articular cartilage PG synthesis in vivo 
Intra-articular injection of BMP-2 (2-1000 ng) resulted in stimulation of 
patellar cartilage PG synthesis which was maximal 2 days after injection. The 
effect of BMP-2 on PG synthesis was dose dependent with a maximum stimulation 
of 250% at a dosage ^ 200 ng (data not shown). To investigate whether BMP-2 
has differential effects on PG synthesis in the central and peripheral areas of the 
patella, PG synthesis of both areas was measured separately. BMP-2 stimulated 
patellar cartilage PG synthesis by both the central and peripheral areas equally 
(Figure 1A). On day 2 after intra-articular injection of TGF-ßl (200 ng) no 
significant effect on articular cartilage PG synthesis was noted (Figure 1A). 
Absence of counteraction by BMP-2 of IL-la-induced PG synthesis inhibition 
Since BMP-2 appeared to be a potent stimulator of patellar cartilage PG 
synthesis we evaluated whether BMP-2 was able to counteract the suppressive 
effect of IL-1 on cartilage PG synthesis. IL-la (10 ng) was injected into murine 
knee joints in the presence or absence of 200 ng BMP-2. Two days after intra-
articular injection of li-Ια, total patellar PG synthesis was -40% lower than in 
controls. Suppression of PG synthesis by IL-la alone was higher in the central part 
(69 ± 20%) than in the peripheral part (16 ± 33%) (Figure IB). Simultaneous 
injection of 10 ng IL-la and 200 ng BMP-2 resulted in suppression of PG 
synthesis to a degree similar to that induced by IL-la alone (Figure IB). 
Coinjection with higher concentrations of BMP-2 (up to 1 μg) had no effect on IL-
la-induced suppression (data not shown). These results demonstrate that although 
BMP-2 is a potent stimulator of articular cartilage PG synthesis, it is unable to 
counteract the inhibition of articular cartilage PG synthesis induced by IL-la. 
Moreover, these results also indicate that the effects of BMP-2 on cartilage PG 
synthesis are blocked when chondrocyte metabolism is affected by IL-la. In 
parallel with BMP-2, coinjection with TGF-ßl (200 ng) demonstrated no effect on 
IL-la-induced suppression of PG synthesis on day 2 after injection (Figure IB). 
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Figure 1 Patellar cartilage synthesis of 
proteoglycans in untreated knees (solid 
bars) and in knees on day 2 after a single 
intra-articular injection of vehicle 
(horizontal-striped bars), BMP-2 (200 
ng) (hatched bars) or TGF-ßl (200 
ng) (vertical striped bars) without (A) or 
with (B) co-injection of 10 ng IL-la. 35S-
sulfate incorporation (mean ± SD 
percentage of incorporation in untreated 
knees; η=6) was measured using an ex-
vivo pulse-labeling of isolated patellae with 
35S-sulfate. 35S-sulfate incorporation by 
central and peripheral areas of untreated 
knees was comparable (400-700 cpm). 
" P< 0.05 versus vehicle-injected knees, by 
Student's t-test. (Note: y-axis scales differ 
in A and B) 
central peripheral 
Effect of long-term BMP-2 exposure on IL-la-induced inhibition of PG synthesis 
In previous studies, we showed that long-term exposure of articular cartilage 
to TGF-ßl resulted in stimulation of articular cartilage PG synthesis while short-
term exposure had no effect on PG synthesis (22). We sought to determine whether 
long-term, rather than short-term, exposure of cartilage to BMP-2 could counter 
IL-la-induced suppression of PG synthesis. We therefore gave 3 coinjections at 
alternate days. BMP-2 (200 ng) and TGF-ßl (200 ng) stimulated articular cartilage 
PG synthesis in both the central and peripheral part of patellar cartilage (Figure 
2A). Coinjections of IL-la (10 ng) and BMP-2 (200 ng) resulted in a strong 
suppression (± 60%) PG synthesis in the central part of the patella which was not 
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significantly different from the synthesis after 3 injections with IL-la alone (Figure 
2B). This indicates that long-term exposure of cartilage to BMP-2 is also not able 
to counteract the effects of IL-la. 
In contrast to the central region, PG synthesis in the peripheral part in mice 
injected with IL-la alone was not different from that of the controls. Knee joints 
injected with IL-la (10 ng) and BMP-2 (200 ng) showed a significant stimulation 
of PG synthesis in the peripheral part of the patella. In contrast to BMP-2, 
injections of TGF-ßl (200 ng) in the presence of IL-la (10 ng) resulted in 
stimulation of PG synthesis in both the central and peripheral regions of the patellar 
cartilage (Figure 2B) demonstrating that TGF-ßl is able to counteract IL-la-
induced suppression of articular cartilage PG synthesis after long-term exposure. 
sulfate incorporation 
250 % 
central peripheral 
sulfate incorporation 
200 · 
150 
100 
Figure 2 Patellar cartilage synthesis of 
proteoglycans in untreated knees (solid 
bars) and in knees on day 2 after a single 
intra-articular injection of vehicle 
(horizontal-striped bars), BMP-2 (200 
ng) (hatched bars) or TGF-ßl (200 
ng) (vertical striped bars) without (A) or 
with (B) co-injection of 10 ng IL-la. 35S-
sulfate incorporation was measured as 
described in Figure 1, and expressed as the 
mean ± SD percentage of incorporation of 
untreated knees (n=6). isS-sulfate 
incorporation by central and peripheral 
areas of untreated knees was comparable 
(400-700 cpm). " P< 0.05 versus vehicle-
injected knees and #=P< 0.05 versus IL-
la-injected knees, by Student's t-test. 
(Note: y-axis scales differ in A and B) 
central peripheral 
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Autoradiographic analysis of local effects of BMP-2 on PG synthesis 
To investigate the effects of BMP-2 on chondrocytes from various sites of 
the joint, PG synthesis was studied by autoradiography on histologic sections. 
Figure 3 shows autoradiographs of the central regions of the patellar cartilage and 
the facing femoral cartilage 1 day after 3 injections. BMP-2 (200 ng) stimulated PG 
synthesis in femoral cartilage to a similar extent as in patellar cartilage and 
homogeneously throughout the articular cartilage (Figure 3B). Injections of IL-la 
(10 ng) resulted in a suppression of PG synthesis in both patellar and femoral 
cartilage (Figure 3D). Coinjections of IL-la (10 ng) and BMP-2 (200 ng) 
suppressed PG synthesis in patellar and femoral cartilage to a similar extent as 
injections of IL-la alone (Figure 3E), demonstrating that BMP-2 did not counteract 
the IL-Ια-induced inhibition of PG synthesis in either patellar or the femoral 
cartilage. In contrast, coinjections of IL-la (10 ng) and TGF-ßl (200 ng) resulted 
in stimulation of PG synthesis in both the patellar and femoral cartilage (Figure 3F) 
as compared with injections of IL-la alone (Figure 3D). Similar effects were 
demonstrated in the femorotibial joint (not shown). 
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Figure 3 Autoradiographs showing "S-sulfate incorporation in the central regions of patellar and 
femoral cartilage on day 1 after three intra-articular injections of A, vehicle, В, BMP-2 (200 ng), 
C, TGF-ßl (200 ng) D, ¡L-la (10 ng) E, IL-la (10 ng) + BMP-2 (200 ng) and F, IL-la (10 ng) 
+ TGF-ßl (200 ng). "S-sulfate was injected intraperitoneally 6 hours before dissection of the knee 
joints. After histologic processing autoradiography was performed. (Original magninification X 
200). P=patella; F=femur 
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Effect of BMP-2 on IL-la-induced PG depletion 
Changes in patellar cartilage PG content were measured after triple 
injections with IL-la alone or in combination with BMP-2 or TGF-ßl. The PG 
content of articular cartilage is reflected in the intensity of safranin О staining on 
histologic sections. As shown in Table 1 significant loss of safranin О staining was 
noted on day 1 and day 4 after 3 injections of 10 ng li-Ια. Injections with IL-la 
(10 ng) in the presence of 200 ng BMP-2 demonstrated that BMP-2 neither affected 
patellar cartilage PG content on day 1 or day 4. Coinjections of IL-la (10 ng) and 
TGF-ßl (200 ng) resulted in an initial depletion of PGs (day 1 after 3 injections) 
that was indistinguishable from depletion induced by IL-la alone. However, 4 days 
after the last injection patellar cartilage safranin О staining was significantly more 
intense in joints that had been injected with both IL-la and TGF ßl than in those 
injected with IL-la alone. These results demonstrate that BMP-2 does not modify 
IL-la-induced PG depletion and, in contrast to TGF-ßl, is not able to accelerate 
the replenishment of PG in the depleted matrix. 
Table 1 Safranin О staining on histologic sections of patellar cartilage on day 1 or day 4 after 
triple intra-articular injection^ 
injected substance 
vehicle 
IL-la (10 ng) 
IL-la (10 ng)/BMP-2 (200 ng) 
IL-la (10 ng)/TGF-/3 1 (200 ng) 
day 1 
100 ± 12 
69 ± 12" 
71 ± 12* 
67 ± 14* 
% staining intensity 
day 4 
100 ± 16 
76 ± 11" 
77 ± 22" 
107 ± 21+ 
'Whole knee joints were dissected 1 or 4 days after triple intra-articular injections. Histologic 
sections were stained with safranin О and quantified using an automated image analyzer. Values 
were corrected for background staining, as measured in completely depleted patellar cartilage. 
Each group contains at least 8 knee joints of which 3 histologic sections were analyzed. 
'P<0.05 versus vehicle-injected knee joints, by Student's t-test. 
Ψ<0.05 versus ¡L-Ια-injected knee joints, by Student's t-test. 
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Induction of chondrophytes by BMP-2 
Histologic sections of knee joints demonstrated that intra-articular injection 
of BMP-2 (200 ng) resulted in the formation of new chondroid tissues (Figure 4B). 
These chondrophytes were predominately localized in the patellofemoral area. 
Chondrophytes were also induced after coinjections of IL-la (10 ng) and BMP-2 
(200 ng)(Figure 4D). This indicates that although IL-la blocks the effects of BMP-
2 on articular cartilage PG synthesis, it does not block the induction of 
chondrophytes by BMP-2. 
Figure 4 Histologic features of knee joint sections stained with safranin О showing the induction 
of chondrophytes by BMP-2 either in the absence or presence of IL-1. Whole knee joints were 
dissected 1 day after triple intra-articular injections of A, vehicle, B, BMP-2 (200 ng), C, TGF-ßl 
(200 ng) D, IL-la (10 ng) E, IL-la (10 ng) + BMP-2 (200 ng) and F, IL-la (10 ng) + TGF-ßl 
(200 ng). (Original magnification X 100). P=patella; F=femur; arrows show chondrophytes. 
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DISCUSSION 
Factors that are able to counteract the deleterious effects of IL-1 on articular 
cartilage PG synthesis and content or that have the potential to accelerate the 
replenishment of proteoglycans in depleted cartilage can be expected to be of 
significant therapeutic value. Because BMP-2 has been demonstrated to be a potent 
regulator of chondrocyte metabolism and differentiation (12-15), we studied the 
ability of BMP-2 to stimulate articular cartilage PG synthesis and to counteract the 
effects of IL-1 on articular cartilage PG synthesis and content in vivo. 
This is the first study in which the in vivo effects of BMP-2 on articular 
cartilage PG synthesis are described. BMP-2 appeared to be a potent stimulator of 
articular cartilage PG synthesis in vivo. PG synthesis was stimulated 
homogeneously throughout articular cartilage. In vitro, members of the BMP 
family like BMP-2, BMP-3, BMP-4 and BMP-7 have been demonstrated to 
stimulate articular chondrocyte PG synthesis (12,23,24) but until now there were 
no in vivo data. Also the BMP-2 related factor TGF-ßl was, as we described 
before (16,22,25), a potent stimulator of articular cartilage PG synthesis in vivo. 
Interestingly, the effect of BMP-2 and TGF-ßl on PG synthesis shows different 
kinetics. For instance, 1 and 2 days after intra-articular injection of BMP-2 
articular cartilage PG synthesis was significantly stimulated whereas injection of 
TGF-ßl did not significantly affect PG synthesis before the third day after 
injection. The difference in kinetics between BMP-2 and TGF-ßl indicates that in 
vivo chondrocytes respond immediately to BMP-2 but the TGF-ßl responses are 
dependent on a second mediator or on changes in chondrocyte reactivity to TGF-ßl 
induced by the injected TGF-ßl itself. 
Although BMP-2 stimulated articular cartilage PG synthesis in vivo, it was 
unable to counteract the suppression of articular cartilage PG synthesis which was 
induced by 10 ng of IL-la. No significant effect of BMP-2 could be demonstrated 
in cartilage showing IL-1-induced inhibition of PG synthesis. However, it cannot 
presently be completely excluded that BMP-2 is able to counteract the effects of 
lower concentrations of IL-la. Other members of the BMP family have been 
reported to inhibit IL-1-induced suppression of articular cartilage PG synthesis in 
vitro. For example, BMP-7 counteracted the effect of IL-la on chondrocyte PG 
synthesis in bovine cartilage expiants (24). However, no data on the in vivo effects 
of BMPs on IL-1-induced suppression of articular cartilage PG synthesis have been 
published until now. 
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The lack of change in articular chondrocyte PG synthesis by BMP-2 in the 
presence of IL-la indicates that the effect of BMP-2 on articular cartilage PG 
synthesis is blocked when chondrocyte metabolism is affected by IL-la. The 
mechanism of IL-1-induced BMP-2 nonresponsiveness is presently unclear at this 
moment. Downregulation of BMP-2 receptors or blocking of intracellular signaling 
pathways by IL-1 are 2 possibilities. In contrast to BMP-2, TGF-ßl was able to 
counteract IL-1-induced suppression of articular cartilage PG synthesis, indicating 
that chondrocytes that are affected by IL-la still have the capability to react to 
TGF-ß. These results indicate that IL-la obstructs the BMP-2, but not the TGF-/31 
signaling pathway in articular chondrocytes. 
Members of the BMP family seem to have, at least in vitro, the potential to 
inhibit the synthesis of PG degrading enzymes and to inhibit PG breakdown itself. 
BMP-7 suppressed IL-1-induced up-regulation of collagenase (MMP-1) mRNA and 
stromelysin (MMP-3) mRNA and counteracted the IL-1-induced inhibition of their 
natural inhibitor (TIMP) (26). BMP-3 and BMP-4 have been shown to inhibit PG 
degradation in cartilage expiants cultured in vitro (23). We therefore examined the 
effects of BMP-2 on IL-Ια-induced PG depletion in articular cartilage. Safranin О 
staining of patellar cartilage on histologic sections demonstrated that BMP-2 did not 
affect IL-la-induced PG depletion. Although TGF-ßl appears to be an inhibitor of 
the catabolic effects of IL-1 on articular cartilage in vitro (27-29), it was unable to 
inhibit IL-1-induced PG depletion in vivo. The discrepancy between in vitro and in 
vivo findings could be attributed to mediators produced by synovial cells or by 
inflammatory cells which are attracted to the joint by co-injections of TGF-ßl and 
IL-1 (16). 
The ability of BMP-2 to accelerate the replenishment of PGs in IL-la-
depleted cartilage was studied by measuring safranin О staining intensity on day 4 
after 3 injections with IL-la. We demonstrated that BMP-2 did not enhance 
restoration of PG content in IL-Ια-depleted matrix at this point of time. In contrast 
to BMP-2, TGF-ßl clearly stimulated repair in the depleted matrix. The different 
effects of BMP-2 and TGF-ßl on the replenishment of PGs in the depleted matrix 
can be explained by the different abilities of BMP-2 and TGF-ßl to counteract the 
IL-1-induced suppression of articular cartilage PG synthesis. 
Intra-articular injections of BMP-2 resulted in the formation of new 
chondroid tissue especially in the patellofemoral area. As we demonstrated 
previously, intra-articular injections of TGF-ßl also induced chondrophytes (22). 
Interestingly BMP-2-induced chondrophytes are quite different from TGF-ß 1-
induced chondrophytes (unpublished observation). The ability of BMP-2 to induce 
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the formation of new cartilage and bone has been demonstrated before by the rat 
ectopic bone formation assay (9,30,31). Other members of the BMP family such as 
BMP-3, BMP-4, BMP-5 and BMP-7 are also able to induce new cartilage and bone 
in vivo (30-33). Although IL-la appeared to block the effects of BMP-2 on 
articular cartilage PG synthesis, the formation of chondrophytes was not inhibited 
by IL-la which demonstrates that IL-1 does not block all ВМР-2-mediated 
responses in the joint. 
In summary, this study demonstrates that BMP-2 is a potent stimulator of 
articular cartilage PG synthesis. However, when chondrocyte metabolism is 
affected by IL-la, the stimulatory effect of BMP-2 on PG synthesis is completely 
blocked. Because IL-1 is present in arthritic joints (34-37) our results indicate that 
BMP-2 alone cannot be used to stimulate cartilage repair during arthritis. Although 
BMP-2 appears to be unable to stimulate cartilage repair when IL-1 is present, 
BMP-2 might stimulate cartilage repair in the presence of IL-1 inhibitors such as 
IL-1 receptor antagonist (IRAP). In addition, BMP-2 could have the potential to 
stimulate cartilage repair in pathologic conditions, such as cartilage trauma, in 
which it is unlikely that IL-1 is involved. However, formation of chondrophytes 
might limit the therapeutic applications of BMP-2. 
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SUMMARY 
A severe consequence of rheumatoid arthritis is depletion of proteoglycans 
(PGs) from articular cartilage leading to functional impairment of this tissue. We 
investigated whether local administration of anabolic factors (TGF-/31, TGF-/32 and 
BMP-2) into joints could stimulate cartilage repair during arthritis. An unilateral 
arthritis was induced in mice by intra-articular injection of zymosan. Starting on 
day 4 after the induction of arthritis, three injections with 200 ng transforming 
growth factor β (TGF-/31) were given (days 4, 6 and 8). On day 11 articular 
cartilage PG synthesis was measured by 35S-sulfate incorporation and histologic 
knee joint sections were prepared which were used to analyze cartilage PG content 
by quantification of safranin О staining. Additionally, histologic sections were used 
to analyze inflammation and chondrophyte-formation. Local administration of TGF-
/31 did not modify inflammation but clearly stimulated PG synthesis and restored 
PG content of depleted cartilage. TGF-/32 appeared to be as potent as TGF-ßl in 
the stimulation of cartilage repair. Both TGF-/3 isoforms stimulated in addition to 
cartilage repair the formation of chondrophytes in this rodent model. In contrast to 
TGF-/3, 3 intra-articular injections with 200 ng bone morphogenetic protein 2 
(BMP-2) did not stimulate the repair process. In summary, this study demonstrates 
for the first time that local administration of TGF-/3 into arthritic joints stimulates 
the replenishment of PGs in depleted cartilage. 
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INTRODUCTION 
Rheumatoid arthritis is a disease which is characterized by inflammation of 
the joints. A severe consequence of the inflammation is degradation of articular 
cartilage of which depletion of proteoglycans (PGs) is an early event. PGs are 
highly negatively charged proteins which are responsible for the mechanical 
properties of articular cartilage. Depletion of proteoglycans is a result of a 
suppressed PG synthesis and an elevated PG degradation. Suppression of PG 
synthesis appears to be mediated by cytokines of which interleukin-1 (IL-1) has 
been demonstrated to be a key mediator (1-3). Degradation of PG seems to be the 
result of cytokine-induced upregulation and activation of matrix-degrading enzymes 
like metalloproteinases and the putative PG degrading enzyme aggrecanase (4-8). 
Articular cartilage has a limited capacity for self renewal. Anabolic factors 
which are able to increase PG synthesis and to decrease PG degradation might 
stimulate cartilage repair in arthritic joints. In this respect transforming growth 
factor β (TGF-/3) seems to be promising. TGF-/31 has been demonstrated to 
stimulate PG synthesis of articular chondrocytes in vitro and in vivo (9-11). In 
addition, TGF-/31 is able to counteract IL-1-induced suppression of cartilage PG 
synthesis (12,13) and has the capacity to reduce IL-1-induced PG depletion in vitro 
(12,14,15). The latter effect appears to be the result of TGF-0-induced down 
regulation of the synthesis of proteolytic enzymes and upregulation of the 
production of enzyme inhibitors (14,16-18). 
The purpose of this study was to investigate whether local administration of 
exogenous TGF-/31 stimulates articular cartilage repair in arthritic joints in which 
significant PG degradation has already occurred. In addition, the effects of TGF-/31 
were compared with the effects of two closely related growth factors: TGF-/32 and 
bone morphogenetic protein-2 (BMP-2). TGF-/32 is a TGF-jS-isoform that has a 
71% (amino acid) homology with TGF-/31 (19). Although TGF-/31 and TGF-/32 are 
quite homologous, their affinities to membrane TGF-/3 receptors are different, 
possibly giving rise to different modulating effects on PG depletion in arthritic 
joints (20-22). BMP-2 was used since this member of the TGF-/3 superfamily has 
been demonstrated to be a very potent stimulator of articular cartilage PG synthesis 
in vitro as well as in vivo (23,24). 
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MATERIALS AND METHODS 
Animals 
Male C57B1/6 mice between 8 and 12 weeks of age were used. They were 
fed a standard diet and tap water ad libitum. 
Growth factors 
Recombinant human TGF-ßl (0.1 mg/ml in 20 mM NaOAc pH 5.0) and 
recombinant human TGF-/32 (lmg/ml in 5% Acetic acid) were supplied by 
Genentech Ine (South San Francisco, USA) and Novartis Farma Ine (Basle, 
Switzerland) respectively. Recombinant human BMP-2 (2.27 mg/ml in 0.5M 
Arginine, 10 mM Histidine pH 6.5) was kindly provided by Elisabeth Morris 
(Genetics Institute Inc.Cambridge, USA). To prevent loss of protein due to 
adherence to plastic only siliconized tubes and tips were used. 
Induction of zymosan-induced arthritis 
To induce an unilateral arthritis in the right mouse knee joints zymosan was 
intra-articularly injected. A homogeneous suspension of zymosan A 
(Saccharomyces cerevisiae) was obtained after boiling twice and sonic 
emulsification of a suspension of 30 mg zymosan A in 1 ml endotoxin-free saline. 
Monoarticular arthritis was induced by injection of 6 μΐ of the suspension (180 ^g 
zymosan A) into the right knee joint. 
Injections of growth factors into arthritic knee joints 
Local administration of TGF-/31, TGF-/32 or BMP-2 into arthritic knee joints 
was carried out by intra-articular injections of 6 μΐ growth factor (20 and 200 ng) 
diluted in physiological saline + 0.1 % bovine serum albumin. Dose-response 
studies performed earlier in our laboratory demonstrated that intra-articular 
injection of 200 ng TGF-/31, TGF-/32 or BMP-2 is optimal for stimulation of 
patellar cartilage PG synthesis in mice (25). 
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Histology 
Whole knee joints were dissected and fixed for 7 days in phosphate-buffered 
formalin. The fixed knee joints were decalcified (5 % formic acid) and dehydrated 
by an automated tissue processing apparatus (VIP, Miles Scientific, Naperville, 
IL). After embedding in paraffin wax semiserial frontal knee sections (6 μΐη) were 
prepared and mounted on gelatin-coated slides. Paraffin was removed by xylol and 
ethanol whereafter sections were stained with safranin О and fast green (26). 
Safranin О staining, a semi-quantitative marker of PG depletion, was measured 
using an automated image analysis system (VIDAS, Kontron Electronics, Munich, 
Germany) (27). Fast green staining was neutralized by use of a green filter. Optical 
density was examined in the non-calcified cartilage of the patella. Measurements 
were corrected for chondrocyte lacunae. Staining values were corrected for 
background staining, as measured in PG-depleted patellar cartilage in which red 
stain was no longer visible. 
The histologic sections were also scored by blinded observers for synovitis and the 
presence of chondrophytes. For both parameters a scale from 0 (no 
synovitis/chondrophytes) to 3 (severe synovitis/chondrophyte-formation) was used. 
Chondrophytes were scored on three different locations: adjacent to the patella, 
nearby the cartilage border of the femur (in the patellofemoral area) and nearby the 
insertions of collateral ligaments on the femur. 
Determination of patellar cartilage proteoglycan synthesis 
Proteoglycan synthesis was measured ex vivo according to the method of 
van den Berg et al (28). Whole patellae were dissected from the knee joints and 
pulse-labeled (3 hours, 37 °C) with 35S-sulfate (30 pCi/ml). Subsequently they 
were washed, fixed in ethanol and decalcified in formic acid. After separation of 
the cartilage layer from the underlying bone the cartilage was dissolved in 
Lumasolve (Hicol, Oud-Beijerland, the Netherlands) and 35S-incorporation was 
counted by liquid scintillation counting. Each experimental group contained at least 
6 patellae. 
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RESULTS 
Intraarticular injection of zymosan inhibits cartilage PG synthesis and induces 
PG depletion 
Intra-articular injection of zymosan into murine knee joints resulted in 
arthritis characterized by pronounced influx of inflammatory cells in the synovium 
and joint cavity. Suppression of PG synthesis (— 45%) and loss of safranin О 
staining (~ 40%) were present on day 4 after induction of arthritis. PG synthesis 
inhibition at day 11 was variable between multiple experiments (range 0-70%) 
reflecting variation in the moment of waning of arthritis and normalization of 
chondrocyte function. However, significant PG depletion was always observed at 
this point of time. Injections of physiological saline plus 0.1% BSA on days 4, 6 
and 8 did not affect PG synthesis or safranin О staining as measured on day 11 
(data not shown). 
Local administration of TGF-ßl into arthritic knee joints stimulates articular 
cartilage PG synthesis 
We studied whether local adminstration of exogenous TGF-ßl into arthritic 
joints results in stimulation of cartilage PG synthesis. Three injections with 20 or 
200 ng TGF-ßl were given on days 4, 6 and 8 respectively. As can be seen in 
figure 1, on day 11 after arthritis induction patellar cartilage PG synthesis in joints 
which received 3 injections with TGF-ßl was clearly stimulated when compared to 
saline-injected joints. PG synthesis was even significantly higher in TGF ß-injected 
arthritic joints as compared to normal, untreated joints. A dose of 200 ng TGF ßl 
appeared to be more potent in stimulating PG synthesis than 20 ng. These results 
demonstrate that suppression of PG synthesis in arthritic joints can be abolished by 
local administration of TGF-ßl. 
Enhanced PG replenishment in depleted cartilage by local administration of TGF-ßl 
It was investigated if TGF ßl, in addition to stimulation of PG synthesis, could 
stimulate the replenishment of proteoglycans in depleted cartilage. Proteoglycan content 
was studied by analysis of safranin О staining of patellar cartilage on day 11 after 
induction of arthritis. Safranin О staining of patellar cartilage from arthritic, saline-
injected joints (controls), was significantly reduced compared to safranin О staining of 
patellar cartilage from normal, untreated joints (Figure,2). However, arthritic joints which 
TGF-/3 stimulates cartilage repair during established arthritis 97 
received 3 injections with 200 ng TGF-ßl demonstrated no significant loss of staining, 
compared to normal knees. Injections with 20 ng TGF-ßl showed also increased 
proteoglycan content but the effect was less pronounced with 20 as compared with 200 ng 
TGF-01 (Figure 2). Since pronounced loss ( — 40%) of safranin О staining was already 
present on day 4 these data show that injections of TGF-ßl in arthritic joints stimulate the 
replenishment of PGs in depleted cartilage (Figure 3). 
% sulfate incorporation Figure 1 Patellar cartilage synthesis of 
proteoglycans in arthritic joints after three 
intra-articular injections with vehicle, 20 
ng TGF-ßl or 200 ng TGF-ßl. 
Monoarticular arthritis was induced by 
injection of 180 μ-g zymosan into the right 
knee joint. Intra-articular injections were 
given on days 4, 6 and 8. On day 11, 35S-
sulfate incorporation (mean ± SD 
percentage of incorporation in untreated, 
left knees; n = 18) was measured after an ex 
vivo pulse-labeling of isolated patellae. * 
= P< 0.05 versus vehicle-injected knees, 
by Student's t-test. # = Ρ< 0.05 versus 
untreated, left knees, by Students's t-test. 
150 
100 
50 
% safranin О staining Figure 2 PG content as measured by 
safranin О staining of articular cartilage 
from arthritic joints after three intra­
articular injections with vehicle, 20 ng or 
200 ng TGF-ßl. Monoarticular arthritis 
was induced by injection of 180 μg 
zymosan into the right knee joint. Intra­
articular injections were given on days 4, 6 
and 8. On day 11, whole knee joints were 
dissected and histologic sections were 
prepared which were stained with safranin 
O. Staining was quantified using an 
automated image analyzer. Values (mean 
± SD percentage of staining in untreated, 
left knees) were corrected for background 
staining, as measured in completely 
depleted patellar cartilage. * = P< 0.05 
versus vehicle-injected knees, by Student's 
t-test (n=18). 
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Figure 3 Histology of arthritic knee joints showing restoration of articular cartilage safranin О 
staining and stimulaton of chondrophyte-formation after intra-articular injections with 200 ng 
TGF-ßl. Monoarticular arthritis was induced by injection of 180 ßg zymosan into the right knee 
joint. Intra-articular injections with vehicle or 200 ng TGF-ßl were given on days 4, 6 and 8. On 
day 4 and 11, whole knee joints were dissected. A, normal, untreated knee joint; B, arthritic knee 
joint before intra-articular injections (day 4). C, arthritic knee joint after 3 injections with vehicle 
(day 11). D, arthritic knee joint after 3 injections with 200 ng TGF-ßl (day 11). (Original 
magnification X100). Ρ = patella; F= femur; arrows indicate chondrophytes. 
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Stimulation of chondrophyte-formation by intra-articular injections of TGF-ßl 
To study if administration of TGF-0 modulates the inflammation and the 
formation of chondrophytes histologic sections were analyzed. As shown in table 1 
no significant differences in synovitis were observed between arthritic joints which 
received injections with physiological saline and joints which were injected with 
TGF-ßl. 
The zymosan-arthritis model we used shows moderate formation of 
chondrophytes in the knee joint on day 11 as can be seen in table 1. Analysis of the 
histologic sections clearly demonstrated that the development of these 
chondrophytes at different locations in the arthritic joints was stimulated by the 
injections of 200 ng TGF-/31 (Table 1, Figure 3). In contrast, injections with 20 ng 
TGF-ßl did not significantly enhance chondrophyte-formation on day 11. 
Table 1 Histologic analysis of the effect of 3 intra-articular injections of 20 ng or 200 ng TGF-ßl 
into arthritic knee joints on synovitis andchondrophyte-formation 
treatment 
saline 
20 ng TGF-01 
200 ng TGF-01 
synovitis 
2.0 ± 0.8 
1.9 ± 0.9 
2.4 ± 0.6 
A 
0.5 ± 0.4 
0.7 ± 0.4 
1.5 ± 0.5" 
Chondrophytes 
В 
0.1 ± 0.1 
0.1 ± 0.2 
0.8 ± 0.6" 
С 
0.6 ± 0.3 
0.9 ± 0.5 
1.5 ± 0.4" 
Monoarticular arthritis was induced by injection of ISO μ# zymosan into the right knee joint. 
Intra-articular injections were given on days 4, 6 and 8. Whole knee joints were dissected on day 
11. Histologic sections were scored by blinded observers for synovitis and the presence of 
chondrophytes. A scale from 0-3 was used. Chondrophytes were scored on three different 
locations: adjacent to the patella (A), nearby the cartilage border of the femur (in the 
patellofemoral area) (B) and at the insertions of collateral ligaments on the femur (C). * = P< 
0.05 versus vehicle-injected knees, by Wilcoxon's rank sum tests (n=16). 
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% sulfate incorporation 
150 
100 
50 
% safranin О staining 
В 
I 
* 
Π vehicle DU TGF-ßl 200 ng •TGF-ß2 200ng 
Figure 4 Synthesis of proteoglycans (A) 
and staining with safranin О (В) of patellar 
articular cartilage from arthritic joints 
receiving three intra-articular injections 
with vehicle, 200 ng TGF-ßl or 200 ng 
TGF-&2. Monoarticular arthritis was 
induced by injection of 180 μg zymosan 
into the right knee joint. Intra-articular 
injections were given on days 4, 6 and 8. 
On day 11, patellae and whole knee joints 
were dissected for 35S-sulfate incorporation 
and preparation of histologic sections. 
Values are expressed as mean ± SD 
percentage of values of untreated, left 
knees; η=8). * = P< 0.05 versus vehicle-
injected knees, by Student's t-test. 
TGF-ßl and TGF-ß2 are equally potent in the stimulation of cartilage repair 
To investigate whether the ability of TGF-ß to stimulate cartilage repair in 
arthritic joints is isoform-specific, the effects of TGF-ßl and TGF-B2 on PG 
synthesis and content were compared. As shown in figure 4 both TGF-ßl and 
TGF-B2 stimulated cartilage PG synthesis in arthritic joints. Significant differences 
between TGF-ßl and TGF-ß2 could not be demonstrated. No depletion of PG was 
observed in joints which were injected with TGF-/31 or TGF-/32, while PG 
depletion was clearly demonstrated in the physiological saline injected joints 
(Figure 4). This indicates that both TGF-/3 isoforms stimulate replenishment of PGs 
in depleted cartilage. Stimulation of chondrophyte-formation, which was observed 
after injections of TGF-/31, was also demonstrated after injections with TGF-/32 
(Table 2). 
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Table 2 Histologic analysis of the effect of 3 intra-articular injections of 200 ng TGF-ßl or 200 ng 
TGF-ß2 into arthritic knee joints on the formation of chondrophytes 
Chondrophytes 
treatment A B C 
saline 0.4 ± 0.4 0.1 ± 0.1 0.8 ± 0.2 
200 ng TGF-/31 1.7 ± 0.4* 0.6 ± 0.4' 1.7 ± 0.3" 
200 ng TGF-02 1.9 ± 0.6" 1.0 ± 0.5" 1.2 ± 0.3" 
Monoarticular arthritis was induced by injection of 180 μg zymosan A into the right knee joint. 
Intra-articular injections were given on days 4, 6 and 8. Whole knee joints were dissected on day 
11. Histologic sections were scored by blinded observers for the presence of chondrophytes. A 
scale from 0-3 was used. Chondrophytes were scored on three different locations: adjacent to the 
patella (A), nearby the cartilage border of the femur (in the patellofemoral area) (B) and at the 
insertions of collateral ligaments on the femur (C). * = P< 0.05 versus vehicle-injected knees, by 
Wilcoxon 's rank sum tests (n=8). 
TGF-ß is more potent than BMP-2 in the stimulation of cartilage repair in 
arthritic joints 
We have previously demonstrated that BMP-2 is a very potent stimulator of 
articular cartilage PG synthesis in vivo, therefore the ability of BMP-2 to stimulate 
cartilage repair in arthritic joints was studied. BMP-2 was, in contrast to TGF-01, 
unable to stimulate PG synthesis in arthritic joints (Figure 5A). Analysis of 
safranin О staining on histologic sections showed'similar loss of staining in vehicle-
injected and ВМР-2-injected joints. In contrast, çafranin О staining of TGF-/3-
injected joints was not different from normal, untreated joints (Figure 5B). These 
results show that local administration of BMP-2 into arthritic joints has, in contrast 
to local administration of TGF-/3, no effects on cartilage repair. 
A single injection of 200 ng TGF-ß2 into arthritic joints does not affect cartilage 
PG synthesis and content 
The observation of enhanced induction of chondrophytes by injection of TGF-/3 
into arthritic joints might limit potential therapeutic application of local TGF-j3 
administration. In an attempt to stimulate cartilage repair without the formation of 
chondrophytes we studied the effects of an alternative protocol of TGF-0 
administration. Studies of our group showed that a single injection of 200 ng TGF-
ß stimulated cartilage PG synthesis in normal joints for several weeks without the 
induction of chondrophytes (25). Therefore a protocol in which a single injection of 
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200 ng TGF-ß2 was given at day 3 or day 4 after the induction of arthritis was 
tested. However, administration of 200 ng TGF-B2 in arthritic joints using this 
protocol neither stimulated PG synthesis nor increased PG content (data not 
shown). 
% sulfate incorporation 
200 
150 
100 
SO 
% safranin О staining 
В 
Ï 
; < 
• vehicle G TGF-ßl 200 ng • BMP-2 200 ng 
Figure 5 Synthesis of proteoglycans (A) 
and staining with safranin О (В) of patellar 
articular cartilage from arthritic joints 
receiving three intra-articular injections 
with vehicle, 200 ng TGF-ßl or 200 ng 
BMP-2. Monoarticular arthritis was 
induced by injection of 180 μg zymosan 
into the right knee joint. Intra-articular 
injections were given on days 4, 6 and 8. 
On day 11, patellae and whole knee joints 
were dissected for "S-sulfate incorporation 
and preparation of histologic sections. 
Values are expressed as mean ± SD 
percentage of values of untreated, left 
knees; η=8). * = P< 0.05 versus vehicle-
injected knees, by Student's t-test. 
DISCUSSION 
We investigated whether local administration of exogenous TGF-ß into murine 
arthritic knee joints stimulates repair of PG-depleted articular cartilage. We 
demonstrated in this study that local administration of exogenous TGF-ß into the 
joints stimulates cartilage PG synthesis and enhances the replenishment of PG in 
the depleted matrix. No data about the presence of active TGF-ß in synovial fluid 
of murine arthritic knee joints are available but high concentrations of latent and 
active TGF-0 have been demonstrated in synovial fluids of human rheumatoid 
arthritis patients (29-32). However, although active TGF-ß might be present in 
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murine arthritic joints, local administration of exogenous TGF-ß into these joints 
results in profound effects on cartilage PG synthesis and content. 
In the zymosan-induced arthritis model used, it appeared that three injections of 
TGF-ß 1 abolished the suppression of cartilage PG synthesis and even stimulated 
PG synthesis to a supranormal level. In this model of experimental arthritis IL-1 
has been shown to be a key mediator in the suppression of PG synthesis (3). The 
ability of TGF-/3 to abolish suppression of cartilage PG synthesis during zymosan-
induced arthritis is in line with the ability of TGF-0 to counteract the effects of IL-
I on PG synthesis which has been demonstrated in vitro and in vivo by our group 
(12,13). The mechanism of this action is unclear but the abolishment of IL-1-
effects might be the result of TGF-0-induced down-regulation of IL-1 receptors 
(33,34) or suppression of nitric oxide (NO) synthesis (35,36), a factor involved in 
IL-1-induced suppression of PG synthesis (37,38). 
Zymosan-induced arthritis resulted in a significant depletion of PG from 
articular cartilage at day 4. No significant PG depletion was demonstrated on day 
II in joints which received three intra-articular injections of 200 ng TGF-/31 
starting at day 4, although a severe and similar inflammation was present in the 
control joints and TGF ß-injected joints. Because PG depletion was already 
demonstrated at day 4 after arthritis induction it can be concluded that injections of 
TGF-/31 stimulated replenishment of PG. Stimulation of PG replenishment in 
depleted cartilage by TGF-ß has been described before in vitro and in vivo 
(13,39,40) but this is the first report of replenishment of PG in depleted articular 
cartilage during persistent arthritis. It is likely that stimulation of PG synthesis by 
TGF-ß plays an important role in the enhanced replenishment of PG in depleted 
cartilage but also the concominant stimulation of the synthesis of hyaluronic acid by 
TGF-ß (10) might contribute to the repair process. Moreover, TGF-ß might 
enhance the retention of newly synthesized matrix molecules by increasing the 
expression of integrine on chondrocytes (41,42). 
It has been described that TGF-ß can differentially regulate the expression of 
aggrecan, biglycan and decorin. TGF-ß enhanced biglycan synthesis and decreased 
decorin synthesis in chondrocytes (43), fibroblasts (44,45) and osteosarcoma cells 
(45). In addition, in cultures of meniscal cells TGF-ß stimulated the expression of 
biglycan but did not affect the expression of decorin (46). However, after intra-
articular injection of TGF-ß into normal murine knee joints a consistent 
upregulation of aggrecan mRNA expression but not of biglycan and decorin 
mRNA expression could be demonstrated (25). In addition to differential regulation 
of PG expression by TGF-ß, it has been shown that TGF-ß affects the size and 
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degree of sulfation of PG glycosaminoglycan chains chains (10,44,47). Because of 
the differential regulation of PG expression and the effects of TGF-0 on 
glycosaminoglycan chains it would be of great interest to characterize the newly 
synthesized PGs in the TGF-/3-injected arthritic knee joints. However, due to the 
small size of mice and consequently limited amount of cartilage, it is almost 
impossible to characterize the nature of the newly synthesized PGs in vivo. 
In addition to the effects on matrix synthesis, local administration of TGF-ß 
might also enhance cartilage repair by suppression of PG degradation. TGF-/31 has 
been demonstrated to inhibit IL-1-induced matrix degradation (12,15) probably by 
downregulating the synthesis of matrix degrading enzymes (14,16,17) and 
upregulation of tissue inhibitor of metalloproteinases (TIMP) synthesis (16-18). 
TGF-ß-mediated upregulation of plasminogen activator inhibitor-1 (PAI-1) (48,49) 
might also play a role since plasmin has been suggested to be involved in cartilage 
degradation by direct cleavage of matrix molecules or by the activation of latent 
metalloproteases (50-52). 
Stimulation of cartilage repair in arthritic joints after local adminstration of 
TGF-ß appears mainly to be a direct effect of TGF-ß on chondrocyte metabolism 
since this treatment did not reduce inflammation. However, suppression of 
inflammatory cell activity by TGF-ß might also play a role. TGF-/3 has been 
demonstrated to suppress the release of reactive oxygen, nitrogen metabolites and 
cytokines by activated macrophages (53-55) and has been described to down-
regulate the expression of receptors for tumour necrosis factor-α (TNF-a) and IL-
1 on several types of cells (56,57). 
To study whether the TGF-/3-induced stimulation of cartilage repair is isoform-
specific the effects of TGF-/31 and TGF-/32 were compared. Both isoforms have 
been described to be equally potent in the suppression of IL-1-induced expression 
of metalloproteinases by articular chondrocytes in vitro (17,33) but seem to have 
different abilities to inhibit H202 release by activated macrophages (53) and to 
stimulate chondrogenesis in vivo (58). In our study we demonstrated that TGF-/32 
stimulated articular cartilage PG synthesis, replenishment of PG in depleted 
cartilage, and chondrophyte-formation to a similar extent as TGF-/31. However, 
additional dose-response studies are required for more detailed comparison of the 
relative potency of the two isoforms. 
BMP-2 is a very potent stimulator of articular cartilage PG synthesis in vitro 
(23) and in vivo (24,25). In addition, BMP-2 has been shown to accelerate healing 
of full-thickness cartilage defects in vivo (59). Therefore it was studied if local 
administration of BMP-2 could accelerate cartilage repair in arthritic joints. Intra-
TGF-0 stimulates cartilage repair during established arthritis 105 
articular injections of BMP-2 did not stimulate articular cartilage PG synthesis nor 
stimulated the replenishment of PG in depleted matrix. The disability of BMP-2 to 
stimulate cartilage PG synthesis in arthritic joints might be attributed to the 
presence of IL-1 in these joints. Recently we demonstrated in an in vivo study that 
chondrocytes were totally unresponsive to the stimulating effects of BMP-2 shortly 
after exposure to IL-1 (24). Local administration of TGF-/3 into arthritic joints 
was beneficial for cartilage without significant effects on inflammation. However, 
there are also studies suggesting a pathogenic role of TGF-ß during arthritis. Intra-
articular injection of TGF-0 into normal rat or murine knee joints has been 
described to induce influx of inflammatory cells and to induce synovial hyperplasia 
(13,60-62). In addition, intra-articular injection of TGF-/3 in mice immunized with 
collagen type II stimulated the onset of arthritis (63) and neutralization of TGF-/3 
just before induction of streptococcal cell wall (SCW)-induced arthritis in rats 
reduced acute and chronic arthritis (64). This indicates that endogenous TGF-/3 
could be proinflammatory in the early phase of arthritis but might protect against 
cartilage degradation and is able to stimulate repair in established arthritis. 
Although this study demonstrates that local administration of TGF-ß into 
arthritic knee joints stimulates cartilage repair, therapeutic application of this 
treatment might be limited by the formation of chondrophytes. The ability of TGF-
ß to induce chondrophytes in murine knee joints is in line with previous reports 
from our group (11,13). To reduce the formation of chondrophytes a lower TGF ß 
dose was used. No significant stimulation of chondrophyte-formation was observed 
after three injections of 20 ng TGF-/3 but this protocol was also less effective in 
stimulation of cartilage repair. In another protocol a single instead of three intra-
articular injections of 200 ng TGF-/3 were given. However, also this treatment 
failed to stimulate cartilage repair. The formation of chondrophytes and osteophytes 
is observed in many models of experimental arthritis in rodents but is hardly seen 
in human patients with rheumatoid arthritis. This might indicate that periosteum is 
less responsive to chondrophyte-inducing factors in human arthritic joints as 
compared with murine periosteum and that TGF-ß-induced formation of 
chondrophytes and osteophytes might be a minor problem in humans. This warrants 
testing in non-rodent animal models before clinical application in humans is an 
option. 
In summary, this study demonstrates that local administration of TGF-ß 1 into 
arthritic joints stimulates the replenishment of PG in depleted cartilage. The ability 
of TGF-ß 1 to stimulate cartilage repair in established arthritis was shared with 
TGF-ß2 but not with BMP-2. 
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ABSTRACT 
In earlier studies we have shown that intra-articular injections of 
transforming growth factor beta (TGF-ß) stimulated murine articular cartilage 
proteoglycan synthesis and increased proteoglycan content. Moreover, in these 
short-term experiments we also found formation of new cartilage-like tissues at the 
margins of articular cartilage. In the present study we investigated the long-term 
effects of intra-articular TGF-/3 injections. TGF-ß was injected once or repeatedly, 
whereafter articular cartilage proteoglycan synthesis and content were studied over 
a 2 months period. In addition, histologic sections of total knee joints were 
analyzed. Besides longterm elevation of proteoglycan synthesis and content in 
articular cartilage, no changes could be demonstrated in knee joints after a single 
injection of TGF-ß. In contrast, one month after triple TGF-ß injections lesions 
with severe proteoglycan depletion were found in deeper layers of the posterior 
part of the lateral tibia while the superficial layer of tibial cartilage still had an 
increased proteoglycan content. Additionally, multiple TGF-ß injections induced 
newly formed chondroid tissues along the margins of articular cartilage which were 
transformed into osteophytes via calcification of this tissue. Besides the induction of 
these osteophytes, TGF ß-induced chondroid tissue appeared in medial collateral 
ligaments. All these TGF-ß-induced changes resemble features of experimental and 
spontaneous osteoarthritis in mice, suggesting a role for TGF-ß in the pathogenesis 
of osteoarthritis. 
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INTRODUCTION 
In search for an anabolic agent for cartilage repair and regeneration, 
transforming growth factor beta (TGF-ß) has been considered a suitable candidate. 
TGF-ß is a multipotent regulator of cell growth and differentiation, and of 
extracellular matrix production. Three different isoforms have been found in 
mammalian species: TGF-ßl, -ß2, and -ß3. The mature TGF-beta's are all 25 kDa 
homodimers, with each monomer consisting of 112 amino acids containing 9 
cysteine residues. TGF-ß is normally secreted as an inactive high molecular weight 
complex which has to be dissociated before activation. High levels of active TGF-ß 
have been found in synovial fluids of rheumatoid arthritis and osteoarthritis (OA) 
patients (1,2), indicating that this factor is produced and activated during joint 
pathology. 
In earlier studies (3,4) we have shown that intra-articular injection of TGF-
ßl or TGF-ß2 stimulated articular cartilage proteoglycan synthesis during one 
week. Moreover, TGF-/3 counteracted suppression of proteoglycan synthesis by 
interleukin-1 (IL-1), and accelerated proteoglycan replenishment of depleted 
articular cartilage, suggesting that TGF-ß protects articular cartilage during 
pathology. However, administration of TGF-ß into murine knee joints also induced 
development of cartilage-like structures in periosteum, at sites where osteophytes 
develop in murine arthritis and osteoarthritis models, suggesting a role for TGF-ß 
in osteophyte formation during joint pathology. Because both osteophyte formation 
and enhanced articular cartilage proteoglycan synthesis are found not only after 
TGF-ß injections, but also in early experimental osteoarthritis (5,6), one might 
consider excessive TGF-ß levels as a causative factor in OA. In analogy, a similar 
role of TGF-ß has been emphasized in tissue fibrosis in kidney and liver diseases 
and excessive scar formation in skin healing, and has been termed the dark side of 
tissue repair (7,8). In the present study we investigated changes in cartilage and 
other joint structures, over a two-months period after single and repeated injections 
of TGF-ß into the murine knee joint. 
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MATERIALS AND METHODS 
Animals 
Male C57B1/10 mice aged 12 weeks or 18 months were used. They were fed 
a standard diet and tap water ad libitum. 
Intra-articular injections 
After anaesthetizing the mice with ether, 200 ng recombinant human TGF-
ßl (Genentech Inc., San Francisco, CA, USA.) dissolved in 6 μΐ of physiological 
saline (0.9% NaCl) + 0.1% ultrapure bovine serum albumin (Sigma, St Louis, 
MO, USA.) was injected into the joint cavity of the right knee once or three times 
at alternate days. To study whether the effects of triple TGF-0 injections can be 
augmented, additional injections of TGF-|8 were given in some experiments. 
Experimental osteoarthritis was induced by intra-articular injection of 10 units of 
highly purified collagenase (type VII, Clostridium histolyticum, Sigma, St Louis, 
MO, U.S.A) dissolved in 6 μΐ physiological saline (9,10). 
Determination of patellar cartilage proteoglycan synthesis 
Proteoglycan synthesis was measured ex vivo. Whole patellae, with a 
standard amount of surrounding tissue, were dissected from the knee joints. 
Patellae were then pulse-labeled (2 hours at 37°C) with 35S-sulfate. Subsequently, 
they were washed, fixed, decalcified, punched out of surrounding tissue, and 
dissolved as described before (11). The 35S-content of each patella, which is a 
reliable measure of patellar cartilage proteoglycan synthesis (12), was measured by 
liquid scintillation counting. 
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Determination of patellar cartilage proteoglycan content 
Articular cartilage proteoglycan content is reflected by safranine О staining 
intensity in histologic sections. This was measured, as described before (13), using 
an automated image analysis system (VIDAS, Kontron Elektronik GMBH). 
Microscopic images were recorded by a CDD video camera (Sony) and processed 
by a personal computer. Optical density was measured by integral measurement in 
a 20 μπι layer, along the cartilage surface. The total zone of non-calcified cartilage 
is approximately 30-40 μπι in width. Fast green staining was neutralized by use of 
a green filter. Measurements were corrected for lacunae. Proteoglycan content in 
articular cartilage of TGF-ß-injected joints was compared to the proteoglycan 
content in contralateral untreated joints. 
Histology 
Whole knee joints were dissected at different points of time after repeated 
intra-articular injection of 200 ng TGF-ß and processed as previously described 
(14). Semiserial frontal sections (6 μπι) were mounted on gelatin-coated slides and 
stained with hematoxylin/eosin or safranin O/fast green for examination of cells 
and cartilage matrix, respectively. In addition to TGF-ß-induced changes, we also 
studied histology of naturally occurring murine OA in joints of 18-months-old 
mice, and of experimentally induced OA in collagenase-injected mice. 
RNA isolation and RT-PCR 
Total RNA was isolated from patellar cartilage and synovial tissue by TRIzol 
extraction. RNA was directly extracted from cartilage but synovial tissue was first 
homogenized and then put in TRIzol reagent (Life Technologies). Cartilage and 
synovium of 5 mice were pooled. Before reverse transcription the isolated RNA 
was treated with DNAse I (Life Technologies). The reverse transcription reaction 
was performed with Moloney murine leukemia virus (M-MLV) reverse 
transcriptase (Life Technologies) using an oligo(Dt)15 primer (Eurogentec, Liege, 
Belgium). Amplification of DNA was accomplished by using Taq DNA polymerase 
(Life Technologies) up to a cycle number of 40. To determine the relative mRNA 
levels, 5 μΐ samples were taken at increasing cycle numbers. The PCR products 
were electrophorised in 1.6% agarose gels containing ethidium bromide. The cycle 
number at which the product was first detected on the gel was taken as a measure 
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for the amount of specific mRNA present in the originally isolated RNA. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA levels were used as 
an internal control. This method was validated by van Meurs et al. (15). All RT-
PCR reactions were performed in duplicate. The following primers were used in 
the amplification reactions. 
To detect GAPDH, the primers 5'-AACTCCCTCAAGATTGTCAGCA-3' (upper) 
and 5'-TCCACCACCCTGTTGCTGTA-3' were used (product 553 bp). Murine 
TGF-ßl primers were derived from Clontech (Palo Alto, CA, USA)(product 525 
bp), whereas murine TGF-B2 (product 489 bp) and -ß3 (product 380 bp) were used 
as described by Mulheron et al. (16). 
Statistical analysis 
Differences between groups were tested using the Student's T-test. 
Differences were considered significant if Ρ < 0.05. 
RESULTS 
Proteoglycan synthesis 
Intra-articular injection of 200 ng TGF-ß stimulated articular cartilage 
proteoglycan synthesis after a lag time of about two days. Maximum synthesis 
(>200%) was reached after 4 days. Even three weeks after a single injection, 
proteoglycan synthesis was still significantly increased (Figure 1A). Three 
injections of 200 ng TGF-/3 (given at alternate days) did not further increase or 
prolong stimulation of proteoglycan synthesis as compared with a single injection 
of 200 ng TGF-/3 (Figure IB). 
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% 35S-sulphate Incorporation 
250 
200 
150 
100 
5 10 15 20 25 
days after one TGF-B Injection 
Figure 1. Lang-lasting stimulation 
of proteoglycan synthesis in 
patellar cartilage after one 
injection with 200 ng TGF-ßl (A), 
or after three such injections at 
alternate days (B). Proteoglycan 
synthesis f'S-sulfate incorporation) 
is expressed as percentage of that 
in the contralateral, vehicle-
injected joints. The experiment was 
performed twice, with 6 patellae 
per experimental group at each 
point of time. Therefore the values 
represent the mean of 12 patellae. 
* =p<0.05 
% 35S-sulphate Incorporation 
250 
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days after last of three TGF-f» injections 
Proteoglycan content 
Densitometrie analysis of safranin О staining intensity in histologic sections 
showed that the proteoglycan content in the superficial layer of patellar articular 
cartilage had significantly increased one week after injection of 200 ng of TGF-ßl 
(Table 1). Stimulation of proteoglycan content was not further augmented when 
three injections of 200 ng TGF-/3, in stead of a single injection, were given. The 
increase in proteoglycan content after three injections, lasted for three weeks 
whereafter the content slowly normalized. 
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The increase of proteoglycan content was not only found in patellar articular 
cartilage but was also demonstrated in articular cartilage of the lateral tibia. In the 
tibia, an increase in proteoglycan content was still measured 8 weeks after the last 
of three TGF ß injections (Table 1). 
Table 1. Increase ofsqfranin О staining in superficial anicular cartilage after TGF-ß injections 
group 
3X vehicle 
IX TGF-0 
ЭХ TGF-ß 
3X TGF-0 
3X TGF-/3 
3X TGF-/3 
day» 
D7 
D7 
D7 
D21 
D28 
D56 
η
4 
8 
8 
12 
6 
12 
8 
patella 
increase (% of control) 
-11 ± 9 
19 ± 10" 
21 ± 6" 
11 ± 5 * 
15 + 11 
9 + 7 
η 
12 
8 
lateral tibia 
increase(%of control) 
18 ± 8* 
12 ± 6" 
Safranin О staining of articular cartilage in histologic sections was measured using an automated 
image analyser. The increase in staining intensity is expressed as percentage of the contralateral, 
non-injected control knee-joint. 
4
 number of joints measured: of each joint at least three sections were measured. 
Statistical significance of the TGF-ß- induced increase was tested using the Student's t-test. 
' p<0.05, "p < 0.01 s time after the last of three injections. 
Lesions in tibial cartilage 
Simultaneously with a supranormal proteoglycan content in the superficial 
layer, focal lesions with decreased safranin О staining developed deeper in the 
cartilage of the lateral tibia (Figure 2B). These lesions were found in an area just 
above the tidemark. Sometimes, the surface of the articular cartilage showed some 
roughening. In sections of several knee joints, a crack was found along the tide-
mark (Figure 2C). Interestingly, in early stages of natural murine OA, similar 
lesions were found. In later stages of murine OA noncalcified cartilage was lost 
appearing to have been teared of from the tidemark (Figure 2D). The TGF-/3-
induced lesions were already present one week after the last of three TGF-/3 
injections, but their size increased in time. Lesions were not found in early frontal 
sections of the knee, but emerged in later sections of the posterior part of the joint. 
In a small percentage of control joints some proteoglycan loss was found in the 
same area, but the extent of these spontaneous lesions was minimal. No lesions 
were ever found in patellar cartilage. To study whether additional administration of 
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TGF-j3 further augmented the formation of TGF-/3-induced lesions, experiments 
were performed in which 6 or 8 TGF-ß injections were given. However, the 
additional injections did not elevate the formation of TGF-/3-induced lesions. 
Figure 2. TGF-ß induced changes in lateral tibia. Safranin O/fast green stained frontal sections of 
murine knee joint. A) vehicle-injected control B) 7 days after the last of three TGF-ß-injections 
lesions with low proteoglycan content are present in the lateral tibia C) crack at the level of the 
tidemark in TGF-ß-injected animal with lesion D) for comparison, spontaneously occurring crack 
at the level of the tidemark in a 18 months old mouse. F= femur, M = meniscus, T= tibia, 
Original magnification: 200 χ 
Osteophytes 
Triple injections of 200 ng TGF-ß induced activation of periosteum at the 
margins of articular cartilage. At these locations cartilage-like, proteoglycan-
producing tissue developed (Figure 3B + C). These tissues, which are called 
chondrophytes, were not found after a single TGF-ß injection. One week after the 
last injection, the new tissues had reached their maximum size whereafter they 
calcified and developed into mature osteophytes, containing bone marrow spaces 
(Figure 3D). The periosteum remained responsive to TGF-ß, because two 
additional injections, given three weeks after the last of six injections, caused 
renewed development of cartilage-like tissue on the recently formed osteophytes 
(Figure 3E). 
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Figure 3. Osteophyte induction by TGF-ß. A) patella of vehicle-injected animal B+C) cartilage 
formation at the margins of articular cartilage of patella and femur, one week after third intra-
articular injection of 200 ng TGF-ß D) mature osteophytes, which do not bind safranin О any 
more and contain bone marrow spaces (one month after third injection) E) additional TGF-ß 
injections restimulate periosteum of mature osteophytes (2 extra injections were given 3 weeks after 
the last of 6 injections; tissue was dissected one week after the last injection). Stained with 
safranin O/fast green. F = femur, P= patella, Original magnification: A,В and E: lOOx, С and 
D:400x 
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Chondrogenesis in ligaments 
Striking consequences of triple TGF-ß injections were synovial hyperplasia 
and thickening of ligaments and tendons inside and bordering the injected joint. If 
the joints were injected 6 or even 8 times the effects of TGF-/3 on cartilage 
proteoglycan content, focal proteoglycan depletion, and osteophyte development 
were not further extended compared to triple injections. However, in 9 out of 18 
animals treated this way, safranin О staining indicated proteoglycan deposition in 
medial collateral ligaments. In addition, large rounded cells with lacunae and 
pericellular proteoglycans, presumably fibrochondrocytes, were found in these sites 
(Figure 4B). Interestingly, this phenomenon is also found in collateral ligaments of 
mice with collagenase-induced osteoarthritis (Figure 4C) and in collateral ligaments 
of mice with spontaneously occurring osteoarthritis. 
TGF-ß effects in old mice 
To study whether TGF-/3-induced chondrogenesis also occurs in old mice, 
intra-articular injections of TGF-/3 were given to 18-month-old mice. In these old 
mice, TGF-ß stimulated proteoglycan synthesis and induced the development of 
osteophytes. The effects were comparable to what was seen in young adults. This 
indicates that in old mice the chondrocytes and the cells of the periosteum still 
respond to TGF-ß. Moreover, TGF-ß injections appeared to induce development of 
cartilage-like tissue on already spontaneously formed bony structures (ossicles) in 
ligaments of 18-months-old animals with spontaneously occurring osteoarthritis 
(Figure 4D). These observations suggest that TGF-ß could be involved not only in 
induction, but also in outgrowth of such structures. 
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Figure 4. Effects of TGF-ß injections on medial collateral ligament. A) vehicle-injected joint B) 
cartilaginous tissue present in the ligament one month after 6 injections of TGF-ß С) for 
comparison, cartilaginous tissue present in medial collateral ligament of mouse with collagenase-
induced osteoarthritis. Stained with safranin O/fast green. D) TGF-ß-induced activation of the 
surface cells of bony structure (ossicle marked by arrows) in medial collateral ligament in 18-
months-old mouse with spontaneously occurring osteoarthritis; one week after third injection. 
F = femur, L = ligament, Τ = tibia. Original magnification: 100 x. 
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TGF-ß autoinduction 
Since TGF-ß has long-lasting effects on articular cartilage, we studied TGF-ß 
autoinduction in articular cartilage and neighbouring soft tissue. In patellar 
cartilage, mRNA levels of TGF-ß 1, -ß2, and -ß3 were not elevated on D2 and D8 
after three intra-articular injections with 200 ng TGF-ß 1. In contrast, TGF-ß 1, -ß2, 
and -ß3 mRNA levels were elevated in punches from neighbouring joint capsule on 
both points of time. In the TGF-ß 1-injected knee joints TGF-ßl, -ß2, and -ß3 
mRNA levels were elevated on both timepoints approximately 16-fold compared to 
control joints. 
DISCUSSION 
Previously, we have studied the short-term effects of intra-articular 
injections of TGF-/3 into murine knee joints. In these short-term studies, TGF-/3 
stimulated articular cartilage proteoglycan synthesis and proteoglycan content (3,4). 
In addition, TGF-/3 induced development of cartilage-like tissues. Because both 
osteophyte formation and enhanced cartilage proteoglycan synthesis are also found 
in early experimental osteoarthritis (5,6) we hypothesized that TGF-|8 might be a 
causative factor in OA. Therefore we studied the long-term effects of intra-articular 
TGF-ß injections on articular cartilage and other joint-tissues. 
Intra-articular injections of TGF-ß induced, after a lag time of about 2 days, 
longlasting stimulation of articular cartilage proteoglycan synthesis. This suggests 
changes in chondrocyte phenotype, induction of second mediators, and/or TGF-/3 
autoinduction (17,18). TGF-/3 mRNA induction was not detected in patellar 
cartilage, but strong and longlasting upregulation of mRNA of all three TGF-/3 
isotypes was observed in adjacent joint capsule specimens after intra-articular 
injections of TGF-jSl. This observation suggests that TGF-/3 induction in 
neighbouring soft connective tissue could be involved in the prolonged effect of 
TGF-/3 injections on chondrocyte metabolism. 
In addition to enhanced proteoglycan synthesis, the proteoglycan content in 
the superficial layer of articular cartilage was also significantly increased after 
TGF-/3 injections. However, focal proteoglycan loss occurred in an area just above 
the tidemark, especially in the posterior part of the lateral tibia. In control knees 
similar lesions were sometimes found at the same location but those were much 
smaller. Cracks at the level of the tidemark, which are found in some TGF-ß-
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injected joints, indicate that these regions are highly vulnerable to mechanical 
forces. Proteoglycan loss in the deeper part of articular cartilage after intra-
articular injections with TGF-/3 seems to be a general feature since it has also been 
reported to occur in rats (19). Interestingly, we found similar lesions in early 
stages of collagenase-induced osteoarthritis and in old mice. In late stages of both 
natural and experimental osteoarthritis, noncalcified cartilage was either present or 
had disappeared completely, suggesting that tearing off at the site of the lesions is a 
normal feature of murine OA. In the literature, similar lesions in early stages of 
experimental osteoarthritis in mice, leading to fissuring at later time points, have 
been described (10,20,21). Moreover, spontaneous development of clefts at the 
level of the lateral tibial tidemark in C57 black mice which are genetically predis-
posed to develop osteoarthritis is also reported (22). Since elevation of 
proteoglycan synthesis and the formation of clefts in articular cartilage are induced 
by TGF-/3 and these changes are also features of both natural and experimental 
osteoarthritis, a role for TGF-/3 in the induction of OA is suggested. 
As describe before (3, 23,24), TGF-ß injections in murine knee joints not 
only affected articular cartilage metabolism but also stimulated the periosteum, 
from which new cartilage developed. For development of these new structures 
multiple injections are needed since a single injection of TGF-0 stimulated articular 
cartilage proteoglycan synthesis without inducing the development of these 
structures. This indicates that chondrocytes are more vulnerable to TGF-ß than 
periosteal cells are. The early cartilage-like structures develop into osteophytes and 
fuse with the original bone later on. The osteophytes were found principally along 
the margins of articular cartilage and at insertion sites of ligaments. Since 
osteophytes in spontaneously occurring and experimental osteoarthritis (3,10) are 
located on similar locations as osteophytes induced by TGF-/3 we hypothesize that 
TGF-ß is involved in osteophyte-formation during murine osteoarthritis. 
Furthermore, thickening and the development of proteoglycan producing 
tissue was found in ligaments after 6 and 8 TGF-/3 injections which is in line with 
studies describing TGF-ß-induced proliferation and matrix synthesis by ligament 
fibroblasts (25,26). This proteoglycan-producing tissue could be the experimentally 
induced precursor of ossifications of ligaments found in spontaneously occurring 
osteoarthritis and is in line with the suggested role for TGF-ß in ossification of 
ligaments in humans (27). 
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We conclude that a single TGF-ß injection induces prolonged upregulation of 
articular cartilage proteoglycan synthesis and content, and could therefore be of 
therapeutic value. However, after multiple injections OA-like changes occur in 
cartilage and surrounding tissues. These latter observations suggest a pathogenic 
role for excessive local TGF-/3 production in osteoarthritis. 
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California) for the generous gift of recombinant human TGF-ß 1. 
REFERENCES 
1 Fava R, Olsen Ν, Keski Oja J, Moses H, Pincus Τ Active and latent forms of transforming 
growth factor beta activity in synovial effusions J Exp Med 169 291-296, 1989 
2 Schlaak JF, Pfers I, Zumbuschenfelde KHM, Markerhermann E Different cytokine profiles in the 
synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative 
spondylarthropathies Clin Exp Rheumatol 14 155-162, 1996 
3. van Beuningen HM, van der Kraan PM, Amtz OJ, van den Berg WB Transforming growth 
factor-beta 1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte 
formation in the murine knee joint Lab Invest 71 279-290, 1994 
4 van Beuningen HM, van der Kraan PM, Arntz OJ, van den Berg WB In vivo protection against 
interleukin-1 induced articular cartilage damage by transforming growth factor-beta 1 age-related 
differences Ann Rheum Dis 53 593-600, 1994 
5 Adams ME, Brandt KD Hypertrophic repair of canine articular cartilage in osteoarthritis after 
anterior cruciate ligament transection J Rheumatol 18 428-435, 1991 
6 Brandt KD, Myers SL, Burr D, Albrecht M Osteoarthntic changes in canine articular cartilage, 
subchondral bone, and synovium fifty-four months after transection of the anterior cruciate 
ligament Arthritis Rheum 34 1560-1570, 1991 
7 Border WA, Ruoslahti E Transforming growth factor-beta in disease the dark side of tissue 
repair J Clin Invest 90 1-7, 1992 
8 Shah M, Foreman DM, Ferguson MW Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous 
addition of TGF-beta 3 to cutaneous rat wounds reduces scarring J Cell Sci 108 985-1002, 1995 
9 van der Kraan PM, Vitters EL, van Beuningen HM, van de Putte LB, van den Berg WB 
Degenerative knee joint lesions in mice after a single intra-articular collagenase injection A new 
model of osteoarthritis J Exp Pathol Oxford 71 19-31, 1990 
10 van Osch GJVM, van der Kraan PM, Vitters EL, Blankevoort L, van den Berg WB Induction of 
osteoarthritis by ultra-articular injection of collagenase in mice Stram and sex related differences 
Osteoarthritis Cartilage 1 171-177, 1993 
11 van den Berg WB, Kruysen MWM, van de Putte LBA The mouse patella assay An easy method 
of quantitating articular cartilage chondrocyte function in vivo and in vitro Rheumatol Int 
1 165-169, 1982 
12 de Vries BJ, van den Berg WB, Vitters E, van de Putte LB Quantitation of glycosaminoglycan 
metabolism in anatomically intact articular cartilage of the mouse patella in vitro and ш vivo 
studies with 35S-sulfate, 3H-glucosamine, and ЗН-acetate Rheumatol Int 6 273-281, 1986 
126 CHAPTER 7 
13 van der Kraan PM, de Lange J, Vitters EL, van Beuningen HM, van Osch GJVM, van Lent 
PLEM, van den Berg WB Analysis of changes in proteoglycan content in murine articular cartilage 
using image analysis Osteoarthritis Cartilage 2 207-214, 1994 
14 van den Berg WB, Kruijsen MWM, van de Putte LBA, van Beusekom HJ, van der Sluis-van der 
Pol M, Zwarts WA Antigen-induced and zymosan-induced arthritis ш mice studies on in vivo 
cartilage proteoglycan synthesis and chondrocyte death Br J Exp Pathol 62 308-316, 1981 
15 van Meurs JBJ, van Lent PLEM, Joosten LAB, van der Kraan PM, van den Berg WB 
Quantification of mRNA levels in joint capsule and articular cartilage of the murine knee jomt by 
RT-PCR Kinetics of stromelysin and IL-1 mRNA levels during arthritis Rheum Int 16 197-205, 
1997 
16 Mulheron GW, Mulheron JG, Damelpour D, Schomberg DW Porcme granulosa cells do not 
express transforming growth factor-beta 2 (TGF-beta 2) messenger ribonucleic acid molecular 
basis for their inability to produce TGF-beta activity comparable to that of rat granulosa cells 
Endocrinology 131 2609-2614, 1992 
17 Vilhger PM, Lotz M Differential expression of TGF beta lsoforms by human articular 
chondrocytes in response to growth factors J Cell Physiol 151 318 325, 1992 
18 McCartney Francis N, Mizel D, Wong H, WAHL L, Wahl S TGF-beta regulates production of 
growth factors and TGF-beta by human peripheral blood monocytes Growth Factors 4 27-35, 
1990 
19 Hulth A, Johnell O, Miyazono K, Lmdberg L, Heinegard D, Heldin CH Effect of transforming 
growth factor-beta and platelet- derived growth factor-BB on articular cartilage in rats J Orthopaed 
Res 14 547-553, 1996 
20 Glasson SS, Trubetskoy OV, Harlan PM, Chavarna AE, Haïmes HB, Jimenzez PA Blotchy mice 
a model of osteoarthritis associated with a metabolic defect Osteoarthritis Cartilage 4 209-212, 
1996 
21 Visco DM, Orevillo CI, Kammermann J, Kincaid SA, Widmer WR, Christen AJ Progressive 
chronic osteoarthritis in a surgically induced model in mice Trans Orthop Res Soc 21 241, 1996 
22 Wilhelmi G, Maier R Beobachtungen über den einfluss von druckbelastung und bewegung auf die 
gelenke am modell arthrosedisponierter mause Akt Rheumatol 12 161-167, 1987 
23 Miura Y, Fitzsimmons JS, Commisso CN, Gallay SH, O'Dnscoll SW Enhancement of periosteal 
chondrogenesis in vitro Dose-response for transforming growth factor-beta 1 (TGF-beta 1) Clin 
Orthop 271-280, 1994 
24 Tamguchi Y, Tanaka T, Gotoh K, Satoh R, Inazu M Transforming growth factor beta 1-induced 
cellular heterogeneity in the periosteum of rat parietal bones Calcif Tissue Int 53 122-126, 1993 
25 Marui Τ, Niyibizi С, Georgescu HI, Cao M, Kavalkovich KW, Levine RE, Woo SL Effect of 
growth factors on matrix synthesis by ligament fibroblasts J Orthop Res 15 18-23, 1997 
26 Spindler KP, Imro AK, Mayes CE, Davidson JM Patellar tendon and anterior cruciate ligament 
have different mitogenic responses to platelet-derived growth factor and transforming growth factor 
beta J Orthopaed Res 14 542-546, 1996 
27 Kawaguchi H, Kurokawa T, Hoshmo Y, Kawahara H, Ogata E, Matsumoto Τ 
Immunohistochemical demonstration of bone morphogenetic protein-2 and transforming growth 
factor-beta m the ossification of the postenor longitudinal ligament of the cervical spine Spine 
17 S33-S36, 1992 
EXPRESSION OF RECOMBINANT HUMAN SOLUBLE TYPE II 
TRANSFORMING GROWTH FACTOR-0 RECEPTOR IN PICHIA PASTORIS 
AND ESCHERICHIA COLI: TWO POWERFUL SYSTEMS TO EXPRESS A 
POTENT INHIBITOR OF TRANSFORMING GROWTH FACTOR -β 
Наггіе L. Glansbeek, Henk M. van Beuningen, Elly L. Vitters, 
Peter M. van der Kraan and Wim В. van den Berg 
Department of Rheumatology, University Hospital Nijmegen, Nijmegen, the Netherlands 
Protein Expression and Purification. In Press 
128 CHAPTER 8 
ABSTRACT 
Transforming growth factor β (TGF-/3) is a potent regulator of cell metabolism, 
proliferation and differentiation. To study the role of endogenous TGF-/3 in processes 
such as tissue repair and inflammation, potent and specific inhibitors are required. 
Because the type II TGF-/3 receptor (TGF/3RII) has a high affinity for TGF-/3, the 
extracellular domain of TGF/3RII (TGF-/3sRII) was expressed in Pichia pastoris and 
Escherichia coli. Expression of the soluble TGF/3sRII using P. pastoris resulted in a 
soluble, heterogeneously glycosylated protein which was secreted into the medium. 
Although expression of TGFßsRII in E. coli resulted in the formation of insoluble 
inclusion bodies, solubilization and refolding resulted in a biologically active protein. 
Because in both systems a C-terminal 6XHis coding sequence was inserted behind the 
coding sequence for the extracellular domain of TGF/3RII the recombinant proteins could 
be purified by a powerful, single step procedure using a Ni-NTA agarose. The purified 
proteins appeared to be potent inhibitors of TGF-ßl and TGF-/33. In contrast, TGFßsRII 
was less effective in neutralization of TGF-/32. 
In conclusion, biologically active TGFßsRII can be produced using P. pastoris and 
E. coli expression systems. The ease of these expression systems, the powerful single step 
purification and low costs makes it possible to produce TGF/SsRII in large amounts to 
further elucidate the role of TGF-/31 and TGF-/33 in physiological processes like tissue 
repair and inflammation. 
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INTRODUCTION 
Transforming growth factor β (TGF-/3) is a potent regulator of metabolism, cell 
growth and differentiation (1). One of the physiological processes in which TGF-0 plays 
an important role is tissue repair. It has been shown that TGF-jS stimulates dermal wound 
healing (2,3), bone fracture healing (4) and cartilage repair (5-7). Although TGF-/3 has 
positive effects on tissue repair, overexpression of TGF-/3 might induce pathology. A role 
of TGF-/3 has been suggested in pathological processes such as intimai hyperplasia (8), 
glomerosclerosis (9-11), hepatic fibrosis (12), scarring during dermal wound healing 
(13,14) and articular cartilage lesions and osteophyte formation in joints (15-17). In 
addition to extracellular matrix production, TGF-/3 is also an important regulator of 
inflammation. Because TGF-/3 is a potent chemoattractant for monocytes, neutrophils and 
T-lymphocytes (18-20) it appears to be a proinflammatory factor. On the other hand, 
TGF-/3 has been shown to be immunosuppressive by inhibition of macrophage activity 
(21-23) and suppression of lymphocyte proliferation, differentiation and metabolism 
(24-28). 
To study the role of endogenous TGF-/3 during disease, potent TGF-/3 
inhibitors that can be produced in high levels are required. Because the type II TGF-/J 
receptor (TGF|8RII) has a high affinity for TGF-0 (29,30) we expressed the soluble, 
extracellular domain of the type Π TGF-/3 receptor (TGFßsRII). Pichia pastoris was used 
because this eukaryotic system has many of the advantages of higher eukaryotic 
expression systems such as protein processing, protein folding and posttranslational 
modifications but is more easy and cheaper to handle than other eukaryotic expression 
systems. Escherichia coli was used because of its high expression levels, ease of the 
system and low costs. 
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MATERIALS AND METHODS 
Construction of a yeast expression vector 
Vector H2-3FF containing the complete cDNA of human TGF/3RII (30)(kindly 
provided by H. Lin) was used as a template for PCR amplification of the coding sequence 
of the extracellular domain of TGF/8RII. PCR was performed using a high-fidelity DNA 
polymerase (Vent DNA polymerase, New England Biolabs, Beverly, MA, USA). The 5' 
primer used in the PCR was: 5'-AGACTCGAGAAAAGAGAGATCCCACCGCACGT 
TCAGAAG-3'. Using this primer a Xho I restriction site and a sequence coding for the 
cleavage signal of the Saccharomyces cerevisiae α-factor secretion signal peptide were 
introduced. The 3' primer was: 5'-GGAATTCAGTGATGGTGAATGGTGATGGTCAGG 
ATTGCTGGTGTTATATTCTTC-3'. By use of this primer a sequence coding for six 
consecutive histidine residues (6XHis tag) followed by a termination signal and an EcoW 
restriction site were introduced. The PCR fragment was ligated in pCR-Script1"1 SK(+) 
(Stratagene, la Jolla, CA, USA) whereafter the TGFjSsRII-coding fragment was isolated 
after digestion with EcoRl and Xho I. This fragment was subsequently ligated into 
EcoSllXho I digested expression vector pPic-9 (Invitrogen, San Diego, CA, USA). The 
constructed vector (pPic-9/RII) contains an open reading frame coding for the 
Saccharomyces cerevisiae α-factor secretion signal and the entire sequence of the extra­
cellular domain of TGF/3RII. The sequence was confirmed by dideoxy chain termination 
sequencing. 
Transformation of Pichia pastoris 
Pichia pastoris strain GS 115 was transformed using the spheroplast-method as 
described by Invitrogens protocols (Invitrogen Corporation, San Diego, CA, USA). 
Spheroplasts were incubated with Bgl II-linearized pPic-9/RII and transformants (His+) 
were selected by their ability to grow on media lacking L-histidine. Because Bgl Π 
digestion of pPic9/RII favors recombination at the alcohol oxidase gene AOX1, 
transformants were characterized for the presence of the AOX1 gene by the ability to 
grow on media with methanol as the only carbon source. 
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Expression of TGFßsRIl by Pichia pastoris 
Transformants were cultured at 30 °C in BMGY (1% yeast extract, 2% peptone, 
1.34% yeast nitrogen base, 4 χ IO"5 % biotin, 1% glycerol, 100 raM K-phosphate, 
рНб.О) until the turbidity at 600 nm reached >5. The cultures were centriraged and the 
cell pellets were resuspended in BMMY (1% yeast extract, 2% peptone, 1.34% yeast 
nitrogen base, 4 χ IO"5 % biotin, 0.5% methanol, 100 mM potassium phosphate, рНб.О) 
or BMM (1.34% yeast nitrogen base, 4 χ 10"5 % biotin, 0.5% methanol, 100 mM 
potassium phosphate, рНб.О) until the turbidity at 600 nm reached 60-100. By culturing 
the cells in BMMY or BMM medium recombinant protein expression is induced since 
methanol activates the AOX1 promotor which controls recombinant protein expression. 
The cultures were grown for 2 days at 30 °C. To ensure adequate aeration baffled flasks 
were used and cultures were vigorously shaken (300 rpm). Media were assayed by an 
enzyme-linked immunosorbant assay (ELISA) using a polyclonal antibody against the first 
28 N-terminal residues of human TGF/3RII (Upstate Biotechnology Incorporated, New 
York, NY, USA). 
Purification of TGFßsRIl expressed by Pichia pastoris 
The recombinant protein was purified by use of the 6XHis affinity tag that has a 
very high affinity to nickel-nitrilotriacetic acid (Ni-NTA; Qiagen Ine, Santa Ciarita, CA, 
USA). Culture-medium (80 ml) was diluted 5 times with H20 and pH was adjusted to 
7.8. To reduce nonspecific binding to Ni-NTA imidazole was added to a final 
concentration of 5 mM. The medium was then applied to a 4 ml Ni-NTA agarose column 
with a flow rate of 0.5 ml/min. Subsequently, wash buffer (50 mM Na-phosphate, 300 
mM NaCl, 10% glycerol, pH 6.0) was applied to the column and bound protein was 
eluted with 300 mM imidazole in wash buffer and collected in 1 ml fractions. The 
fractions were dialyzed against 50 mM Na-phosphate, 150 mM NaCl, pH 7.8 whereafter 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and isoelectric 
focusing (IEF) was performed. In addition, the neutralizing activity of the protein was 
determined using a bio-assay. 
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Deglycosylation of TGFßsRII 
Purified TGFjSsRII was dialyzed against deglycosylation buffer (50 mM EDTA, 
1% j3-mercaptoethanol, 1% n-octylglucoside, 0.2% SDS, 50 mM K-phosphate, pH 5.0) 
whereafter the sample was boiled to denaturate the protein. Endoglycosidase F/N-
glycosidase F (Boehringer Mannheim, Mannheim, Germany), was added (2 U/mg 
protein) and the sample was incubated overnight at 37 °C. Samples were analyzed by 
SDS-PAGE. 
Construction of bacterial expression vector 
Vector H2-3FF containing the complete cDNA of human TGF/3RII (30) (kindly 
provided by H. Lin) was used as an template for PCR. PCR was performed using a high-
fidelity DNA polymerase (Vent DNA polymerase, New England Biolabs, Beverly, MA, 
USA) and two oligonucleotides: 5'-ATCGGATCCCACGTTCAGAAGTCGGTTAAT-3' 
and 5'-GAAGATCTGTCAGGATTGCTGGTGTTATATTCTTCTGA-3'. The PCR 
product contained a sequence corresponding to 97% of the extracellular domain of 
TGF/3RII (aa3-aall4), an upstream ВатШ restriction-site and a downstream Bgl II 
restriction-site. The restriction-sites were used to introduce the fragment in the expression 
vector pQE-16 (Qiagen Ine, Santa Clarita, CA, USA). The resulting vector (pQE-16/RII) 
has an open reading frame coding for the extracellular domain of TGF/SRII with 3 
additional amino acids on the N-terminal site and a tag of six consecutive histidine 
residues (6XHis tag) on the C-terminus. The sequence of the open reading frame was 
confirmed by dideoxy chain termination sequencing. 
Expression of TGFßsRII in Escherichia coli 
E. coli strain M15[pREP4] (Qiagen Ine, Santa Clarita, CA, USA) was transformed 
with the vector pQE-16/RII and ampicillin resistant transformants were selected. For 
expression of the recombinant protein LB medium (10 g/1 bacto-tryptone, 5 g/1 yeast 
extract and 5 g/1 NaCl) containing 100 μg/ml ampicillin and 25 ^g/ml kanamycin was 
inoculated with a single colony. Bacteria were grown at 37 °C until the turbidity at 600 
nm reaches 0.7-0.9. Expression of the recombinant protein was induced by addition of 
isopropyl-]3-D-thiogalactopyranoside (IPTG) to a final concentration of 2 mM and the 
culture was grown for an additional 5 hours at 37 °C. Cells were harvested by 
centrifugation. 
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Purification and refolding of TGFßsRII expressed by E. coli 
Purification of the recombinant protein was performed using Ni-NTA resin (Qiagen 
Ine, Santa Ciarita, CA, USA) as this resin has a very high affinity to the C-terminal 
6XHis tag of the protein. A 50 ml culture cell pellet was solubilized in 20 ml 8M urea 
(8M urea; 0.1M NaH2P04, 0.01 M Tris, pH 8.0) whereafter the lysate was centrifugated 
(30 min, 12000xg, RT) and sonicated. Ni-NTA resin (4 ml) was added and after an 
incubation period of 1 hour at RT, the resin was collected by centrifugation (5 min, 
800xg, RT) and washed for 3 times with wash-buffer (8M urea, 50 mM Tris/HCl, pH 
8.0). Ni-NTA was resuspended in 10 ml wash-buffer and dialysed (o/n; 4 °C) against 1 
liter refolding-buffer (0.1 M urea, 50 mM Tris/HCl pH 8.0) containing a redox couple 
of reduced glutathione (2 mM) and oxidized glutathione (0.2 mM or 0.02 mM) in the 
presence or absence of 0.5 M L-arginine. After dialysis Ni-NTA agarose was gathered 
and the recombinant protein was eluted by addition of 5 ml dialysisbuffer + 300 mM 
imidazole. After an incubation period of 5 minutes at RT the suspension was centrifugated 
(5 min, 800xg, RT) and the supernatant was subsequently dialyzed against 50 mM Na-
phosphate, 150 mM NaCl, pH 7.8 (o/n, 4 °C) and analyzed by SDS-PAGE and IEF. In 
addition, the neutralizing activity was determined using a bio-assay. 
SDS-PAGE 
SDS-PAGE analysis was performed on 12 % Polyacrylamide gels under 
denaturating conditions. Gels were stained with Coomassie brilliant blue R250. A 10 kDa 
protein ladder (Life Technologies, Gaithersburg, MD, USA) was used as a molecular 
mass marker. 
Isoelectric focusing (IEF) 
PhastGels IEF 3-9 (Pharmacia, Uppsala, Sweden) were used for IEF analysis. 
Proteins were visualized by silver staining whereafter isoelectric point (pi) of the 
recombinant proteins was determined using IEF standards ranging from pi 4.5 - 9.6 (Bio-
Rad, Hercules, CA, USA). 
134 CHAPTER 8 
NOB-1/CTLL TGF-ß bioassay 
To examine the neutralizing activity of TGF-ßsRII we used a modified bioassay 
for interleukin-1 (IL-1) which was originally described by Gearing et al. (31). In this 
modified assay TGF-ß inhibits the IL-1-dependent production of IL-2 by NOB-1 cells. 
Synthesis of IL-2 was assayed by proliferation CTLL cells, present in the same culture 
well as the NOB-1 cells. In microtiter plates NOB cells (100 μ\ of 2.5 χ IO5 cells/ml) and 
CTLL cells (50μ1 of 8 χ IO4 cells/ml) were plated out in RPMI medium supplemented 
with 5% fetal calf serum. In addition, IL-1/3 (25 μΐ of 500 pg/ml) and sample (25 μΐ 
containing TGF-/3 with or without TGFßsRII) were added to each well. After a culture 
period of 20 hours in a humidified 5% C02 atmosphere 1 ^ Ci/ml 3H-thymidine (du Pont 
de Nemours, Den Bosch, the Netherlands) was added. After a further 4 hours incubation, 
the cells were harvested by an automated cell harvester and the incorporated radioactivity 
was quantified by liquid scintillation counting. Commercially available TGFßsRII 
(expressed in mouse myeloma NSO cells; R&D Systems Ine, Minneapolis, MN, USA) 
was used as a positive control for TGF-/3 neutralization. 
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RESULTS 
Expression of TGFßsRII by P. pastoris 
To express TGFßsRII, an expression vector was constructed with an open reading 
frame coding for the extra-cellular domain of TGF/3RII with an additional C-terminal a-
factor secretion signal and a N-terminal 6XHis tag. The 6XHis tag was introduced to ease 
purification and the α-factor secretion signal is needed for efficient secretion of the 
recombinant protein. The secreted protein will not contain the α-factor secretion signal 
as this signal is cleaved during secretion. 
After transformation of P. pastoris strain GS 115 both Muts (containing no AOX1 
gene) and Mut+ (containing AOX1 gene) transformants were identified. Expression of 
TGFßsRII was assayed by analysis of media. Using an ELISA, positive clones were 
identified showing that TGFßsRII was expressed and secreted in the medium. Both Muts 
and Mut+ clones were positive but the highest expression was found among Mutsclones. 
Maximal production of about 10 mg/1 was reached after two days culture. 
Purification of TGFßsRII produced by P. pastoris 
Because a 6XHis tag was cloned behind the coding sequence for the extracellular 
domain of TGFjSRII the recombinant protein could be purified from the culture medium 
by a single step procedure using a Ni-NTA agarose column. Purification appeared to be 
more effective from BMM medium as compared with BMMY medium suggesting that 
yeast extract and peptone negatively influence the binding of the recombinant protein to 
Ni-NTA. SDS-PAGE analysis of the purified protein did not show a distinct band but a 
band of 25 kDa with a smear up to 60 kDa was present (figure 1). To study whether this 
was the result of differential glycosylation of the three potential N-glycosylation sites, the 
protein was treated with glycosidases. As shown in figure 1, treatment with 
endoglycosidase F/N-glycosidase F resulted in a distinct band showing that TGFßsRII 
produced by P. pastoris is heterogeneously glycosylated. The molecular mass of the 
deglycosylated protein is about 22 kDa which is in line with the expected molecular mass 
of TGFßsRII. SDS-PAGE analysis of the deglycosylated protein showed that TGFßsRII 
was about 90% pure after a single purification step using Ni-NTA. The pi of purified, 
glycosylated TGFßsRII was determined by IEF analysis and appeared to be 7.0. 
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Figure 1 SDS-PAGE analysis of TGFßsRIl 
I_ produced by P. pastoris before (lane 1) and after 
60 kDa- " I (lane 2) deglycosylation with endoglycosidase 
F/N-glycosidase F. SDS-PAGE analysis was 
40 kDa- - performed on 12 % Polyacrylamide gels under 
denaturating conditions. A 10 kDa protein 
*
mm
'
0
 ladder was used as a molecular mass marker. 
20 kDa- mem 
M 1 2 
Expression of TGFßsRIl by E. coli 
Bacteria were transformed with a pQE-16 vector containing a sequence coding for the 
extracellular domain of TGF/3RII with an additional 6XHis tag. Production of recombinant 
protein by transformants was induced by addition of IPTG and was assayed by SDS-PAGE. As 
shown in figure 2, addition of IPTG induced the expression of a recombinant protein with a 
molecular mass of 22 kDa. Maximal expression of about 15 mg/1 was reached after 5 hours 
incubation in the presence of IPTG. Almost the entire fraction of TGFßsRIl was insoluble, 
indicating that inclusion bodies were formed. 
Figure 2 Analysis of recombinant TGFßsRIl 
ι ! production by E. coli after induction with IPTG. 
60 kDa- . Samples of cultures were taken at t=0 (lane 1), 3 
*T\) K i - 1 3 " ""'¡и ЦЕНИ, 
t=3 hours (lane 2) and t= 5 hours (lane 3) after 
addition of IPTG. Samples were centrifugea and 
pellets were solubilized in 8M urea. SDS-PAGE 
was performed on 12 % Polyacrylamide gels 
under denaturating conditions. A 10 kDa protein 
ladder was used as a molecular mass marker. 
The position of TGFßsRIl is indicated with an 
20 kDa- arrow-
--H 
M 1 2 3 
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Purification and renaturation of TGFßsRII produced by E. coli 
After solubilization of the cell pellet in 8M urea, TGFßsRII was purified using Ni-NTA 
agarose in a batch procedure. As shown in figure 3 the purification procedure was very efficient 
and resulted in a >90% pure protein as determined by SDS-PAGE. To produce a functional 
TGF-/J inhibitor the purified protein was renaturated. To prevent the formation of misfolded 
aggregates, refolding was performed while TGFßsRII was immobilized on Ni-NTA agarose. 
Several refolding procedures were used and the neutralizing activities of the proteins were tested 
in a TGF-ß bioassay. As can be seen in figure 4 the procedure in which refolding was performed 
in 2 mM reduced glutathione, 0.02 mM oxidized glutathione and 0.5M L-arginine was most 
effective in the production of a functional protein. Using IEF analysis the pi of purified and 
refolded TGFßsRII was shown to be 7.5. 
Figure 3 Purification of TGFßsRII produced by 
E. coli. After a 5 hours culture period in the 
60 kDa- presence of IPTG, cells were solubilized using 
~~~ 4ЙМ —' ят 8M urea and Ni-NTA agarose was added to the 
40 kDa- lysate. After an incubation period of 1 hour the 
cell lysate was removed and Ni-NTA was washed 
whereafter proteins were eluted using 300 mM 
imidazole. SDS-PAGE analysis was performed 
on a 12 % Polyacrylamide gel under 
^ ч т denaturating conditions. M: 10 kDa protein 
ladder; Lane 1: lysate before incubation with Ni-
NTA agarose; Lane 2: lysate after incubation 
with Ni-NTA agarose; Lane 3: eluate from Ni-
M 1 2 3
 MA agarose. 
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Figure 4 Effect of different refolding conditions on TGF-ß neutralizing activity of E. coli TGFßsRII. 
TGFßsRII was refolded using reduced glutathione (2 mM) and oxidized glutathione (0.2 or 0.02 mM) in 
the absence or presence of 0.5 M L-arginine. After refolding, the neutralizing acrìvity of TGFßsRII was 
determined using the NOB/CTLL bioassay in which TGF-ß inhibits 3H-thymidine incorporation. Samples 
containing 3 ng/ml TGF-ßl and 100 μg/mt TGFßsRII were tested. 1: medium; 2: TGF-ß; 3: TGF-ß + 
TGFßsRII (2 mM reduced glutathione/0.2 mM oxidized glutathione) 4: TGF-ß + TGFßsRII (2 mM 
reduced glutathione/0.02 oxidized glutathione) 5: TGF-ß + TGFßsRII (2 mM reduced glutathione/0.2 mM 
oxidized glutathione + 0.5M L-arginine) 6: TGF-ß + TGFßsRII (2 mM reduced glutathione/0.02 oxidized 
glutathione + 0.5 M L-arginine). 3H-thymidine incorporation in the absence of TGF-ß is indicated by 
the dotted line. 
Characterization of neutralizing activity of TGFßsRII 
The neutralizing activities of TGFßsRII produced by E. coli and TGFßsRII produced by 
P. pastoris were compared using the NOB/CTLL bioassay. As shown in figure 5 both 
recombinant proteins were able to inhibit TGF-jSl. However, TGF/3sRII produced by E. coli 
appeared to be a more potent inhibitor than TGFßsRII produced by P. pastoris. Dose-response 
studies demonstrated that a 400-800 fold molar excess of TGFßsRII (E. coli) was required for 
complete neutralization of TGF-ßl. A similar amount of commercially available TGFßsRII 
(expressed in NSO cells) was required for complete neutralization of TGF-ßl showing that the 
neutralizing activity of prokaryotic, refolded TGFßsRII (E. coli) and commercially available 
eukaryotic TGFßsRII were comparable (data not shown). 
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Figure S Comparison of 
neutralizing activities of 
TGFßsRII produced by E. coli 
and TGFßsRII produced by P. 
pastoris. Samples containing 3 
ng/ml TGF-ßl and 0-20 ng/ml 
TGFßsRII were analyzed using 
the NOB/CTLL TGF-ß bioassay. 
3H-thymidine incorporation in 
the absence of TGF-ß is 
indicated by the dotted line. 
Shown is a representative 
experiment of three. 
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In addition, the ability of TGFßsRII to inhibit biological activity of other mammalian 
TGF-j3 isoforms was studied. As shown in figure 6 TGFßsRII is not only a potent inhibitor for 
TGF-ßl but is also a potent inhibitor of TGF-B3. In contrast, TGFßsRII was less effective in 
neutralization of TGF-02. 
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Figure 6 Determination of 
neutralizing activity of TGFßsRII 
for TGF-ßl, TGF-ß2 and TGF-
ß3. Samples containing 1.5 
ng/ml TGF-ßl, TGF-ß2 or TGF-
ß3 in the presence of 30 ng/ml 
BSA or 30 ng/ml TGFßsRII 
were tested using the 
NOB/CTLL bioassay. 3H-
thymidine incorporation in the 
absence of TGF-ß is indicated 
by the dotted line. Shown is a 
representative experiment of 
three. 
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DISCUSSION 
TGF-/3 seems to play an important regulatory role in inflammation and tissue 
repair. To study the role of endogenous TGF-0 in pathological processes potent and 
specific TGF-/3 inhibitors are required. Because the soluble, extracellular domain of the 
type II TGF-jS receptor (TGF/3sRIT) has been shown to neutralize TGF-0 (32) we studied 
whether active TGFßsRII can be produced by E. coli and P. pastoris. 
The yeast P. pastoris expressed and secreted heterogeneously glycosylated 
TGFjSsRII. Comparable heterogeneous glycosylation was previously shown on TGFßsRII 
produced by NSO or COS cells (32,33). These results indicate that TGF/3sRII produced 
by P. pastoris was not hyperglycosylated which is in line with other reports showing that 
P. pastoris, in contrast to other yeasts like Saccharomyces cerevisiae, does not 
hyperglycosylate recombinant proteins (34,35). 
Expression of TGF/3sRH in E. coli resulted in high levels ( ~ 15 mg/1) of insoluble 
recombinant protein. Since TGF/3sRII was denaturated during solubilization, a 
renaturation procedure was required to obtain a biologically active protein. Unless very 
low protein concentrations are used, formation of misfolded aggregates often occurs 
during the renaturation process (36). To overcome this problem we performed refolding 
while the recombinant protein was immobilized on the Ni-NTA agarose. Formation of 
disulfide bonds was stimulated using a widely applied redox couple of reduced and 
oxidized glutathione (36-38). The efficiency of refolding appeared to be dependent on the 
ratio of reduced and oxidized glutathione used. Although a ratio of 10:1 is generally used 
(39), refolding of TGFßsRII was most efficient using a ratio of 100:1. The efficiency of 
refolding was clearly improved in the presence of 0.5M L-arginine. This is in line with 
other reports showing more efficient refolding of proteins in the presence of 0.5M L-
arginine (36,40). TGFjSsRII contains 12 cysteines, which are conserved between species 
(30,41), suggesting that they are all involved in the Expression of TGFßsRII by P. 
pastoris formation of disulfide linkages. Regardless of the high number of cysteines, in 
vitro refolding of TGFjSsRTI resulted in a protein with a TGF-/3-neutralizing activity that 
is comparable with the neutralizing activity of commercially available, eukaryotic 
TGFj3sRII. 
The ability of TGFßsRII produced by E. coli and P. pastoris to neutralize TGF-01 
was compared. Both proteins were able to neutralize TGF-0 showing that the C-terminal 
6XHÌS tag does not eliminate the neutralizing activity of TGF/JsRII. To our surprise, 
TGF/3sRII produced by E. coli appeared to be a more potent inhibitor of TGF-/31 than 
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TGF(3sRII produced by P. pastoris. Since it can be hypothesized that in vitro refolding 
of TGFßsRII might be inefficient due to the high number of conserved cysteines, this 
observation was unexpected. In addition, this finding was surprising as it has been 
described that unglycosylated TGF/3sRII is about 40 fold less potent in binding TGF-03 
than glycosylated TGF/ЖП (42). Until now the explanation for the different neutralizing 
activities of TGF/3sRII produced by E. coli and TGF/3sRII produced by P. pastoris 
remains obscure. 
TGF-/3sRTI appeared to be a potent inhibitor for TGF-jSl and TGF-/S3 but was less 
effective in the neutralization of TGF-/32. This is in line with earlier reports that describe 
the low affinity of TGF/3RII for TGF-02 (32,33,43-45). The lower affinity for TGF-/32 
might be the result of the different structure of TGF-/32 as compared with TGF-01 and 
TGF-03 (46-48). 
In summary, TGFßsRII can be efficiently expressed by P. pastoris and E. coli. 
The proteins, produced by both expression systems, appear to be potent inhibitors for 
TGF-01 and TGF-03. Because of the ease and low costs of both systems, the high 
expression levels and the powerful one-step purification, TGF/JsRII can now be produced 
and purified in high amounts to further study the role of TGF-/3 in inflammation, tissue 
repair and disease in vitro and in vivo. 
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SUMMARY AND FINAL CONSIDERATIONS 
Progressive destruction of articular cartilage is a main feature of osteoarthritis 
(OA) and rheumatoid arthritis (RA). The destruction of cartilage is the result of a 
disbalance between matrix synthesis and matrix degradation. In OA and RA degradation 
of matrix is enhanced due to elevated activity of proteinases produced by inflammatory 
cells, synovial tissue and articular chondrocytes. Besides enhanced degradation of matrix 
molecules, suppression of matrix synthesis also contributes to the process of cartilage 
destruction in arthritis. In contrast to arthritis, synthesis of matrix molecules is elevated 
in early OA but this is not able to overcome matrix degradation. Anabolic factors which 
are able to increase PG synthesis and decrease PG degradation might stimulate cartilage 
repair in arthritic and osteoarthritic joints. In this respect transforming growth factor /3 
(TGF-0) and bone morphogenetic proteins (BMPs) seem promising. 
TGF-/3 is a growth factor which is able to stimulate articular cartilage PG synthesis 
(1-3). However, the effects of TGF-/3 on PG synthesis of articular chondrocytes are 
contradictory since both stimulating and inhibitory effects of TGF-/3 on chondrocyte PG 
synthesis have been described (2,4,5). Studies were performed to investigate whether 
these differential effects of TGF-/3 are related to differences in the expression of TGF-/3 
receptors. In Chapter 2 TGF-/3 receptor expression of freshly isolated and cultured 
bovine articular chondrocytes was analyzed since we have previously shown that TGF-/3 
inhibits PG synthesis of freshly isolated articular chondrocytes while PG synthesis of 
cultured chondrocytes is stimulated by TGF-/3 (5). Both types of chondrocytes expressed 
type I, type Π and type Ш TGF-/3 receptors. Interestingly, the type II TGF-ß receptor of 
cultured chondrocytes was about 15 kilodaltons smaller than the type II TGF-/3 receptor 
of freshly isolated chondrocytes. Because the type II TGF-/3 receptor appears to be 
directly involved in signal transduction, these results suggest that the differential TGF-/3 
responses between freshly isolated and cultured chondrocytes are related to the differences 
in the size of the type II TGF-/3 receptor. Until now the mechanism of this action is 
unknown. Initially it was assumed that the type I and type II TGF-/3 receptors mediate 
distinct signal pathways independently. The type II TGF-0 receptor seemed responsible 
for inhibition of chondrocyte metabolism while activation of the type I TGF-|3 receptor 
appeared to stimulate chondrocyte metabolism (6,7). We postulated that the small sized 
type Π TGF-/3 receptor is a nonfunctional receptor leading to stimulating effects of TGF-/3 
by activation of only type I TGF-/3 receptors. However, nowadays there is accumulating 
evidence that type I and type II TGF-/3 receptors signal through a heteromeric receptor 
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complex and that a functional type II TGF-/3 receptor is required for phosphorylation of 
the type I TGF-0 receptor (8-10). It is not yet clear whether the type I and type II 
receptors in this complex mediate different signals as suggested by Chen et al (11) or that 
this complex induces only one signal pathway as is suggested by others (12-14). These 
new insights make it unlikely that the small sized type Π TGF-/8 receptor is a nonfuctional 
receptor, as we initially postulated. Recently, 2 different isoforms of the type II TGF-j3 
receptor have been described (15-18). It is unclear whether these isoforms are encoded 
by different genes or that they are generated by alternative splicing of a single gene. 
Because the difference in size between the "normal" type Π TGF-/3 receptor and the small 
sized type Π TGF-/3 receptor appears not to be the result of differences in glycosylation 
(non-published data) we assume that the small sized receptor is a new isoform. 
Hypothetically, a heteromeric receptor complex in which this isoform is included might 
phosphorylate different substrates leading to different cellular responses. 
The discovery of a new isoform of the type Π TGF-/3 receptor (TGF(3RII2)(15-17) 
prompted us to study the expression of this isoform in articular cartilage. This isoform 
contains an insertion of 25 amino acids in the extracellular domain. Although the function 
of TGFßRII2 is unknown an important role of this isoform is suggested since this isoform 
is highly conserved between species (17). Therefore it was hypothesized that this isoform 
mediates TGF-0 responses distinct from the 'normal' type II TGF-/3 receptor (TGF/3RII,) 
and that differential effects of TGF-/3 on chondrocytes might be the result of differences 
between the relative expression of these isoforms. As described in Chapter 3 both 
TGFjSRII, mRNA and TGFj3RII2 mRNA are expressed in human and murine articular 
cartilage. However, TGF/3RII2 mRNA was not detected in bovine articular cartilage. This 
implicates that it is unlikely that TGFj3RII2 plays an essential role in homeostasis of 
normal bovine articular cartilage. Because TGF-/3 responses appear to be age related 
(19-22) and differential TGF-/3 responses have been described between normal cartilage 
and cartilage undergoing repair (23-25), the relative expression of TGFj8RII[ and 
TGFj3RII2 was studied during cartilage repair and aging. No differences in the relative 
mRNA expression of the two isoforms could be demonstrated in murine articular cartilage 
during aging or during the repair phase after mild PG depletion suggesting that it is 
unlikely that differential TGF-/3 responses are the result of differences in the relative 
expression of the two isoforms. 
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Both BMP-2 and TGF-/3 have been shown to stimulate articular cartilage PG 
synthesis in vitro (1-3,26,27). To study the effects of these factors in vivo, they were 
directly injected into normal murine knee joints (Chapter 4). Both factors stimulated PG 
synthesis but intra-articular injection of BMP-2 induced a much earlier and more 
impressive stimulation of articular cartilage PG synthesis than intra-articular injection of 
TGF-/3. However, one month after one injection of TGF-/3 PG synthesis was still 
significantly increased, while stimulation by BMP-2 only lasted for a few days. 
Stimulation of PG synthesis by TGF-/3 resulted in a prolonged enhancement of PG content 
while BMP-2, even after repeated administration, did not result in a long-lasting 
enhancement of PG content. To get insight in the effect of TGF-/3 and BMP-2 on mRNA 
expression of different PG types, RT-PCR was performed. TGF-/3 induced a very short 
stimulation of aggrecan mRNA expression while no effects on biglycan mRNA and 
decorin mRNA could be detected. BMP-2 stimulated mainly the expression of aggrecan 
mRNA but also the expression of biglycan mRNA and decorin mRNA. Remarkably, 
mRNA for collagen type X was unchanged after TGF-/3 exposure, but highly upregulated 
after BMP-2 injections. The latter observation suggests that BMP-2 triggers chondrocytes 
to differentiate into hypertrophic chondrocytes. After prolonged administration, both 
BMP-2 and TGF-/3 induced the formation of new chondroid tissues. These tissues were 
called chondrophytes. Interestingly, chondrophytes induced by BMP-2 seem to be derived 
from the growth plates while TGF-/3-induced chondrophytes originate from the periosteum 
at sites remote from the growth plates. 
It is assumed that IL-1 is a key mediator in the process of cartilage destruction. IL-
1 seems to be responsible for suppression of PG synthesis during arthritis (28-30) and IL-
1 is able to induce PG depletion after intra-articular injections into normal joints (31,32). 
The abilities of TGF-/3 and BMP-2 to counteract IL-1 effects on articular cartilage PG 
synthesis and content were compared (Chapter 5). Normal murine knee joints were 
injected with TGF-/3 or BMP-2 in combination with IL-1 and the effects on PG synthesis 
and content were analysed. TGF-/3 did not prevent initial IL-1-induced PG depletion but 
counteracted the effects of IL-1 on PG synthesis and clearly stimulated replenishment of 
proteoglycans in depleted matrix. Although BMP-2 is a very potent stimulator of articular 
cartilage PG synthesis it was, in contrast to TGF-/3, not able to counteract the deleterious 
effects of IL-1 on articular cartilage PG synthesis and content. Since no significant effects 
of BMP-2 on chondrocyte PG synthesis could be demonstrated when chondrocyte 
metabolism is affected by IL-1 it is assumed that IL-1 induces BMP-2 unresponsiveness. 
Interestingly, ВМР-2-induced formation of chondrophytes was not inhibited by IL-1. 
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TGF-/3 and BMP-2 appeared to be potent stimulators of articular cartilage PG 
synthesis in vivo. Therefore, the ability of these factors to stimulate articular cartilage 
repair in established arthritis was studied (Chapter 6). An unilateral arthritis was induced 
in mice by intra-articular injection of zymosan (heat killed S. cerevisiae). Four days after 
the induction of arthritis three intra-articular injections with 200 ng TGF-/3 or BMP-2 
were given at alternate days. Although it has been described that high levels of active 
TGF-/3 are present in human arthritic joints (33-36), local administration of TGF-/31 or 
TGF-/32 in murine arthritic joints clearly stimulated articular cartilage PG synthesis and 
stimulated replenishment of proteoglycans in depleted cartilage. Inflammation was not 
affected by the TGF-/3 injections. Unfortunately, TGF-/3 not only stimulated articular 
cartilage repair but also stimulated the formation of chondrophytes. The latter might limit 
therapeutic application of local TGF-/3 administration. In contrast to TGF-/3, local 
administration of BMP-2 did not affect PG synthesis and no effects on PG content were 
detectable. The disability of BMP-2 to stimulate cartilage repair in arthritic joints might 
be attributed to the presence of IL-1 in these joints. 
To elucidate the significance of possible side-effects, long-term results of local 
administration of TGF-/3 into normal murine knee joints were studied. As described in 
Chapter 7, the chondrophytes, which are induced after 3 injections of 200 ng TGF-/3, 
do not disappear but calcify and develop into mature osteophytes. Moreover, histologic 
analysis of the articular cartilage in TGF-0-injected joints demonstrated areas with a 
decreased PG content in the cartilage of the lateral tibia. Because elevated PG synthesis, 
induction of osteophytes and PG depletion in cartilage of the lateral tibia are changes 
similar to changes observed in experimental and spontaneously occuring OA, these data 
suggest a role for TGF-/3 in the induction of OA. To study whether prolonged TGF-/3 
administration induces real О A pathology, like fissures and irregularities at the cartilage 
surface, 8 injections of 200 ng TGF-/3 were given. This treatment did not extend PG 
depletion neither induced fissures or irregularities of the cartilage surface but induced 
chondrogenesis in ligaments. The latter is also a feature observed in spontaneously 
occurring OA. These data indicate that care must be taken with local application of TGF-
ß and that TGF-/3 might have a pathogenic role in the development of some aspects of 
OA. 
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To further investigate the role of endogenous TGF-/3 in the formation of 
osteophytes and the induction of OA, potent inhibitors for TGF-/3 are required. Because 
the type Π TGF-/3 receptor (TGF/3RÜ) has a high affinity for TGF-/3 (8,37,38), a soluble 
type II TGF-/3 receptor (TGFjSsRII) was constructed and expressed by Escherichia coli 
and Pichia postons (Chapter 8). The ability of TGFjSsRII to neutralize the biological 
activity of TGF-/3 was studied using bioassays. TGF/3SRII appeared to be a potent 
inhibitor for TGF-jSl and TGF-/J3 but was less efficient in neutralizing the biological 
activity of TGF-/32. Since high amounts of this inhibitor can be produced, in vivo studies 
can now be performed to elucidate the role of endogenous TGF-/3 in experimental arthritis 
and osteoarthritis. 
In summary, this thesis demonstrates that local administration of TGF-/3 might be 
a promising treatment to stimulate articular cartilage repair in established arthritis. In 
contrast to TGF-/3, BMP-2 is a very potent stimulator of articular cartilage PG synthesis 
but is not able to counteract IL-1 effects on PG synthesis and content and does not 
stimulate repair in established arthritis. Although TGF-/3 is a very potent stimulator of 
cartilage repair, therapeutic value might be limited due to the induction of osteophytes. 
However, future research might find ways to prevent the unwanted side effects by 
improving the protocol of TGF-/3 administration, pharmacological intervention or 
selective blocking of TGF-/3 responses in periosteum, synovium and ligaments. In contrast 
to the ability of TGF-/3 to stimulate cartilage repair, this thesis also showed a possible 
role of TGF-/3 in pathogenesis since OA-like changes are induced after prolonged 
administration of TGF-/3 in normal joints. Specific TGF-/3 inhibitors like TGFjSsRII will 
be useful to further investigate the role of TGF-/3 in OA pathogenesis. 
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Articulair kraakbeen is een weefsel dat de uiteinden van de pijpbeenderen in een 
gewricht bekleedt. Het kraakbeen bestaat uit een veerkrachtige matrix dat de krachten die 
tijdens bewegen ontwikkeld worden goed kan opvangen waardoor het onderliggende bot 
tegen deze krachten beschermd wordt. Het kraakbeen zorgt er tevens voor dat 
gewrichtsoppervlakten met een minimale wrijving over elkaar kunnen glijden. De 
belangrijkste bestanddelen van de kraakbeenmatrix zijn proteoglycanen en collagenen. 
Deze eiwitten worden gemaakt door gespecialiseerde cellen die in de matrix liggen: de 
chondrocyten. Tijdens gewrichtsaandoeningen zoals reumatische artritis en osteoartritis 
vindt er degeneratie van het articulaire kraakbeen plaats. Dit resulteert in functieverlies 
van de gewrichten waardoor het vermogen om te bewegen beperkt wordt. Degeneratie 
van kraakbeen tijdens reumatische artritis is o.a. het gevolg van een verhoogde afbraak 
en een verlaagde aanmaak van proteoglycanen. In tegenstelling tot artritis is de aanmaak 
van proteoglycanen tijdens Osteoarthrose hoger dan in normaal kraakbeen. Deze 
verhoogde aanmaak blijkt echter niet voldoende te zijn om de verhoogde afbraak van 
proteoglycanen te compenseren. Eiwitten die de afbraak van proteoglycanen kunnen 
remmen en de aanmaak van proteoglycanen kunnen stimuleren zouden een rol kunnen 
spelen bij het herstel van gedegenereerd kraakbeen. In dit proefschrift zijn twee 
groeifactoren nader onderzocht op hun vermogen het herstel van kraakbeen te stimuleren. 
Deze groeifactoren zijn: transforming growth factor-/3 (TGF-/3) en bone morphogenetic 
protein-2 (BMP-2). 
TGF-/3 blijkt chondrocyten te kunnen aanzetten om meer proteoglycanen 
produceren. Echter in sommige omstandigheden wordt de aanmaak van proteoglycanen 
door chondrocyten juist geremd onder invloed van TGF-ß. Om te achterhalen waarom 
TGF-/3 in bepaalde omstandigheden stimuleert en in andere omstandigheden juist remt, 
is onderzoek gedaan naar de aanwezigheid van TGF-/3 receptoren op chondrocyten. TGF-
ß receptoren zijn eiwitten die heel specifiek TGF-/3 kunnen binden. Chondrocyten hebben 
minstens 4 verschillende typen TGF-0 receptoren (typen 1,11,III en V). De type I en type 
Π TGF-/3 receptoren kunnen door TGF-/3 geactiveerd worden waarna ze een signaal aan 
de cel doorgeven dat het gedrag van de cel doet veranderen. In hoofdstuk 2 en 
hoofdstuk 3 van dit proefschrift wordt beschreven dat de verschillende effecten van TGF-
ß op chondrocyten niet in verband stonden met veranderingen in de aanmaak van 2 
verschillende vormen van type II TGF-/3 receptoren (TGF/JRII] en TGFj8RII2) door deze 
chondrocyten. Er leek echter wel een relatie te bestaan tussen het effect van TGF-/3 en 
de grootte van de type II TGF-/3 receptor op deze cellen. 
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Om de effecten van TGF-/3 en BMP-2 op de aanmaak van proteoglycanen door 
chondrocyten in een normaal gewricht te bestuderen, zijn deze factoren in het 
kniegewricht van muizen ingespoten. Zoals beschreven in hoofdstuk 4 bleken zowel 
TGF-ß als BMP-2 de aanmaak van proteoglycanen in het kraakbeen flink te stimuleren. 
Opvallend is dat de stimulatie o.i.v. TGF-ß meer dan 3 weken aanhield terwijl BMP-2 
slechts een stimulatie van enkele dagen gaf. 
Interleukine-1 (IL-1) is een eiwit dat in verhoogde concentraties aanwezig is in 
zieke gewrichten en blijkt een belangrijke factor te zijn bij kraakbeendestructie. IL-1 kan 
namelijk de afbraak van proteoglycanen stimuleren en blijkt verantwoordelijk te zijn voor 
de geremde aanmaak van proteoglycanen tijdens artritis. Omdat IL-1 zo'n belangrijke rol 
speelt tijdens het proces van kraakbeendestructie is bestudeerd of TGF-/3 en BMP-2 de 
effecten van IL-1 op het kraakbeen kunnen tegenwerken. In hoofdstuk 5 is beschreven 
dat het injecteren van IL-1 in een muizengewricht resulteerde in een geremde aanmaak 
van proteoglycanen en in een verminderd proteoglycaan-gehalte in het kraakbeen. 
Wanneer IL-1 en TGF-/3 tegelijkertijd werden geïnjecteerd bleek TGF-jS niet in staat te 
zijn om te voorkomen dat het proteoglycaan-gehalte in het kraakbeen afneemt. Echter, 
TGF-/3 bleek wel heel duidelijk het herstelproces van het kraakbeen te stimuleren. Dit 
versnelde herstel was o.a. het gevolg van het feit dat TGF-/3, zelfs in de aanwezigheid 
van IL-1, de aanmaak van proteoglycanen stimuleerde. Ondanks dat BMP-2 chondrocyten 
kon aanzetten om meer proteoglycanen te produceren (hoofdstuk 4), bleek BMP-2 in de 
aanwezigheid van IL-1 totaal geen effect te hebben op de aanmaak van proteoglycanen 
en het kraakbeenherstel. Kennelijk wordt de invloed van BMP-2 op chondrocyten geremd 
door de aanwezigheid van IL-1. 
Omdat TGF-/3 en BMP-2 potente stimulatoren van de aanmaak van proteoglycanen 
door chondrocyten bleken te zijn, is onderzocht of deze factoren het herstel van 
kraakbeen in ontstoken gewrichten kunnen stimuleren. Hiervoor zijn TGF-/3 en BMP-2 
ingespoten in ontstoken muizenkniegewrichten. Het kraakbeen in deze ontstoken 
gewrichten had een geremde aanmaak van proteoglycanen en een verlaagd proteoglycaan-
gehalte. Zoals in hoofdstuk 6 is beschreven, had het toedienen van BMP-2 geen 
duidelijke effecten op het kraakbeen. Dit zou mogelijk kunnen komen door de 
aanwezigheid van IL-1 in het gewricht. Het toedienen van TGF-/3 had wel duidelijk 
positieve effecten op het kraakbeen. Na injecties van TGF-/3 in artritische gewrichten 
bleek de aanmaak van proteoglycanen niet geremd maar zelfs hoger te zijn dan in normale 
gewrichten. Ook had het injecteren van TGF-/3 een positief effect op het proteoglycaan-
gehalte van het kraakbeen. Dit gehalte was verlaagd in ontstoken gewrichten die niet met 
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TGF-/3 waren ingespoten maar was normaal in ontstoken gewrichten die ingespoten waren 
met TGF-j8. De mate van ontsteking werd niet door TGF-/3 beïnvloed. TGF-/3 bleek dus 
on staat om, zelfs in de aanwezigheid van een ontsteking, kraakbeenherstel te stimuleren. 
Therapeutische toepassing van TGF-/3 wordt echter mogelijk beperkt doordat TGF-0 ook 
de vorming van nieuw kraakbeenachtig weefsel (chondrofyten) in het gewricht 
stimuleerde. 
In hoofdstuk 7 zijn de lange-termijn effecten van het injecteren van TGF-j8 in 
normale gewrichten beschreven. De door TGF-/3 gevormde chondrofyten bleken niet te 
verdwijnen maar te veranderden in botstructuren (osteofyten). Ook werden andere 
pathologische veranderingen in het gewricht waargenomen. Zo bleek TGF-0 de vorming 
van kraakbeenachtig weefsel in de pezen te veroorzaken en werd er in het articulaire 
kraakbeen plaatselijk een verlaagd proteoglycaan-gehalte aangetoond. Aangezien 
vergelijkbare veranderingen ook worden waargenomen in muizenkniegewrichten met 
beginnende osteoartritis, suggereren deze waarnemingen dat TGF-0 betrokken zou 
kunnen zijn bij het onstaan van deze gewrichtsaandoening. 
De rol van TGF-/3 bij het ontstaan van osteoartritis kan nader bestudeerd worden 
door de biologische activiteit van TGF-/3 te remmen. Dit kan door middel van eiwitten 
die aan TGF-/3 binden waardoor TGF-/3 niet meer in staat is om TGF-/3 receptoren te 
activeren. Omdat TGF-/3 sterk aan de type II TGF-jS receptor bindt hebben we bacteriën 
( E. coli) en gisten (P. pastoris) zodanig verandert dat deze organismen het TGF-/3 
bindende deel van de type Π TGF-/8 receptor gaan produceren. De methoden die gebruikt 
zijn om de bacteriën en gisten te veranderen en om de geproduceerde eiwitten te isoleren 
zijn beschreven in hoofdstuk 8. De gezuiverde eiwitten blijken potente remmers te zijn 
voor TGF-0 en kunnen gebruikt worden om de rol van TGF-/3 tijdens het ontstaan van 
osteoartrose nader te bestuderen. 
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Belangrijkste conclusies: 
Ondanks het feit dat BMP-2 in normale gewrichten de chondrocyten stimuleert om 
meer proteoglycanen te maken, heeft BMP-2 geen effect op de aanmaak van 
proteoglycanen in de aanwezigheid van IL-1. Tevens bleek het injecteren van BMP-2 in 
ontstoken muizenkniegewrichten geen effect te hebben op de aanmaak van proteoglycanen 
en op het proteoglycaan-gehalte van het articulaire kraakbeen. In tegenstelling tot BMP-2 
blijkt TGF-/3 de effecten van IL-1 wel heel goed te kunnen tegenwerken en heeft het 
toedienen van TGF-/3 in ontstoken gewrichten een duidelijk positief effect op het 
kraakbeen. TGF-/3 stimuleert namelijk, zelfs in de aanwezigheid van een ontsteking, de 
aanmaak van proteoglycanen en blijkt ook het proteoglycaan-gehalte van het articulaire 
kraakbeen weer te normaliseren. TGF-/3 lijkt dus een potentiële factor om het herstel van 
kraakbeen te bevorderen. Therapeutische toepassing van TGF-/3 wordt echter mogelijk 
beperkt doordat TGF-/3 ook de vorming van osteofyten stimuleert en dat het toedienen 
van TGF-0 in een normaal muizenkniegewricht pathologische veranderingen tot stand kan 
brengen die vergelijkbaar zijn met veranderingen die waargenomen worden in een 
kniegewricht van een muis met beginnende Osteoarthrose. Dit laatste suggereert dat TGF-
ß een rol zou kunnen spelen bij het ontstaan van Osteoarthrose. Het beschreven onderzoek 
toont aan dat TGF-/3 het herstel van gedegenereerd kraakbeen kan stimuleren maar dat 
een teveel aan TGF-/3 ook een rol zou kunnen spelen bij het onstaan van kraakbeenschade 
in normale gewrichten. 
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Elly, jou ben ik ontzettend dankbaar voor de wijze waarop je aan mijn onderzoek hebt 
meegewerkt. Ondanks de vele tegenslagen die we gehad hebben, ben je altijd met 
enorme inzet en grote betrokkenheid aan het onderzoek blijven meewerken. Zonder jouw 
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Ook de bijdrage van Henk van Beuningen was onmisbaar voor het tot stand komen van 
dit proefschrift. Henk, bedankt! 
Brigitte en Lariska wil ik bedanken voor de inspanningen die zij tijdens hun stage hebben 
verricht en voor het feit dat ik op hen mocht oefenen met het begeleiden van studenten. 
Zeer belangrijk voor het in stand houden van mijn motivatie en werkplezier was de goede 
sfeer op de werkvloer. Hiervoor wil ik alle medewerkers en ex-medewerkers van Lab 
Reuma enorm bedanken. Dus....Wim, Marianne, Peter, Peter, Elly, Henk, Onno, Astrid, 
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Marike, Gerjo, Pernette en Lex, BEDANKT!!!! 
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laatste gaat mijn dank uit naar Anja. Anja, jij hebt ongetwijfeld het meest te lijden gehad 
van mijn dips, stress en tijdgebrek maar daarover klaagde je nooit en heb je me altijd 
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STELLINGEN 
behorende bij het proefschrift 
REGULATION OF ARTICULAR CHONDROCYTE PROTEOGLYCAN 
METABOLISM BY TRANSFORMING GROWTH FACTOR β 
AND BONE MORPHOGENETIC PROTEIN-2 
I 
IL-la induceert ВМР-2-ongevoeligheid bij articulaire chondrocyten {ditproefschrift). 
II 
TGF-ß kan, zelfs in de aanwezigheid van een heftige gewrichtsontsteking, het herstelproces 
van articulair kraakbeen stimuleren {dit proefschrift). 
Ш 
Aangezien kraakbeen tijdens de vroege fase van osteoartritis gekenmerkt wordt door een 
verhoogde proteoglycaan-synthese en een verhoogd proteoglycaan-gehalte is het 
onwaarschijnlijk dat IL-1 een belangrijke rol speelt bij het ontstaan van deze ziekte. 
IV 
Het renatureren van sommige eiwitten verloopt efficiënter in de aanwezigheid van L-arginine 
{dit proefschrift). 
V 
Het voorkomen van een type Π TGF-ß receptor isovorm met een insertie van 25 aminozuren 
geeft aan dat het gen van de type II TGF-ß receptor meer dan de 7 beschreven exonen moet 
bevatten. 
VI 
Indien ouders van spijbelende kinderen verplicht worden tot het volgen van opvoedkundige 
cursussen zal men spoedig ook met spijbelende ouders te maken krijgen. 
VII 
Het feit dat mobiele telefoons steeds vaker kinderlijke melodietjes produceren geeft aan dat 
deze apparaten vooral fungeren als speeltjes voor volwassenen. 
Vili 
Invoering van de 36-urige werkweek betekent voor veel onderzoekers vooral meer onbetaald 
overwerk. 
Di 
Het weren van supporters van uitspelende voetbalclubs zal niet alleen leiden tot een 
vermindering van het voetbalvandalisme maar ook tot een amarne van het aantal gewonnen 
uitwedstrijden. 
X 
Vooruitgang is iets anders dan voortrazen op de ingeslagen weg (Ode). 
XI 
Pas nadat de eerste mens gekloond is, zal de maatschappelijke discussie omtrent klonen goed 
op gang komen. 
XII 
Bij verdere commercialisering van de wetenschap zullen straks ook wetenschappelijke 
presentaties onderbroken worden voor reclame. 
Harrie Glansbeek 
Nijmegen, 15 december 1997 
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